Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.
A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
Malaria caused by PLASMODIUM VIVAX. This form of malaria is less severe than MALARIA, FALCIPARUM, but there is a higher probability for relapses to occur. Febrile paroxysms often occur every other day.
Proteins found in any species of protozoan.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
A genus of protozoa that comprise the malaria parasites of mammals. Four species infect humans (although occasional infections with primate malarias may occur). These are PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE, and PLASMODIUM VIVAX. Species causing infection in vertebrates other than man include: PLASMODIUM BERGHEI; PLASMODIUM CHABAUDI; P. vinckei, and PLASMODIUM YOELII in rodents; P. brasilianum, PLASMODIUM CYNOMOLGI; and PLASMODIUM KNOWLESI in monkeys; and PLASMODIUM GALLINACEUM in chickens.
Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
The product of meiotic division of zygotes in parasitic protozoa comprising haploid cells. These infective cells invade the host and undergo asexual reproduction producing MEROZOITES (or other forms) and ultimately gametocytes.
A surface protein found on Plasmodium species which induces a T-cell response. The antigen is polymorphic, sharing amino acid sequence homology among PLASMODIUM FALCIPARUM; PLASMODIUM CHABAUDI; PLASMODIUM VIVAX; and PLASMODIUM YOELII.
A condition characterized by somnolence or coma in the presence of an acute infection with PLASMODIUM FALCIPARUM (and rarely other Plasmodium species). Initial clinical manifestations include HEADACHES; SEIZURES; and alterations of mentation followed by a rapid progression to COMA. Pathologic features include cerebral capillaries filled with parasitized erythrocytes and multiple small foci of cortical and subcortical necrosis. (From Adams et al., Principles of Neurology, 6th ed, p136)
Two or more vaccines in a single dosage form.
A country in western Africa, east of MAURITANIA and south of ALGERIA. Its capital is Bamako. From 1904-1920 it was known as Upper Senegal-Niger; prior to 1958, as French Sudan; 1958-1960 as the Sudanese Republic and 1959-1960 it joined Senegal in the Mali Federation. It became an independent republic in 1960.
The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
A protozoan parasite that causes vivax malaria (MALARIA, VIVAX). This species is found almost everywhere malaria is endemic and is the only one that has a range extending into the temperate regions.
A species of PLASMODIUM causing malaria in rodents.
Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585)
A genus of mosquitoes (CULICIDAE) that are known vectors of MALARIA.
Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.
A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
A protozoan parasite of rodents transmitted by the mosquito Anopheles dureni.
Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.
A republic in eastern Africa, south of ETHIOPIA, west of SOMALIA with TANZANIA to its south, and coastline on the Indian Ocean. Its capital is Nairobi.
Uninuclear cells or a stage in the life cycle of sporozoan protozoa. Merozoites, released from ruptured multinucleate SCHIZONTS, enter the blood stream and infect the ERYTHROCYTES.
The constant presence of diseases or infectious agents within a given geographic area or population group. It may also refer to the usual prevalence of a given disease with such area or group. It includes holoendemic and hyperendemic diseases. A holoendemic disease is one for which a high prevalent level of infection begins early in life and affects most of the child population, leading to a state of equilibrium such that the adult population shows evidence of the disease much less commonly than do children (malaria in many communities is a holoendemic disease). A hyperendemic disease is one that is constantly present at a high incidence and/or prevalence rate and affects all groups equally. (Last, A Dictionary of Epidemiology, 3d ed, p53, 78, 80)
Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.
I'm afraid there seems to be a misunderstanding - "Africa" is not a medical term and does not have a medical definition. Africa is the world's second-largest and second-most populous continent, consisting of 54 countries with diverse cultures, peoples, languages, and landscapes. If you have any questions related to medical topics or definitions, I would be happy to help answer those for you!
A republic in southern Africa, south of TANZANIA, east of ZAMBIA and ZIMBABWE, bordered on the west by the Indian Ocean. Its capital is Maputo. It was formerly called Portuguese East Africa.
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
A protozoan parasite of rodents transmitted by the mosquito Anopheles stephensi.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.
Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.
A republic in eastern Africa, south of UGANDA and north of MOZAMBIQUE. Its capital is Dar es Salaam. It was formed in 1964 by a merger of the countries of TANGANYIKA and ZANZIBAR.
Insects that transmit infective organisms from one host to another or from an inanimate reservoir to an animate host.
A republic in western Africa, south of BURKINA FASO and west of TOGO. Its capital is Accra.
Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.
Inbred BALB/c mice are a strain of laboratory mice that have been selectively bred to be genetically identical to each other, making them useful for scientific research and experiments due to their consistent genetic background and predictable responses to various stimuli or treatments.
Schedule giving optimum times usually for primary and/or secondary immunization.
Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.
The reduction or regulation of the population of mosquitoes through chemical, biological, or other means.
The co-occurrence of pregnancy and parasitic diseases. The parasitic infection may precede or follow FERTILIZATION.
A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)
The continuous sequence of changes undergone by living organisms during the post-embryonic developmental process, such as metamorphosis in insects and amphibians. This includes the developmental stages of apicomplexans such as the malarial parasite, PLASMODIUM FALCIPARUM.
A family of the order DIPTERA that comprises the mosquitoes. The larval stages are aquatic, and the adults can be recognized by the characteristic WINGS, ANIMAL venation, the scales along the wing veins, and the long proboscis. Many species are of particular medical importance.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
A country consisting of the eastern half of the island of New Guinea and adjacent islands, including New Britain, New Ireland, the Admiralty Islands, and New Hanover in the Bismarck Archipelago; Bougainville and Buka in the northern Solomon Islands; the D'Entrecasteaux and Trobriand Islands; Woodlark (Murua) Island; and the Louisiade Archipelago. It became independent on September 16, 1975. Formerly, the southern part was the Australian Territory of Papua, and the northern part was the UN Trust Territory of New Guinea, administered by Australia. They were administratively merged in 1949 and named Papua and New Guinea, and renamed Papua New Guinea in 1971.
A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.
A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.
Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.
A family of the New World monkeys inhabiting the forests of South and Central America. There is a single genus and several species occurring in this family, including AOTUS TRIVIRGATUS (Northern night monkeys).
Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.
A diuretic and renal diagnostic aid related to sorbitol. It has little significant energy value as it is largely eliminated from the body before any metabolism can take place. It can be used to treat oliguria associated with kidney failure or other manifestations of inadequate renal function and has been used for determination of glomerular filtration rate. Mannitol is also commonly used as a research tool in cell biological studies, usually to control osmolarity.
A republic in western Africa, constituting an enclave within SENEGAL extending on both sides of the Gambia River. Its capital is Banjul, formerly Bathurst.
Bites and stings inflicted by insects.
Aluminum metal sulfate compounds used medically as astringents and for many industrial purposes. They are used in veterinary medicine for the treatment of ulcerative stomatitis, leukorrhea, conjunctivitis, pharyngitis, metritis, and minor wounds.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A protozoan parasite from Southeast Asia that causes monkey malaria. It is naturally acquired by man in Malaysia and can also be transmitted experimentally to humans.
A republic in west equatorial Africa, south of CAMEROON and west of the CONGO. Its capital is Libreville.
A republic in western Africa, south and east of MALI and west of NIGER. Its capital is Ouagadougou. It was formerly called Upper Volta until 1984.
Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
Deoxyribonucleic acid that makes up the genetic material of protozoa.
The relationship between an invertebrate and another organism (the host), one of which lives at the expense of the other. Traditionally excluded from definition of parasites are pathogenic BACTERIA; FUNGI; VIRUSES; and PLANTS; though they may live parasitically.
A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)
Any of a group of infections of fowl caused by protozoa of the genera PLASMODIUM, Leucocytozoon, and Haemoproteus. The life cycles of these parasites and the disease produced bears strong resemblance to those observed in human malaria.
Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.
Immunoglobulins produced in response to VIRAL ANTIGENS.
Antigenic determinants recognized and bound by the B-cell receptor. Epitopes recognized by the B-cell receptor are located on the surface of the antigen.
A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.
A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).
A species in the family AOTIDAE, inhabiting the forested regions of Central and South America (from Panama to the Amazon). Vocalizations occur primarily at night when they are active, thus they are also known as Northern night monkeys.
Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.
Species of the genus MASTADENOVIRUS associated with respiratory and enteric infections in primate hosts.
Divisions of the year according to some regularly recurrent phenomena usually astronomical or climatic. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)
The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Antibody-mediated immune response. Humoral immunity is brought about by ANTIBODY FORMATION, resulting from TH2 CELLS activating B-LYMPHOCYTES, followed by COMPLEMENT ACTIVATION.
A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.
Aspects of health and disease related to travel.
Institutional funding for facilities and for equipment which becomes a part of the assets of the institution.
An abnormal elevation of body temperature, usually as a result of a pathologic process.
Vaccines or candidate vaccines used to prevent STREPTOCOCCAL INFECTIONS.
One of the FOLIC ACID ANTAGONISTS that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.
Vaccines or candidate vaccines used to prevent ANTHRAX.
Semi-synthetic complex derived from nucleic-acid free viral particles. They are essentially reconstituted viral coats, where the infectious nucleocapsid is replaced by a compound of choice. Virosomes retain their fusogenic activity and thus deliver the incorporated compound (antigens, drugs, genes) inside the target cell. They can be used for vaccines (VACCINES, VIROSOME), drug delivery, or gene transfer.
Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.
A group of fatty acids that contain 18 carbon atoms and a double bond at the omega 9 carbon.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
A family of diphenylenemethane derivatives.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
An infant during the first month after birth.
Any vaccine raised against any virus or viral derivative that causes hepatitis.
A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)
A family of New World monkeys in the infraorder PLATYRRHINI, consisting of nine subfamilies: ALOUATTINAE; AOTINAE; Atelinae; Callicebinae; CALLIMICONINAE; CALLITRICHINAE; CEBINAE; Pithecinae; and SAIMIRINAE. They inhabit the forests of South and Central America, comprising the largest family of South American monkeys.
Vaccine used to prevent YELLOW FEVER. It consists of a live attenuated 17D strain of the YELLOW FEVER VIRUS.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
The use of instrumentation and techniques for visualizing material and details that cannot be seen by the unaided eye. It is usually done by enlarging images, transmitted by light or electron beams, with optical or magnetic lenses that magnify the entire image field. With scanning microscopy, images are generated by collecting output from the specimen in a point-by-point fashion, on a magnified scale, as it is scanned by a narrow beam of light or electrons, a laser, a conductive probe, or a topographical probe.
A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.
Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
Articles of cloth, usually cotton or rayon and other synthetic or cotton-blend fabrics, used in households, hospitals, physicians' examining rooms, nursing homes, etc., for sheets, pillow cases, toweling, gowns, drapes, and the like.
Proteins prepared by recombinant DNA technology.
Suspensions of attenuated or killed fungi administered for the prevention or treatment of infectious fungal disease.
A species of mosquito in the genus Anopheles and the principle vector of MALARIA in Africa.
Lightweight meshwork fabric made of cotton, silk, polyester, nylon (polyamides), or other material impregnated with insecticide, having openings too small to allow entry of mosquitoes or other insects, thereby offering protection against insect bite and insect-borne diseases.
The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.
The use of humans as investigational subjects.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunized and do not have serum antibodies to rubella. Children are usually immunized with measles-mumps-rubella combination vaccine. (Dorland, 28th ed)
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
The process of finding chemicals for potential therapeutic use.
Vaccines that are produced by using only the antigenic part of the disease causing organism. They often require a "booster" every few years to maintain their effectiveness.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
A protozoan parasite that occurs primarily in subtropical and temperate areas. It is the causal agent of quartan malaria. As the parasite grows it exhibits little ameboid activity.
Vaccines or candidate vaccines designed to prevent SAIDS; (SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME); and containing inactivated SIMIAN IMMUNODEFICIENCY VIRUS or type D retroviruses or some of their component antigens.
Vaccines or candidate vaccines used to prevent infection with SALMONELLA. This includes vaccines used to prevent TYPHOID FEVER or PARATYPHOID FEVER; (TYPHOID-PARATYPHOID VACCINES), and vaccines used to prevent nontyphoid salmonellosis.
A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans.
Inbred C57BL mice are a strain of laboratory mice that have been produced by many generations of brother-sister matings, resulting in a high degree of genetic uniformity and homozygosity, making them widely used for biomedical research, including studies on genetics, immunology, cancer, and neuroscience.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Vaccines using supra-molecular structures composed of multiple copies of recombinantly expressed viral structural proteins. They are often antigentically indistinguishable from the virus from which they were derived.
DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.
Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.
Sites on an antigen that interact with specific antibodies.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
Elements of limited time intervals, contributing to particular results or situations.
A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Termination of all transmission of infection by global extermination of the infectious agent through surveillance and containment (From Porta, A Dictionary of Epidemiology, 5th ed).
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
A republic in western Africa, southwest of MAURITANIA and east of MALI. Its capital is Dakar.
Formerly known as Siam, this is a Southeast Asian nation at the center of the Indochina peninsula. Bangkok is the capital city.
Staphylococcal vaccines are prophylactic agents developed to prevent infections caused by Staphylococcus aureus, a pathogenic bacterium that frequently colonizes human skin and mucous membranes, often targeting surface proteins or toxins for immune response induction.
The classes of immunoglobulins found in any species of animal. In man there are nine classes that migrate in five different groups in electrophoresis; they each consist of two light and two heavy protein chains, and each group has distinguishing structural and functional properties.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.
Research that involves the application of the natural sciences, especially biology and physiology, to medicine.
Vaccines or candidate vaccines used to prevent infection with CYTOMEGALOVIRUS.
Organized services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international.
The study of parasites and PARASITIC DISEASES.
The functional hereditary units of protozoa.
A republic in eastern Africa, south of SUDAN and west of KENYA. Its capital is Kampala.
A specialized agency of the United Nations designed as a coordinating authority on international health work; its aim is to promote the attainment of the highest possible level of health by all peoples.
Free-standing or supported lightweight meshwork fabric made of cotton, silk, polyester or other material, having openings too small to allow entry of mosquitoes or other insects, thereby protecting against INSECT BITES; INSECT STINGS, and insect-borne diseases.
The concept pertaining to the health status of inhabitants of the world.
The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level.
A type of glycoside widely distributed in plants. Each consists of a sapogenin as the aglycone moiety, and a sugar. The sapogenin may be a steroid or a triterpene and the sugar may be glucose, galactose, a pentose, or a methylpentose.
A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.
Delivery of medications through the nasal mucosa.
Vaccines used to prevent POLIOMYELITIS. They include inactivated (POLIOVIRUS VACCINE, INACTIVATED) and oral vaccines (POLIOVIRUS VACCINE, ORAL).
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
Vaccines or candidate vaccines used to prevent or treat both enterotoxigenic and enteropathogenic Escherichia coli infections.
Vaccines or candidate vaccines used to prevent infection with WEST NILE VIRUS.
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
Measure of the number of the PARASITES present in a host organism.
A 4-aminoquinoline compound with anti-inflammatory properties.
Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.
Vaccines or candidate vaccines used to prevent bacillary dysentery (DYSENTERY, BACILLARY) caused by species of SHIGELLA.
Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product.
Sesquiterpenes are a class of terpenes consisting of three isoprene units, forming a 15-carbon skeleton, which can be found in various plant essential oils and are known for their diverse chemical structures and biological activities, including anti-inflammatory, antimicrobial, and cytotoxic properties.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Diagnostic procedures, such as laboratory tests and x-rays, routinely performed on all individuals or specified categories of individuals in a specified situation, e.g., patients being admitted to the hospital. These include routine tests administered to neonates.
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
An attenuated vaccine used to prevent and/or treat HERPES ZOSTER, a disease caused by HUMAN HERPESVIRUS 3.
Sorbitan mono-9-octadecanoate poly(oxy-1,2-ethanediyl) derivatives; complex mixtures of polyoxyethylene ethers used as emulsifiers or dispersing agents in pharmaceuticals.
Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time.
Invertebrates or non-human vertebrates which transmit infective organisms from one host to another.
A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats.
AMINO ALCOHOLS containing the ETHANOLAMINE; (-NH2CH2CHOH) group and its derivatives.
Programs of surveillance designed to prevent the transmission of disease by any means from person to person or from animal to man.
Genotypic differences observed among individuals in a population.
Tetanus toxoid is a purified and chemically inactivated form of the tetanus toxin, used as a vaccine to induce active immunity against tetanus disease by stimulating the production of antibodies.

Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. (1/977)

Immunological intervention, in addition to vector control and malaria chemotherapy, will be needed to stop the resurgence of malaria, a disease with a devastating impact on the health of 300 to 500 million people annually. We have pursued a vaccination strategy, based on DNA immunization in mice with genes encoding two antigens present on the sexual stages of Plasmodium falciparum, Pfs25 and Pfg27, to induce biologically important antibodies that can block development of the parasite in the Anopheles mosquito and thus transmission of the disease. DNA encoding Pfs25 when administered by the intramuscular route, either alone or with DNA encoding Pfg27, had the most potent transmission-blocking effects, resulting in up to a 97% decrease in oocyst numbers in mosquito midguts and a 75% decrease in rate of infection. Immunization with DNA encoding a Pfg27-Pfs25 fusion protein was less effective and DNA encoding Pfg27 elicited antibodies in sera that had only modest effects on the infectivity of the parasite. These results show for the first time that DNA vaccination can result in potent transmission-blocking antibodies in mice and suggest that the Pfs25 gene should be included as part of a multicomponent DNA vaccine.  (+info)

Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains. (2/977)

The 19 kDa carboxy-terminal domain of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) was expressed in Salmonella vaccine strains as a carboxy-terminal fusion to fragment C of tetanus toxin (TetC). This study demonstrates that antibodies that recognize disulphide-dependent conformational epitopes in native MSP1 react with the TetC-MSP1(19) fusion protein expressed in Salmonella. The proper folding of MSP1(19) polypeptide is dependent on both the Salmonella host strain and the protein to which the MSP1(19) polypeptide is fused. Serum from mice immunized with Salmonella typhimurium C5aroD expressing TetC-MSP1(19) recognized native MSP1 as shown by immunofluorescence with P. yoelii-infected erythrocytes. Antibody levels to MSP1(19) were highest in out-bred mice immunized with S. typhimurium C5aroD carrying pTECH2-MSP1(19) and antibody was mostly directed against reduction-sensitive conformational epitopes. However, antibody levels were lower than in BALB/c mice immunized with a glutathione S-transferase (GST)-MSP1(19) fusion protein in Freund's adjuvant, and which were protected against P. yoelii challenge infection. In challenge experiments with P. yoelii the Salmonella-immunized mice were not protected, probably reflecting the magnitude of the antibody response. The results of this study have important implications in the design of live multivalent bacterial vaccines against eukaryotic pathogens.  (+info)

Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1. (3/977)

Vaccination of mice with the leading malaria vaccine candidate homologue, the 19-kDa carboxyl terminus of merozoite surface protein-1 (MSP119), results in sterile immunity to Plasmodium yoelii, with no parasites detected in blood. Although such immunity depends upon high titer Abs at challenge, high doses of immune sera transferred into naive mice reduce parasitemia (and protect from death) but do not result in a similar degree of protection (with most mice experiencing high peak parasitemias); this finding suggests that ongoing parasite-specific immune responses postchallenge are essential. We analyzed this postchallenge response by transferring Abs into manipulated but malaria-naive mice and observed that Abs cannot protect SCID, nude, CD4+ T cell-depleted, or B cell knockout mice, with all mice dying. Thus, in addition to the Abs that develop following MSP119 vaccination, a continuing active immune response postchallenge is required for protection. MSP119-specific Abs can adoptively transfer protection to strains of mice that are not protected following vaccination with MSP119, suggesting that the Ags targeted by the immune response postchallenge include Ags apart from MSP119. These data have important implications for the development of a human malaria vaccine.  (+info)

Interleukin-10 responses to liver-stage antigen 1 predict human resistance to Plasmodium falciparum. (4/977)

The design of an effective vaccine against Plasmodium falciparum, the most deadly malaria parasite of humans, requires a careful definition of the epitopes and the immune responses involved in protection. Liver-stage antigen 1 (LSA-1) is specifically expressed during the hepatic stage of P. falciparum and elicits cellular and humoral immune responses in naturally exposed individuals. We report here that interleukin-10 (IL-10) production in response to LSA-1 predicts resistance to P. falciparum after eradication therapy. Resistance was not related to gamma interferon or tumor necrosis factor alpha production. This is the first report that human IL-10 responses are associated with resistance after eradication therapy, and our findings support the inclusion of LSA-1 in a vaccine against malaria.  (+info)

IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. (5/977)

CD8+ T cells have been implicated as critical effector cells in protection against preerythrocytic stage malaria, including the potent protective immunity of mice and humans induced by immunization with radiation-attenuated Plasmodium spp. sporozoites. This immunity is directed against the Plasmodium spp. parasite developing within the host hepatocyte and for a number of years has been presumed to be mediated directly by CD8+ CTL or indirectly by IFN-gamma released from CD8+ T cells. In this paper, in BALB/c mice, we establish that after immunization with irradiated sporozoites or DNA vaccines parasite-specific CD8+ T cells trigger a novel mechanism of adaptive immunity that is dependent on T cell- and non-T cell-derived cytokines, in particular IFN-gamma and IL-12, and requires NK cells but not CD4+ T cells. The absolute requirement for CD8+ T cells to initiate such an effector mechanism, and the requirement for IL-12 and NK cells in such vaccine-induced protective immunity, are unique and underscore the complexity of the immune responses that protect against malaria and other intracellular pathogens.  (+info)

Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania. (6/977)

BACKGROUND: Malaria control programmes need to protect young children, who bear the brunt of malaria disease and death in Africa. The development of a vaccine is a priority if improved and sustained malaria control is to be achieved. The best use of a vaccine in Africa will be achieved if it can be delivered through the expanded programme of immunization (EPI). We conducted a trial designed to evaluate the efficacy of SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania. METHODS: The study was a two-arm, double blind, individually randomized placebo controlled trial involving 1207 infants. The primary objective of the trial was to estimate the efficacy of three doses of SPf66 given at 1, 2 and 7 months of age in preventing clinical episodes of malaria. These were documented through a health facility-based passive case detection system. RESULTS: Among 1207 randomized children, overall compliance for third dose was 91%. SPf66 was safe, immunogenic and did not interfere with the humoral immune responses to EPI vaccines. There were 294 children among SPf66 recipients and 288 among placebo recipients with at least one malaria episode, yielding a vaccine efficacy estimate of 2% (95% CI: -16, 16; P = 0.84). CONCLUSION: This has been the first trial of a malaria vaccine among very young infants. It provides information on the safety of peptide vaccines administered at this early age as well as their capacity to induce immune responses without negatively interacting with EPI vaccines. Given the modest protection previously documented in older age groups and the lack of efficacy in younger infants, this vaccine in its current alum-based formulation does not appear to have a role in malaria control in sub-Saharan Africa. The lack of efficacy found in this trial also raises concerns about potential difficulties of inducing protective immune responses against malaria through immunization in infants.  (+info)

Safety in infants of SPf66, a synthetic malaria vaccine, delivered alongside the EPI. (7/977)

The most likely mechanism to deliver a malaria vaccine in African countries is through the Expanded Program of Immunization (EPI). So far only SPf66, a multistage synthetic peptide, has shown any evidence of protection in Phase III field trials. In Tanzania, SPf66 reduced the risk of clinical malaria by 31% in children aged 1-5 years. In order to progress in the critical path of vaccine development and testing towards the implementation of a new vaccine in malaria control programs, we carried out a randomized double-blind placebo controlled efficacy trial of SPf66 when given alongside the EPI scheme. Monitoring of safety and reactogenicity during this trial included detailed clinical and laboratory assessments on 98 infants and assessment of adverse effects within 1 h of vaccination for all 1207 children vaccinated. Surveillance systems monitored attendances as outpatients, admissions to hospital and fatal events in the community. No serious adverse effects were detected more frequently amongst SPf66 recipients compared to placebo. This first assessment in very young infants of a synthetic vaccine provides evidence of a good safety profile.  (+info)

Infectivity of Plasmodium berghei sporozoites delivered by intravenous inoculation versus mosquito bite: implications for sporozoite vaccine trials. (8/977)

Plasmodium berghei sporozoites delivered by mosquito bite were more infectious to outbred CD-1 mice than were sporozoites delivered by intravenous inoculation. The route of challenge also affected vaccine efficacy. In view of these findings and the fact that mosquito bites are the natural mode of sporozoite delivery, infectious mosquito bites should be considered the challenge protocol of choice for sporozoite vaccine efficacy trials.  (+info)

Malaria vaccines are biological preparations that induce immunity against malaria parasites, thereby preventing or reducing the severity of malaria disease. They typically contain antigens (proteins or other molecules derived from the parasite) that stimulate an immune response in the recipient, enabling their body to recognize and neutralize the pathogen upon exposure.

The most advanced malaria vaccine candidate is RTS,S/AS01 (Mosquirix), which targets the Plasmodium falciparum parasite's circumsporozoite protein (CSP). This vaccine has shown partial protection in clinical trials, reducing the risk of severe malaria and hospitalization in young children by about 30% over four years. However, it does not provide complete immunity, and additional research is ongoing to develop more effective vaccines against malaria.

Malaria is not a medical definition itself, but it is a disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. Here's a simple definition:

Malaria: A mosquito-borne infectious disease caused by Plasmodium parasites, characterized by cycles of fever, chills, and anemia. It can be fatal if not promptly diagnosed and treated. The five Plasmodium species known to cause malaria in humans are P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi.

Malaria, Falciparum is defined as a severe and often fatal form of malaria caused by the parasite Plasmodium falciparum. It is transmitted to humans through the bites of infected Anopheles mosquitoes. This type of malaria is characterized by high fever, chills, headache, muscle and joint pain, and vomiting. If left untreated, it can cause severe anemia, kidney failure, seizures, coma, and even death. It is a major public health problem in many tropical and subtropical regions of the world, particularly in Africa.

'Plasmodium falciparum' is a specific species of protozoan parasite that causes malaria in humans. It is transmitted through the bites of infected female Anopheles mosquitoes and has a complex life cycle involving both human and mosquito hosts.

In the human host, the parasites infect red blood cells, where they multiply and cause damage, leading to symptoms such as fever, chills, anemia, and in severe cases, organ failure and death. 'Plasmodium falciparum' malaria is often more severe and life-threatening than other forms of malaria caused by different Plasmodium species. It is a major public health concern, particularly in tropical and subtropical regions of the world where access to prevention, diagnosis, and treatment remains limited.

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically contains an agent that resembles the disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it encounters in the future.

Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight disease that is already present). The administration of vaccines is called vaccination. Vaccinations are generally administered through needle injections, but can also be administered by mouth or sprayed into the nose.

The term "vaccine" comes from Edward Jenner's 1796 use of cowpox to create immunity to smallpox. The first successful vaccine was developed in 1796 by Edward Jenner, who showed that milkmaids who had contracted cowpox did not get smallpox. He reasoned that exposure to cowpox protected against smallpox and tested his theory by injecting a boy with pus from a cowpox sore and then exposing him to smallpox, which the boy did not contract. The word "vaccine" is derived from Variolae vaccinae (smallpox of the cow), the term devised by Jenner to denote cowpox. He used it in 1798 during a conversation with a fellow physician and later in the title of his 1801 Inquiry.

Antigens are substances (usually proteins) found on the surface of cells, or viruses, that can be recognized by the immune system and stimulate an immune response. In the context of protozoa, antigens refer to the specific proteins or other molecules found on the surface of these single-celled organisms that can trigger an immune response in a host organism.

Protozoa are a group of microscopic eukaryotic organisms that include a diverse range of species, some of which can cause diseases in humans and animals. When a protozoan infects a host, the host's immune system recognizes the protozoan antigens as foreign and mounts an immune response to eliminate the infection. This response involves the activation of various types of immune cells, such as T-cells and B-cells, which recognize and target the protozoan antigens.

Understanding the nature of protozoan antigens is important for developing vaccines and other immunotherapies to prevent or treat protozoan infections. For example, researchers have identified specific antigens on the surface of the malaria parasite that are recognized by the human immune system and have used this information to develop vaccine candidates. However, many protozoan infections remain difficult to prevent or treat, and further research is needed to identify new targets for vaccines and therapies.

Malaria, Vivax:

A type of malaria caused by the parasite Plasmodium vivax. It is transmitted to humans through the bites of infected Anopheles mosquitoes. Malaria, Vivax is characterized by recurring fevers, chills, and flu-like symptoms, which can occur every other day or every third day. This type of malaria can have mild to severe symptoms and can sometimes lead to complications such as anemia and splenomegaly (enlarged spleen). One distinguishing feature of Malaria, Vivax is its ability to form dormant stages in the liver (called hypnozoites), which can reactivate and cause relapses even after years of apparent cure. Effective treatment includes medication to kill both the blood and liver stages of the parasite. Preventive measures include using mosquito nets, insect repellents, and antimalarial drugs for prophylaxis in areas with high transmission rates.

I'm sorry for any confusion, but "Protozoan Proteins" is not a specific medical or scientific term. Protozoa are single-celled eukaryotic organisms, and proteins are large biological molecules consisting of one or more chains of amino acid residues. Therefore, "Protozoan Proteins" generally refers to the various types of proteins found in protozoa.

However, if you're looking for information about proteins specific to certain protozoan parasites with medical relevance (such as Plasmodium falciparum, which causes malaria), I would be happy to help! Please provide more context or specify the particular protozoan of interest.

Synthetic vaccines are artificially produced, designed to stimulate an immune response and provide protection against specific diseases. Unlike traditional vaccines that are derived from weakened or killed pathogens, synthetic vaccines are created using synthetic components, such as synthesized viral proteins, DNA, or RNA. These components mimic the disease-causing agent and trigger an immune response without causing the actual disease. The use of synthetic vaccines offers advantages in terms of safety, consistency, and scalability in production, making them valuable tools for preventing infectious diseases.

Antibodies, protozoan, refer to the immune system's response to an infection caused by a protozoan organism. Protozoa are single-celled microorganisms that can cause various diseases in humans, such as malaria, giardiasis, and toxoplasmosis.

When the body is infected with a protozoan, the immune system responds by producing specific proteins called antibodies. Antibodies are produced by a type of white blood cell called a B-cell, and they recognize and bind to specific antigens on the surface of the protozoan organism.

There are five main types of antibodies: IgA, IgD, IgE, IgG, and IgM. Each type of antibody has a different role in the immune response. For example, IgG is the most common type of antibody and provides long-term immunity to previously encountered pathogens. IgM is the first antibody produced in response to an infection and is important for activating the complement system, which helps to destroy the protozoan organism.

Overall, the production of antibodies against protozoan organisms is a critical part of the immune response and helps to protect the body from further infection.

Inactivated vaccines, also known as killed or non-live vaccines, are created by using a version of the virus or bacteria that has been grown in a laboratory and then killed or inactivated with chemicals, heat, or radiation. This process renders the organism unable to cause disease, but still capable of stimulating an immune response when introduced into the body.

Inactivated vaccines are generally considered safer than live attenuated vaccines since they cannot revert back to a virulent form and cause illness. However, they may require multiple doses or booster shots to maintain immunity because the immune response generated by inactivated vaccines is not as robust as that produced by live vaccines. Examples of inactivated vaccines include those for hepatitis A, rabies, and influenza (inactivated flu vaccine).

"Plasmodium" is a genus of protozoan parasites that are the causative agents of malaria in humans and other animals. There are several species within this genus, including Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, among others.

These parasites have a complex life cycle that involves two hosts: an Anopheles mosquito and a vertebrate host (such as humans). When a person is bitten by an infected mosquito, the parasites enter the bloodstream and infect red blood cells, where they multiply and cause the symptoms of malaria.

Plasmodium species are transmitted through the bites of infected female Anopheles mosquitoes, which become infected after taking a blood meal from an infected person. The parasites then develop in the mosquito's midgut, eventually making their way to the salivary glands, where they can be transmitted to another human through the mosquito's bite.

Malaria is a serious and sometimes fatal disease that affects millions of people worldwide, particularly in tropical and subtropical regions. It is characterized by fever, chills, headache, muscle and joint pain, and anemia, among other symptoms. Prompt diagnosis and treatment are essential to prevent severe illness and death from malaria.

I could not find a specific medical definition for "Vaccines, DNA." However, I can provide you with some information about DNA vaccines.

DNA vaccines are a type of vaccine that uses genetically engineered DNA to stimulate an immune response in the body. They work by introducing a small piece of DNA into the body that contains the genetic code for a specific antigen (a substance that triggers an immune response). The cells of the body then use this DNA to produce the antigen, which prompts the immune system to recognize and attack it.

DNA vaccines have several advantages over traditional vaccines. They are relatively easy to produce, can be stored at room temperature, and can be designed to protect against a wide range of diseases. Additionally, because they use DNA to stimulate an immune response, DNA vaccines do not require the growth and culture of viruses or bacteria, which can make them safer than traditional vaccines.

DNA vaccines are still in the experimental stages, and more research is needed to determine their safety and effectiveness. However, they have shown promise in animal studies and are being investigated as a potential tool for preventing a variety of infectious diseases, including influenza, HIV, and cancer.

A viral vaccine is a biological preparation that introduces your body to a specific virus in a way that helps your immune system build up protection against the virus without causing the illness. Viral vaccines can be made from weakened or inactivated forms of the virus, or parts of the virus such as proteins or sugars. Once introduced to the body, the immune system recognizes the virus as foreign and produces an immune response, including the production of antibodies. These antibodies remain in the body and provide immunity against future infection with that specific virus.

Viral vaccines are important tools for preventing infectious diseases caused by viruses, such as influenza, measles, mumps, rubella, polio, hepatitis A and B, rabies, rotavirus, chickenpox, shingles, and some types of cancer. Vaccination programs have led to the control or elimination of many infectious diseases that were once common.

It's important to note that viral vaccines are not effective against bacterial infections, and separate vaccines must be developed for each type of virus. Additionally, because viruses can mutate over time, it is necessary to update some viral vaccines periodically to ensure continued protection.

A subunit vaccine is a type of vaccine that contains a specific piece or component of the microorganism (such as a protein, sugar, or part of the bacterial outer membrane), instead of containing the entire organism. This piece of the microorganism is known as an antigen, and it stimulates an immune response in the body, allowing the development of immunity against the targeted infection without introducing the risk of disease associated with live vaccines.

Subunit vaccines offer several advantages over other types of vaccines. They are generally safer because they do not contain live or weakened microorganisms, making them suitable for individuals with weakened immune systems or specific medical conditions that prevent them from receiving live vaccines. Additionally, subunit vaccines can be designed to focus on the most immunogenic components of a pathogen, potentially leading to stronger and more targeted immune responses.

Examples of subunit vaccines include the Hepatitis B vaccine, which contains a viral protein, and the Haemophilus influenzae type b (Hib) vaccine, which uses pieces of the bacterial polysaccharide capsule. These vaccines have been crucial in preventing serious infectious diseases and reducing associated complications worldwide.

Sporozoites are a stage in the life cycle of certain parasitic protozoans, including Plasmodium species that cause malaria. They are infective forms that result from the sporulation of oocysts, which are produced in the vector's midgut after the ingestion of gametocytes during a blood meal.

Once mature, sporozoites are released from the oocyst and migrate to the salivary glands of the vector, where they get injected into the host during subsequent feedings. In the host, sporozoites infect liver cells, multiply within them, and eventually rupture the cells, releasing merozoites that invade red blood cells and initiate the erythrocytic stage of the parasite's life cycle.

Sporozoites are typically highly motile and possess a unique gliding motility, which enables them to traverse various host tissues during their invasion process. This invasive ability is facilitated by an actin-myosin motor system and secretory organelles called micronemes and rhoptries, which release adhesive proteins that interact with host cell receptors.

In summary, sporozoites are a crucial stage in the life cycle of Plasmodium parasites, serving as the infective forms responsible for transmitting malaria between hosts via an insect vector.

Merozoite Surface Protein 1 (MSP1) is a malarial antigen, which is a protein present on the surface of merozoites, which are the invasive forms of the Plasmodium parasites that cause malaria. MSP1 plays a crucial role in the invasion of red blood cells by the merozoites during the erythrocytic stage of the parasite's life cycle.

The MSP1 protein is synthesized and processed through several stages, resulting in multiple fragments, including the C-terminal 42 kDa fragment (MSP1-42) that is further cleaved into four smaller fragments (MSP1-19, MSP1-33, MSP1-38, and MSP1-42). These fragments are involved in the recognition and attachment of merozoites to the red blood cells, followed by the formation of a tight junction between the parasite and the host cell membranes.

MSP1 is one of the most abundant and immunogenic proteins on the surface of the merozoites, making it an attractive vaccine candidate. However, despite extensive research, a successful MSP1-based malaria vaccine has yet to be developed due to challenges in eliciting a protective immune response against this complex antigen.

Cerebral malaria is a severe form of malaria that affects the brain. It is caused by Plasmodium falciparum parasites, which are transmitted to humans through the bites of infected Anopheles mosquitoes. In cerebral malaria, the parasites infect and destroy red blood cells, leading to their accumulation in small blood vessels in the brain. This can cause swelling of the brain, impaired consciousness, seizures, coma, and even death if left untreated.

The medical definition of cerebral malaria is:

A severe form of malaria caused by Plasmodium falciparum parasites that affects the brain and results in altered mental status, seizures, coma, or other neurological symptoms. It is characterized by the sequestration of infected red blood cells in the cerebral microvasculature, leading to inflammation, endothelial activation, and disruption of the blood-brain barrier. Cerebral malaria can cause long-term neurological deficits or death if not promptly diagnosed and treated with appropriate antimalarial therapy.

Combined vaccines are defined in medical terms as vaccines that contain two or more antigens from different diseases, which are given to provide protection against multiple diseases at the same time. This approach reduces the number of injections required and simplifies the immunization schedule, especially during early childhood. Examples of combined vaccines include:

1. DTaP-Hib-IPV (e.g., Pentacel): A vaccine that combines diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b (Hib) disease, and poliovirus components in one injection to protect against these five diseases.
2. MMRV (e.g., ProQuad): A vaccine that combines measles, mumps, rubella, and varicella (chickenpox) antigens in a single injection to provide immunity against all four diseases.
3. HepA-HepB (e.g., Twinrix): A vaccine that combines hepatitis A and hepatitis B antigens in one injection, providing protection against both types of hepatitis.
4. MenACWY-TT (e.g., MenQuadfi): A vaccine that combines four serogroups of meningococcal bacteria (A, C, W, Y) with tetanus toxoid as a carrier protein in one injection for the prevention of invasive meningococcal disease caused by these serogroups.
5. PCV13-PPSV23 (e.g., Vaxneuvance): A vaccine that combines 13 pneumococcal serotypes with PPSV23, providing protection against a broader range of pneumococcal diseases in adults aged 18 years and older.

Combined vaccines have been thoroughly tested for safety and efficacy to ensure they provide a strong immune response and an acceptable safety profile. They are essential tools in preventing various infectious diseases and improving overall public health.

I'm sorry for any confusion, but "Mali" is not a medical term or condition in English. Mali is the name of a country located in West Africa, and its capital city is Bamako. If you have any questions about Mali or anything else, please let me know!

Parasitemia is a medical term that refers to the presence of parasites, particularly malaria-causing Plasmodium species, in the bloodstream. It is the condition where red blood cells are infected by these parasites, which can lead to various symptoms such as fever, chills, anemia, and organ damage in severe cases. The level of parasitemia is often used to assess the severity of malaria infection and to guide treatment decisions.

Bacterial vaccines are types of vaccines that are created using bacteria or parts of bacteria as the immunogen, which is the substance that triggers an immune response in the body. The purpose of a bacterial vaccine is to stimulate the immune system to develop protection against specific bacterial infections.

There are several types of bacterial vaccines, including:

1. Inactivated or killed whole-cell vaccines: These vaccines contain entire bacteria that have been killed or inactivated through various methods, such as heat or chemicals. The bacteria can no longer cause disease, but they still retain the ability to stimulate an immune response.
2. Subunit, protein, or polysaccharide vaccines: These vaccines use specific components of the bacterium, such as proteins or polysaccharides, that are known to trigger an immune response. By using only these components, the vaccine can avoid using the entire bacterium, which may reduce the risk of adverse reactions.
3. Live attenuated vaccines: These vaccines contain live bacteria that have been weakened or attenuated so that they cannot cause disease but still retain the ability to stimulate an immune response. This type of vaccine can provide long-lasting immunity, but it may not be suitable for people with weakened immune systems.

Bacterial vaccines are essential tools in preventing and controlling bacterial infections, reducing the burden of diseases such as tuberculosis, pneumococcal disease, meningococcal disease, and Haemophilus influenzae type b (Hib) disease. They work by exposing the immune system to a harmless form of the bacteria or its components, which triggers the production of antibodies and memory cells that can recognize and fight off future infections with that same bacterium.

It's important to note that while vaccines are generally safe and effective, they may cause mild side effects such as pain, redness, or swelling at the injection site, fever, or fatigue. Serious side effects are rare but can occur, so it's essential to consult with a healthcare provider before receiving any vaccine.

Vaccination is a simple, safe, and effective way to protect people against harmful diseases, before they come into contact with them. It uses your body's natural defenses to build protection to specific infections and makes your immune system stronger.

A vaccination usually contains a small, harmless piece of a virus or bacteria (or toxins produced by these germs) that has been made inactive or weakened so it won't cause the disease itself. This piece of the germ is known as an antigen. When the vaccine is introduced into the body, the immune system recognizes the antigen as foreign and produces antibodies to fight it.

If a person then comes into contact with the actual disease-causing germ, their immune system will recognize it and immediately produce antibodies to destroy it. The person is therefore protected against that disease. This is known as active immunity.

Vaccinations are important for both individual and public health. They prevent the spread of contagious diseases and protect vulnerable members of the population, such as young children, the elderly, and people with weakened immune systems who cannot be vaccinated or for whom vaccination is not effective.

"Plasmodium vivax" is a species of protozoan parasite that causes malaria in humans. It's one of the five malaria parasites that can infect humans, with P. falciparum being the most deadly.

P. vivax typically enters the human body through the bite of an infected Anopheles mosquito. Once inside the human host, the parasite travels to the liver where it multiplies and matures. After a period of development that can range from weeks to several months, the mature parasites are released into the bloodstream, where they infect red blood cells and continue to multiply.

The symptoms of P. vivax malaria include fever, chills, headache, muscle and joint pain, and fatigue. One distinctive feature of P. vivax is its ability to form dormant stages (hypnozoites) in the liver, which can reactivate and cause relapses of the disease months or even years after the initial infection.

P. vivax malaria is treatable with medications such as chloroquine, but resistance to this drug has been reported in some parts of the world. Prevention measures include using insecticide-treated bed nets and indoor residual spraying to reduce mosquito populations, as well as taking prophylactic medications for travelers visiting areas where malaria is common.

'Plasmodium yoelii' is a species of protozoan parasite belonging to the genus Plasmodium, which causes malaria in rodents. It is primarily used as a model organism in malaria research due to its similarity to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. The life cycle of P. yoelii involves two hosts: an Anopheles mosquito vector and a rodent host. The parasite undergoes asexual reproduction in the red blood cells of the rodent host, leading to the symptoms of malaria such as fever, anemia, and organ failure if left untreated. P. yoelii is not known to infect humans.

An AIDS vaccine is a type of preventive vaccine that aims to stimulate the immune system to produce an effective response against the human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS). The goal of an AIDS vaccine is to induce the production of immune cells and proteins that can recognize and eliminate HIV-infected cells, thereby preventing the establishment of a persistent infection.

Despite decades of research, there is still no licensed AIDS vaccine available. This is due in part to the unique challenges posed by HIV, which has a high mutation rate and can rapidly evolve to evade the immune system's defenses. However, several promising vaccine candidates are currently being tested in clinical trials around the world, and researchers continue to explore new approaches and strategies for developing an effective AIDS vaccine.

Antimalarials are a class of drugs that are used for the prevention, treatment, and elimination of malaria. They work by targeting the malaria parasite at various stages of its life cycle, particularly the erythrocytic stage when it infects red blood cells. Some commonly prescribed antimalarials include chloroquine, hydroxychloroquine, quinine, mefloquine, and artemisinin-based combinations. These drugs can be used alone or in combination with other antimalarial agents to increase their efficacy and prevent the development of drug resistance. Antimalarials are also being investigated for their potential use in treating other diseases, such as autoimmune disorders and cancer.

'Anopheles' is a genus of mosquitoes that are known for their role in transmitting malaria parasites to humans. These mosquitoes have a distinctive resting posture, with their abdomens raised and heads down, and they typically feed on human hosts at night. Only female Anopheles mosquitoes transmit the malaria parasite, as they require blood meals to lay eggs.

There are over 400 species of Anopheles mosquitoes worldwide, but only about 30-40 of these are considered significant vectors of human malaria. The distribution and behavior of these mosquitoes can vary widely depending on the specific species and geographic location.

Preventing and controlling the spread of malaria involves a variety of strategies, including the use of insecticide-treated bed nets, indoor residual spraying, antimalarial drugs, and vaccines. Public health efforts to reduce the burden of malaria have made significant progress in recent decades, but the disease remains a major global health challenge, particularly in sub-Saharan Africa.

Conjugate vaccines are a type of vaccine that combines a part of a bacterium with a protein or other substance to boost the body's immune response to the bacteria. The bacterial component is usually a polysaccharide, which is a long chain of sugars that makes up part of the bacterial cell wall.

By itself, a polysaccharide is not very immunogenic, meaning it does not stimulate a strong immune response. However, when it is conjugated or linked to a protein or other carrier molecule, it becomes much more immunogenic and can elicit a stronger and longer-lasting immune response.

Conjugate vaccines are particularly effective in protecting against bacterial infections that affect young children, such as Haemophilus influenzae type b (Hib) and pneumococcal disease. These vaccines have been instrumental in reducing the incidence of these diseases and their associated complications, such as meningitis and pneumonia.

Overall, conjugate vaccines work by mimicking a natural infection and stimulating the immune system to produce antibodies that can protect against future infections with the same bacterium. By combining a weakly immunogenic polysaccharide with a protein carrier, these vaccines can elicit a stronger and more effective immune response, providing long-lasting protection against bacterial infections.

Aluminum hydroxide is a medication that contains the active ingredient aluminum hydroxide, which is an inorganic compound. It is commonly used as an antacid to neutralize stomach acid and relieve symptoms of acid reflux and heartburn. Aluminum hydroxide works by reacting with the acid in the stomach to form a physical barrier that prevents the acid from backing up into the esophagus.

In addition to its use as an antacid, aluminum hydroxide is also used as a phosphate binder in patients with kidney disease. It works by binding to phosphate in the gut and preventing it from being absorbed into the bloodstream, which can help to control high phosphate levels in the body.

Aluminum hydroxide is available over-the-counter and by prescription in various forms, including tablets, capsules, and liquid suspensions. It is important to follow the dosage instructions carefully and to talk to a healthcare provider if symptoms persist or worsen.

Immunologic adjuvants are substances that are added to a vaccine to enhance the body's immune response to the antigens contained in the vaccine. They work by stimulating the immune system and promoting the production of antibodies and activating immune cells, such as T-cells and macrophages, which help to provide a stronger and more sustained immune response to the vaccine.

Immunologic adjuvants can be derived from various sources, including bacteria, viruses, and chemicals. Some common examples include aluminum salts (alum), oil-in-water emulsions (such as MF59), and bacterial components (such as lipopolysaccharide or LPS).

The use of immunologic adjuvants in vaccines can help to improve the efficacy of the vaccine, particularly for vaccines that contain weak or poorly immunogenic antigens. They can also help to reduce the amount of antigen needed in a vaccine, which can be beneficial for vaccines that are difficult or expensive to produce.

It's important to note that while adjuvants can enhance the immune response to a vaccine, they can also increase the risk of adverse reactions, such as inflammation and pain at the injection site. Therefore, the use of immunologic adjuvants must be carefully balanced against their potential benefits and risks.

"Plasmodium berghei" is a species of protozoan parasites belonging to the genus Plasmodium, which are the causative agents of malaria. This particular species primarily infects rodents and is not known to naturally infect humans. However, it is widely used in laboratory settings as a model organism to study malaria and develop potential interventions, such as drugs and vaccines, due to its similarities with human-infecting Plasmodium species.

The life cycle of P. berghei involves two hosts: an Anopheles mosquito vector and a rodent host. The parasite undergoes asexual reproduction in the red blood cells of the rodent host, leading to the symptoms of malaria, such as fever, anemia, and organ damage. When an infected mosquito bites another rodent, the parasites are transmitted through the saliva and infect the new host, continuing the life cycle.

While P. berghei is not a direct threat to human health, studying this species has contributed significantly to our understanding of malaria biology and the development of potential interventions against this devastating disease.

Rabies vaccines are medical products that contain antigens of the rabies virus, which stimulate an immune response in individuals who receive them. The purpose of rabies vaccines is to prevent the development of rabies, a viral disease that is almost always fatal once symptoms appear.

There are two primary types of rabies vaccines available:

1. Pre-exposure prophylaxis (PrEP) vaccines: These vaccines are given to individuals who are at high risk of coming into contact with the rabies virus, such as veterinarians, animal handlers, and travelers visiting areas where rabies is common. The vaccine series typically consists of three doses given over a period of 28 days.
2. Post-exposure prophylaxis (PEP) vaccines: These vaccines are administered to individuals who have already been exposed to the rabies virus, usually through a bite or scratch from an infected animal. The vaccine series typically consists of four doses given over a period of 14 days, along with a dose of rabies immune globulin (RIG) to provide immediate protection while the immune system responds to the vaccine.

Both types of rabies vaccines are highly effective at preventing the disease, but it is essential to receive them as soon as possible after exposure or before potential exposure, as the virus can be fatal if left untreated.

I'm sorry for any confusion, but "Kenya" is not a medical term. It is the name of a country located in East Africa, known for its diverse wildlife and geography, including savannas, lakelands, the dramatic Great Rift Valley, and mountain highlands. It is also where you can find the Maasai Mara Reserve, known for its annual wildebeest migrations, and vast Nairobi National Park. The capital city of Kenya is Nairobi. If you have any questions about medical terms or concepts, I would be happy to help with those!

Merozoites are infective forms of certain protozoan parasites, including those that cause malaria. They are produced during the asexual reproduction of these parasites within the red blood cells of their hosts. Merozoites are released from the infected red blood cells when they rupture and can then invade other red blood cells to continue the cycle of infection. These organisms have an outer membrane that allows them to interact with and invade host cells, and they contain proteins on their surface that help them evade the host's immune system. Merozoites are typically small, oval-shaped structures that measure around 1 micrometer in diameter.

An endemic disease is a type of disease that is regularly found among particular people or in a certain population, and is spread easily from person to person. The rate of infection is consistently high in these populations, but it is relatively stable and does not change dramatically over time. Endemic diseases are contrasted with epidemic diseases, which suddenly increase in incidence and spread rapidly through a large population.

Endemic diseases are often associated with poverty, poor sanitation, and limited access to healthcare. They can also be influenced by environmental factors such as climate, water quality, and exposure to vectors like mosquitoes or ticks. Examples of endemic diseases include malaria in some tropical countries, tuberculosis (TB) in many parts of the world, and HIV/AIDS in certain populations.

Effective prevention and control measures for endemic diseases typically involve improving access to healthcare, promoting good hygiene and sanitation practices, providing vaccinations when available, and implementing vector control strategies. By addressing the underlying social and environmental factors that contribute to the spread of these diseases, it is possible to reduce their impact on affected populations and improve overall health outcomes.

Papillomavirus vaccines are vaccines that have been developed to prevent infection by human papillomaviruses (HPV). HPV is a DNA virus that is capable of infecting the skin and mucous membranes. Certain types of HPV are known to cause cervical cancer, as well as other types of cancer such as anal, penile, vulvar, and oropharyngeal cancers. Other types of HPV can cause genital warts.

There are currently two papillomavirus vaccines that have been approved for use in the United States: Gardasil and Cervarix. Both vaccines protect against the two most common cancer-causing types of HPV (types 16 and 18), which together cause about 70% of cervical cancers. Gardasil also protects against the two most common types of HPV that cause genital warts (types 6 and 11).

Papillomavirus vaccines are given as a series of three shots over a period of six months. They are most effective when given to people before they become sexually active, as this reduces the risk of exposure to HPV. The Centers for Disease Control and Prevention (CDC) recommends that all boys and girls get vaccinated against HPV at age 11 or 12, but the vaccine can be given to people as young as age 9 and as old as age 26.

It is important to note that papillomavirus vaccines do not protect against all types of HPV, and they do not treat existing HPV infections or cervical cancer. They are intended to prevent new HPV infections and the cancers and other diseases that can be caused by HPV.

I'm sorry for any confusion, but the term "Africa" actually refers to a continent, not a medical condition or concept. Africa is the second-largest continent in the world, consisting of 54 countries and a wide range of diverse ethnic groups, cultures, languages, and landscapes. It is home to a vast array of wildlife, including many species that are not found anywhere else in the world. If you have any questions about Africa's geography, history, or culture, I would be happy to try to help answer them!

I'm sorry for any confusion, but "Mozambique" is not a medical term or concept. It is the name of a country located in Southeast Africa, known officially as the Republic of Mozambique. If you have any questions related to medicine or healthcare, I would be happy to try and help answer those for you.

Secondary immunization, also known as "anamnestic response" or "booster," refers to the enhanced immune response that occurs upon re-exposure to an antigen, having previously been immunized or infected with the same pathogen. This response is characterized by a more rapid and robust production of antibodies and memory cells compared to the primary immune response. The secondary immunization aims to maintain long-term immunity against infectious diseases and improve vaccine effectiveness. It usually involves administering additional doses of a vaccine or booster shots after the initial series of immunizations, which helps reinforce the immune system's ability to recognize and combat specific pathogens.

"Plasmodium chabaudi" is a species of parasitic protozoa belonging to the genus Plasmodium, which includes the causative agents of malaria in various animals and humans. "P. chabaudi" primarily infects rodents, particularly mice, and serves as a model organism for studying the fundamental biology and pathogenesis of malaria.

The life cycle of "P. chabaudi" involves both sexual and asexual reproduction, similar to other Plasmodium species. The parasite is transmitted through the bite of an infected Anopheles mosquito, which injects sporozoites into the host's bloodstream. These sporozoites then infect liver cells, where they undergo schizogony (asexual reproduction) and produce merozoites.

Merozoites released from the liver invade red blood cells, initiating the erythrocytic stage of the life cycle. Within the red blood cells, the parasites multiply by schizogony, forming new merozoites that are eventually released to infect other red blood cells. Some of these parasites differentiate into male and female gametocytes, which can be taken up by a mosquito during a blood meal, completing the life cycle.

"P. chabaudi" infections in mice can lead to various pathological changes, including anemia, splenomegaly (enlarged spleen), and immune responses that contribute to disease progression. Researchers use this model organism to investigate aspects of malaria biology, such as host-parasite interactions, immunity, drug development, and vaccine design.

Immunoglobulin G (IgG) is a type of antibody, which is a protective protein produced by the immune system in response to foreign substances like bacteria or viruses. IgG is the most abundant type of antibody in human blood, making up about 75-80% of all antibodies. It is found in all body fluids and plays a crucial role in fighting infections caused by bacteria, viruses, and toxins.

IgG has several important functions:

1. Neutralization: IgG can bind to the surface of bacteria or viruses, preventing them from attaching to and infecting human cells.
2. Opsonization: IgG coats the surface of pathogens, making them more recognizable and easier for immune cells like neutrophils and macrophages to phagocytose (engulf and destroy) them.
3. Complement activation: IgG can activate the complement system, a group of proteins that work together to help eliminate pathogens from the body. Activation of the complement system leads to the formation of the membrane attack complex, which creates holes in the cell membranes of bacteria, leading to their lysis (destruction).
4. Antibody-dependent cellular cytotoxicity (ADCC): IgG can bind to immune cells like natural killer (NK) cells and trigger them to release substances that cause target cells (such as virus-infected or cancerous cells) to undergo apoptosis (programmed cell death).
5. Immune complex formation: IgG can form immune complexes with antigens, which can then be removed from the body through various mechanisms, such as phagocytosis by immune cells or excretion in urine.

IgG is a critical component of adaptive immunity and provides long-lasting protection against reinfection with many pathogens. It has four subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their structure, function, and distribution in the body.

Immunization is defined medically as the process where an individual is made immune or resistant to an infectious disease, typically through the administration of a vaccine. The vaccine stimulates the body's own immune system to recognize and fight off the specific disease-causing organism, thereby preventing or reducing the severity of future infections with that organism.

Immunization can be achieved actively, where the person is given a vaccine to trigger an immune response, or passively, where antibodies are transferred to the person through immunoglobulin therapy. Immunizations are an important part of preventive healthcare and have been successful in controlling and eliminating many infectious diseases worldwide.

Meningococcal vaccines are vaccines that protect against Neisseria meningitidis, a type of bacteria that can cause serious infections such as meningitis (inflammation of the lining of the brain and spinal cord) and septicemia (bloodstream infection). There are several types of meningococcal vaccines available, including conjugate vaccines and polysaccharide vaccines. These vaccines work by stimulating the immune system to produce antibodies that can protect against the different serogroups of N. meningitidis, including A, B, C, Y, and W-135. The specific type of vaccine used and the number of doses required may depend on a person's age, health status, and other factors. Meningococcal vaccines are recommended for certain high-risk populations, such as infants, young children, adolescents, and people with certain medical conditions, as well as for travelers to areas where meningococcal disease is common.

Virosomes are artificially constructed spherical vesicles composed of lipids and viral envelope proteins. They are used as a delivery system for vaccines and other therapeutic agents. In the context of vaccines, virosomes can be used to present viral antigens to the immune system in a way that mimics a natural infection, thereby inducing a strong immune response.

Virosome-based vaccines have several advantages over traditional vaccines. For example, they are non-infectious, meaning they do not contain live or attenuated viruses, which makes them safer for certain populations such as immunocompromised individuals. Additionally, virosomes can be engineered to target specific cells in the body, leading to more efficient uptake and presentation of antigens to the immune system.

Virosome-based vaccines have been developed for a variety of diseases, including influenza, hepatitis A, and HIV. While they are not yet widely used, they show promise as a safe and effective alternative to traditional vaccine approaches.

I'm sorry for any confusion, but "Tanzania" is not a medical term. It is the name of a country located in East Africa. If you have any questions about medical terms or conditions, I would be happy to help clarify those for you.

Insect vectors are insects that transmit disease-causing pathogens (such as viruses, bacteria, parasites) from one host to another. They do this while feeding on the host's blood or tissues. The insects themselves are not infected by the pathogen but act as mechanical carriers that pass it on during their bite. Examples of diseases spread by insect vectors include malaria (transmitted by mosquitoes), Lyme disease (transmitted by ticks), and plague (transmitted by fleas). Proper prevention measures, such as using insect repellent and reducing standing water where mosquitoes breed, can help reduce the risk of contracting these diseases.

I'm sorry for any confusion, but "Ghana" is not a medical term. It is the name of a country located in West Africa, known officially as the Republic of Ghana. If you have any questions about medical terms or conditions, I would be happy to help with those!

Erythrocytes, also known as red blood cells (RBCs), are the most common type of blood cell in circulating blood in mammals. They are responsible for transporting oxygen from the lungs to the body's tissues and carbon dioxide from the tissues to the lungs.

Erythrocytes are formed in the bone marrow and have a biconcave shape, which allows them to fold and bend easily as they pass through narrow blood vessels. They do not have a nucleus or mitochondria, which makes them more flexible but also limits their ability to reproduce or repair themselves.

In humans, erythrocytes are typically disc-shaped and measure about 7 micrometers in diameter. They contain the protein hemoglobin, which binds to oxygen and gives blood its red color. The lifespan of an erythrocyte is approximately 120 days, after which it is broken down in the liver and spleen.

Abnormalities in erythrocyte count or function can lead to various medical conditions, such as anemia, polycythemia, and sickle cell disease.

BALB/c is an inbred strain of laboratory mouse that is widely used in biomedical research. The strain was developed at the Institute of Cancer Research in London by Henry Baldwin and his colleagues in the 1920s, and it has since become one of the most commonly used inbred strains in the world.

BALB/c mice are characterized by their black coat color, which is determined by a recessive allele at the tyrosinase locus. They are also known for their docile and friendly temperament, making them easy to handle and work with in the laboratory.

One of the key features of BALB/c mice that makes them useful for research is their susceptibility to certain types of tumors and immune responses. For example, they are highly susceptible to developing mammary tumors, which can be induced by chemical carcinogens or viral infection. They also have a strong Th2-biased immune response, which makes them useful models for studying allergic diseases and asthma.

BALB/c mice are also commonly used in studies of genetics, neuroscience, behavior, and infectious diseases. Because they are an inbred strain, they have a uniform genetic background, which makes it easier to control for genetic factors in experiments. Additionally, because they have been bred in the laboratory for many generations, they are highly standardized and reproducible, making them ideal subjects for scientific research.

An immunization schedule is a series of planned dates when a person, usually a child, should receive specific vaccines in order to be fully protected against certain preventable diseases. The schedule is developed based on scientific research and recommendations from health organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).

The immunization schedule outlines which vaccines are recommended, the number of doses required, the age at which each dose should be given, and the minimum amount of time that must pass between doses. The schedule may vary depending on factors such as the individual's age, health status, and travel plans.

Immunization schedules are important for ensuring that individuals receive timely protection against vaccine-preventable diseases, and for maintaining high levels of immunity in populations, which helps to prevent the spread of disease. It is important to follow the recommended immunization schedule as closely as possible to ensure optimal protection.

"Hepatitis B vaccines are vaccines that prevent infection caused by the hepatitis B virus. They work by introducing a small and harmless piece of the virus to your body, which triggers your immune system to produce antibodies to fight off the infection. These antibodies remain in your body and provide protection if you are exposed to the real hepatitis B virus in the future.

The hepatitis B vaccine is typically given as a series of three shots over a six-month period. It is recommended for all infants, children and adolescents who have not previously been vaccinated, as well as for adults who are at increased risk of infection, such as healthcare workers, people who inject drugs, and those with certain medical conditions.

It's important to note that hepatitis B vaccine does not provide protection against other types of viral hepatitis, such as hepatitis A or C."

'Mosquito Control' is not a medical term per se, but it is a public health concept that refers to the systematic reduction or elimination of mosquito populations through various methods to prevent or minimize the transmission of mosquito-borne diseases. This multidisciplinary field involves entomologists, ecologists, engineers, and public health professionals working together to manage mosquito habitats, apply insecticides, and educate communities about personal protection measures. By controlling mosquito populations, we can significantly reduce the risk of contracting vector-borne illnesses such as malaria, dengue fever, yellow fever, Zika virus, and West Nile virus, among others.

Parasitic pregnancy complications refer to a rare condition where a parasitic twin takes over the development of the dominant twin's reproductive system and becomes pregnant. This condition is also known as fetus in fetu or vanishing twin syndrome with a parasitic twin. The parasitic twin may have some organs developed, but it is not fully formed and relies on the dominant twin for survival. The pregnancy can pose risks to the dominant twin, such as abnormal growth patterns, organ damage, and complications during childbirth. This condition is usually detected during prenatal ultrasound examinations.

A measles vaccine is a biological preparation that induces immunity against the measles virus. It contains an attenuated (weakened) strain of the measles virus, which stimulates the immune system to produce antibodies that protect against future infection with the wild-type (disease-causing) virus. Measles vaccines are typically administered in combination with vaccines against mumps and rubella (German measles), forming the MMR vaccine.

The measles vaccine is highly effective, with one or two doses providing immunity in over 95% of people who receive it. It is usually given to children as part of routine childhood immunization programs, with the first dose administered at 12-15 months of age and the second dose at 4-6 years of age.

Measles vaccination has led to a dramatic reduction in the incidence of measles worldwide and is considered one of the greatest public health achievements of the past century. However, despite widespread availability of the vaccine, measles remains a significant cause of morbidity and mortality in some parts of the world, particularly in areas with low vaccination coverage or where access to healthcare is limited.

'Life cycle stages' is a term used in the context of public health and medicine to describe the different stages that an organism goes through during its lifetime. This concept is particularly important in the field of epidemiology, where understanding the life cycle stages of infectious agents (such as bacteria, viruses, parasites) can help inform strategies for disease prevention and control.

The life cycle stages of an infectious agent may include various forms such as spores, cysts, trophozoites, schizonts, or vectors, among others, depending on the specific organism. Each stage may have different characteristics, such as resistance to environmental factors, susceptibility to drugs, and ability to transmit infection.

For example, the life cycle stages of the malaria parasite include sporozoites (the infective form transmitted by mosquitoes), merozoites (the form that infects red blood cells), trophozoites (the feeding stage inside red blood cells), schizonts (the replicating stage inside red blood cells), and gametocytes (the sexual stage that can be taken up by mosquitoes to continue the life cycle).

Understanding the life cycle stages of an infectious agent is critical for developing effective interventions, such as vaccines, drugs, or other control measures. For example, targeting a specific life cycle stage with a drug may prevent transmission or reduce the severity of disease. Similarly, designing a vaccine to elicit immunity against a particular life cycle stage may provide protection against infection or disease.

'Culicidae' is the biological family that includes all species of mosquitoes. It consists of three subfamilies: Anophelinae, Culicinae, and Toxorhynchitinae. Mosquitoes are small, midge-like flies that are known for their ability to transmit various diseases to humans and other animals, such as malaria, yellow fever, dengue fever, and Zika virus. The medical importance of Culicidae comes from the fact that only female mosquitoes require blood meals to lay eggs, and during this process, they can transmit pathogens between hosts.

An Enzyme-Linked Immunosorbent Assay (ELISA) is a type of analytical biochemistry assay used to detect and quantify the presence of a substance, typically a protein or peptide, in a liquid sample. It takes its name from the enzyme-linked antibodies used in the assay.

In an ELISA, the sample is added to a well containing a surface that has been treated to capture the target substance. If the target substance is present in the sample, it will bind to the surface. Next, an enzyme-linked antibody specific to the target substance is added. This antibody will bind to the captured target substance if it is present. After washing away any unbound material, a substrate for the enzyme is added. If the enzyme is present due to its linkage to the antibody, it will catalyze a reaction that produces a detectable signal, such as a color change or fluorescence. The intensity of this signal is proportional to the amount of target substance present in the sample, allowing for quantification.

ELISAs are widely used in research and clinical settings to detect and measure various substances, including hormones, viruses, and bacteria. They offer high sensitivity, specificity, and reproducibility, making them a reliable choice for many applications.

I'm sorry for any confusion, but "Papua New Guinea" is not a medical term or concept. It is the name of a country located in the southwest Pacific Ocean, made up of the eastern half of the island of New Guinea and numerous offshore islands. If you have any questions about medical topics or definitions, I would be happy to help with those!

A Pertussis vaccine is a type of immunization used to protect against pertussis, also known as whooping cough. It contains components that stimulate the immune system to produce antibodies against the bacteria that cause pertussis, Bordetella pertussis. There are two main types of pertussis vaccines: whole-cell pertussis (wP) vaccines and acellular pertussis (aP) vaccines. wP vaccines contain killed whole cells of B. pertussis, while aP vaccines contain specific components of the bacteria, such as pertussis toxin and other antigens. Pertussis vaccines are often combined with diphtheria and tetanus to form combination vaccines, such as DTaP (diphtheria, tetanus, and acellular pertussis) and TdaP (tetanus, diphtheria, and acellular pertussis). These vaccines are typically given to young children as part of their routine immunization schedule.

BCG (Bacillus Calmette-Guérin) vaccine is a type of immunization used primarily to prevent tuberculosis (TB). It contains a live but weakened strain of Mycobacterium bovis, which is related to the bacterium that causes TB in humans (Mycobacterium tuberculosis).

The BCG vaccine works by stimulating an immune response in the body, enabling it to better resist infection with TB bacteria if exposed in the future. It is often given to infants and children in countries where TB is common, and its use varies depending on the national immunization policies. The protection offered by the BCG vaccine is moderate and may not last for a very long time.

In addition to its use against TB, the BCG vaccine has also been investigated for its potential therapeutic role in treating bladder cancer and some other types of cancer. The mechanism of action in these cases is thought to be related to the vaccine's ability to stimulate an immune response against abnormal cells.

Haemophilus vaccines are vaccines that are designed to protect against Haemophilus influenzae type b (Hib), a bacterium that can cause serious infections such as meningitis, pneumonia, and epiglottitis. There are two main types of Hib vaccines:

1. Polysaccharide vaccine: This type of vaccine is made from the sugar coating (polysaccharide) of the bacterial cells. It is not effective in children under 2 years of age because their immune systems are not yet mature enough to respond effectively to this type of vaccine.
2. Conjugate vaccine: This type of vaccine combines the polysaccharide with a protein carrier, which helps to stimulate a stronger and more sustained immune response. It is effective in infants as young as 6 weeks old.

Hib vaccines are usually given as part of routine childhood immunizations starting at 2 months of age. They are administered through an injection into the muscle. The vaccine is safe and effective, with few side effects. Vaccination against Hib has led to a significant reduction in the incidence of Hib infections worldwide.

Poliovirus Vaccine, Inactivated (IPV) is a vaccine used to prevent poliomyelitis (polio), a highly infectious disease caused by the poliovirus. IPV contains inactivated (killed) polioviruses of all three poliovirus types. It works by stimulating an immune response in the body, but because the viruses are inactivated, they cannot cause polio. After vaccination, the immune system recognizes and responds to the inactivated viruses, producing antibodies that protect against future infection with wild, or naturally occurring, polioviruses. IPV is typically given as an injection in the leg or arm, and a series of doses are required for full protection. It is a safe and effective way to prevent polio and its complications.

Rotavirus vaccines are preventive measures used to protect against rotavirus infections, which are the leading cause of severe diarrhea and dehydration among infants and young children worldwide. These vaccines contain weakened or inactivated forms of the rotavirus, a pathogen that infects and causes symptoms by multiplying inside cells lining the small intestine.

The weakened or inactivated virus in the vaccine stimulates an immune response in the body, enabling it to recognize and fight off future rotavirus infections more effectively. The vaccines are usually administered orally, as a liquid droplet or on a sugar cube, to mimic natural infection through the gastrointestinal tract.

There are currently two licensed rotavirus vaccines available globally:

1. Rotarix (GlaxoSmithKline): This vaccine contains an attenuated (weakened) strain of human rotavirus and is given in a two-dose series, typically at 2 and 4 months of age.
2. RotaTeq (Merck): This vaccine contains five reassortant viruses, combining human and animal strains to provide broader protection. It is administered in a three-dose series, usually at 2, 4, and 6 months of age.

Rotavirus vaccines have been shown to significantly reduce the incidence of severe rotavirus gastroenteritis and related hospitalizations among infants and young children. The World Health Organization (WHO) recommends the inclusion of rotavirus vaccination in national immunization programs, particularly in countries with high child mortality rates due to diarrheal diseases.

Aotidae is a family of nocturnal primates also known as lorises or slow lorises. They are native to Southeast Asia and are characterized by their small size, round head, large eyes, and a wet-nosed face. Slow lorises have a toxic bite, which they use to defend themselves against predators. They are currently listed as vulnerable or endangered due to habitat loss and hunting.

Cholera vaccines are preventive measures used to protect against the infection caused by the bacterium Vibrio cholerae. There are several types of cholera vaccines available, including:

1. Inactivated oral vaccine (ICCV): This vaccine contains killed whole-cell bacteria and is given in two doses, with each dose administered at least 14 days apart. It provides protection for up to six months and can be given to adults and children over the age of one year.
2. Live attenuated oral vaccine (LCV): This vaccine contains weakened live bacteria that are unable to cause disease but still stimulate an immune response. The most commonly used LCV is called CVD 103-HgR, which is given in a single dose and provides protection for up to three months. It can be given to adults and children over the age of six years.
3. Injectable cholera vaccine: This vaccine contains inactivated bacteria and is given as an injection. It is not widely available and its effectiveness is limited compared to oral vaccines.

Cholera vaccines are recommended for travelers visiting areas with known cholera outbreaks, particularly if they plan to eat food or drink water that may be contaminated. They can also be used in response to outbreaks to help control the spread of the disease. However, it is important to note that vaccination alone is not sufficient to prevent cholera infection and good hygiene practices, such as handwashing and safe food handling, should always be followed.

Mannitol is a type of sugar alcohol (a sugar substitute) used primarily as a diuretic to reduce brain swelling caused by traumatic brain injury or other causes that induce increased pressure in the brain. It works by drawing water out of the body through the urine. It's also used before surgeries in the heart, lungs, and kidneys to prevent fluid buildup.

In addition, mannitol is used in medical laboratories as a medium for growing bacteria and other microorganisms, and in some types of chemical research. In the clinic, it is also used as an osmotic agent in eye drops to reduce the pressure inside the eye in conditions such as glaucoma.

It's important to note that mannitol should be used with caution in patients with heart or kidney disease, as well as those who are dehydrated, because it can lead to electrolyte imbalances and other complications.

I'm sorry for any confusion, but "Gambia" is not a medical term. It is the name of a country located in West Africa, officially known as the Republic of The Gambia. If you have any questions about medical terminology or health-related topics, I would be happy to try and help answer those for you.

Insect bites and stings refer to the penetration of the skin by insects, such as mosquitoes, fleas, ticks, or bees, often resulting in localized symptoms including redness, swelling, itching, and pain. The reaction can vary depending on the individual's sensitivity and the type of insect. In some cases, systemic reactions like anaphylaxis may occur, which requires immediate medical attention. Treatment typically involves relieving symptoms with topical creams, antihistamines, or in severe cases, epinephrine. Prevention measures include using insect repellent and protective clothing.

Alum compounds are a type of double sulfate salt, typically consisting of aluminum sulfate and another metal sulfate. The most common variety is potassium alum, or potassium aluminum sulfate (KAl(SO4)2·12H2O). Alum compounds have a wide range of uses, including water purification, tanning leather, dyeing and printing textiles, and as a food additive for baking powder and pickling. They are also used in medicine as astringents to reduce bleeding and swelling, and to soothe skin irritations. Alum compounds have the ability to make proteins in living cells become more stable, which can be useful in medical treatments.

Clinical trials are research studies that involve human participants and are designed to evaluate the safety and efficacy of new medical treatments, drugs, devices, or behavioral interventions. The purpose of clinical trials is to determine whether a new intervention is safe, effective, and beneficial for patients, as well as to compare it with currently available treatments. Clinical trials follow a series of phases, each with specific goals and criteria, before a new intervention can be approved by regulatory authorities for widespread use.

Clinical trials are conducted according to a protocol, which is a detailed plan that outlines the study's objectives, design, methodology, statistical analysis, and ethical considerations. The protocol is developed and reviewed by a team of medical experts, statisticians, and ethicists, and it must be approved by an institutional review board (IRB) before the trial can begin.

Participation in clinical trials is voluntary, and participants must provide informed consent before enrolling in the study. Informed consent involves providing potential participants with detailed information about the study's purpose, procedures, risks, benefits, and alternatives, as well as their rights as research subjects. Participants can withdraw from the study at any time without penalty or loss of benefits to which they are entitled.

Clinical trials are essential for advancing medical knowledge and improving patient care. They help researchers identify new treatments, diagnostic tools, and prevention strategies that can benefit patients and improve public health. However, clinical trials also pose potential risks to participants, including adverse effects from experimental interventions, time commitment, and inconvenience. Therefore, it is important for researchers to carefully design and conduct clinical trials to minimize risks and ensure that the benefits outweigh the risks.

"Plasmodium knowlesi" is a species of protozoan parasite that causes malaria in certain primates, particularly macaques. It can also infect humans, and has been identified as a significant cause of malaria in Southeast Asia. The life cycle of P. knowlesi involves two hosts: anopheline mosquitoes and primates. The parasite is transmitted to the host through the bite of an infected mosquito, and then invades and reproduces within the host's red blood cells, leading to symptoms such as fever, chills, headache, and muscle and joint pain. In severe cases, P. knowlesi infections can lead to complications such as respiratory distress, kidney failure, and coma.

It is important to note that "Plasmodium knowlesi" malaria is different from the more common forms of human malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae. P. knowlesi infections can be effectively treated with antimalarial drugs, but early diagnosis and prompt treatment are crucial to prevent severe disease and complications.

I'm sorry for any confusion, but "Gabon" is not a medical term. It is the name of a country located in Central Africa, known officially as the Gabonese Republic. If you have any questions about medical terminology or health-related topics, I would be happy to help with those!

I apologize for any confusion, but "Burkina Faso" is not a medical term or concept. It is the name of a country located in West Africa. The name "Burkina Faso" translates to "Land of Incorruptible People" in Mossi and Dioula, two languages spoken in the region. The country was known as Upper Volta when it gained independence from France in 1960. It was renamed Burkina Faso in 1984 by then-President Thomas Sankara, who aimed to promote a sense of national identity and unity among the diverse population.

Burkina Faso is a landlocked country with a population of around 21 million people (as of 2021). It shares borders with six countries: Mali to the northwest, Niger to the northeast, Benin to the southeast, Togo and Ghana to the south, and Côte d'Ivoire to the southwest. The capital city is Ouagadougou.

The primary languages spoken in Burkina Faso are French (the official language), Mooré, Dioula, Fula, and Gourmanchéma. The country has a diverse cultural heritage with numerous ethnic groups, including the Mossi, Fulani, Bobo, Gurunsi, Senufo, and Lobi.

Burkina Faso faces various challenges, such as poverty, food insecurity, limited access to education, and health issues like malaria, HIV/AIDS, and neglected tropical diseases. The country also struggles with political instability and security threats from extremist groups operating in the Sahel region.

Typhoid-Paratyphoid vaccines are immunizations that protect against typhoid fever and paratyphoid fevers, which are caused by the Salmonella enterica serovars Typhi and Paratyphi, respectively. These vaccines contain inactivated or attenuated bacteria or specific antigens that stimulate an individual's immune system to develop immunity against these diseases without causing the illness itself. There are several types of typhoid-paratyphoid vaccines available, including:

1. Ty21a (oral live attenuated vaccine): This is a live but weakened form of the Salmonella Typhi bacteria. It is given orally in capsule form and requires a series of 4 doses taken every other day. The vaccine provides protection for about 5-7 years.
2. Vi polysaccharide (ViPS) typhoid vaccine: This vaccine contains purified Vi antigens from the Salmonella Typhi bacterium's outer capsular layer. It is given as an injection and provides protection for approximately 2-3 years.
3. Combined typhoid-paratyphoid A and B vaccines (Vi-rEPA): This vaccine combines Vi polysaccharide antigens from Salmonella Typhi and Paratyphi A and B. It is given as an injection and provides protection for about 3 years against typhoid fever and paratyphoid fevers A and B.
4. Typhoid conjugate vaccines (TCVs): These vaccines combine the Vi polysaccharide antigen from Salmonella Typhi with a protein carrier to enhance the immune response, particularly in children under 2 years of age. TCVs are given as an injection and provide long-lasting protection against typhoid fever.

It is important to note that none of these vaccines provides 100% protection, but they significantly reduce the risk of contracting typhoid or paratyphoid fevers. Additionally, good hygiene practices, such as handwashing and safe food handling, can further minimize the risk of infection.

A drug combination refers to the use of two or more drugs in combination for the treatment of a single medical condition or disease. The rationale behind using drug combinations is to achieve a therapeutic effect that is superior to that obtained with any single agent alone, through various mechanisms such as:

* Complementary modes of action: When different drugs target different aspects of the disease process, their combined effects may be greater than either drug used alone.
* Synergistic interactions: In some cases, the combination of two or more drugs can result in a greater-than-additive effect, where the total response is greater than the sum of the individual responses to each drug.
* Antagonism of adverse effects: Sometimes, the use of one drug can mitigate the side effects of another, allowing for higher doses or longer durations of therapy.

Examples of drug combinations include:

* Highly active antiretroviral therapy (HAART) for HIV infection, which typically involves a combination of three or more antiretroviral drugs to suppress viral replication and prevent the development of drug resistance.
* Chemotherapy regimens for cancer treatment, where combinations of cytotoxic agents are used to target different stages of the cell cycle and increase the likelihood of tumor cell death.
* Fixed-dose combination products, such as those used in the treatment of hypertension or type 2 diabetes, which combine two or more active ingredients into a single formulation for ease of administration and improved adherence to therapy.

However, it's important to note that drug combinations can also increase the risk of adverse effects, drug-drug interactions, and medication errors. Therefore, careful consideration should be given to the selection of appropriate drugs, dosing regimens, and monitoring parameters when using drug combinations in clinical practice.

There doesn't seem to be a specific medical definition for "DNA, protozoan" as it is simply a reference to the DNA found in protozoa. Protozoa are single-celled eukaryotic organisms that can be found in various environments such as soil, water, and the digestive tracts of animals.

Protozoan DNA refers to the genetic material present in these organisms. It is composed of nucleic acids, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), which contain the instructions for the development, growth, and reproduction of the protozoan.

The DNA in protozoa, like in other organisms, is made up of two strands of nucleotides that coil together to form a double helix. The four nucleotide bases that make up protozoan DNA are adenine (A), thymine (T), guanine (G), and cytosine (C). These bases pair with each other to form the rungs of the DNA ladder, with A always pairing with T and G always pairing with C.

The genetic information stored in protozoan DNA is encoded in the sequence of these nucleotide bases. This information is used to synthesize proteins, which are essential for the structure and function of the organism's cells. Protozoan DNA also contains other types of genetic material, such as regulatory sequences that control gene expression and repetitive elements with no known function.

Understanding the DNA of protozoa is important for studying their biology, evolution, and pathogenicity. It can help researchers develop new treatments for protozoan diseases and gain insights into the fundamental principles of genetics and cellular function.

Host-parasite interactions refer to the relationship between a parasitic organism (the parasite) and its host, which can be an animal, plant, or human body. The parasite lives on or inside the host and derives nutrients from it, often causing harm in the process. This interaction can range from relatively benign to severe, depending on various factors such as the species of the parasite, the immune response of the host, and the duration of infection.

The host-parasite relationship is often categorized based on the degree of harm caused to the host. Parasites that cause little to no harm are called commensals, while those that cause significant damage or disease are called parasitic pathogens. Some parasites can even manipulate their hosts' behavior and physiology to enhance their own survival and reproduction, leading to complex interactions between the two organisms.

Understanding host-parasite interactions is crucial for developing effective strategies to prevent and treat parasitic infections, as well as for understanding the ecological relationships between different species in natural ecosystems.

The Smallpox vaccine is not a live virus vaccine but is instead made from a vaccinia virus, which is a virus related to the variola virus (the virus that causes smallpox). The vaccinia virus used in the vaccine does not cause smallpox, but it does cause a milder illness with symptoms such as a fever and a rash of pustules or blisters at the site of inoculation.

The smallpox vaccine was first developed by Edward Jenner in 1796 and is one of the oldest vaccines still in use today. It has been highly effective in preventing smallpox, which was once a major cause of death and disability worldwide. In fact, smallpox was declared eradicated by the World Health Organization (WHO) in 1980, thanks in large part to the widespread use of the smallpox vaccine.

Despite the eradication of smallpox, the smallpox vaccine is still used today in certain circumstances. For example, it may be given to laboratory workers who handle the virus or to military personnel who may be at risk of exposure to the virus. The vaccine may also be used as an emergency measure in the event of a bioterrorism attack involving smallpox.

It is important to note that the smallpox vaccine is not without risks and can cause serious side effects, including a severe allergic reaction (anaphylaxis), encephalitis (inflammation of the brain), and myocarditis (inflammation of the heart muscle). As a result, it is only given to people who are at high risk of exposure to the virus and who have been determined to be good candidates for vaccination by a healthcare professional.

I'm sorry for any confusion, but there seems to be a mistake in your question. Avian malaria is a disease that affects birds, not humans. It is caused by parasites from the genus Plasmodium, which are different than the ones causing human malaria (Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae).

Avian malaria is not a significant public health concern, and it's not transmitted to humans through mosquitoes or any other means. However, it can have serious impacts on bird populations.

A tuberculosis vaccine, also known as the BCG (Bacillus Calmette-Guérin) vaccine, is a type of immunization used to prevent tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. The BCG vaccine contains a weakened strain of the bacteria that causes TB in cattle.

The BCG vaccine works by stimulating an immune response in the body, which helps to protect against severe forms of TB, such as TB meningitis and TB in children. However, it is not very effective at preventing pulmonary TB (TB that affects the lungs) in adults.

The BCG vaccine is not routinely recommended for use in the United States due to the low risk of TB infection in the general population. However, it may be given to people who are at high risk of exposure to TB, such as healthcare workers, laboratory personnel, and people traveling to countries with high rates of TB.

It is important to note that the BCG vaccine does not provide complete protection against TB and that other measures, such as testing and treatment for latent TB infection, are also important for controlling the spread of this disease.

Antibodies, viral are proteins produced by the immune system in response to an infection with a virus. These antibodies are capable of recognizing and binding to specific antigens on the surface of the virus, which helps to neutralize or destroy the virus and prevent its replication. Once produced, these antibodies can provide immunity against future infections with the same virus.

Viral antibodies are typically composed of four polypeptide chains - two heavy chains and two light chains - that are held together by disulfide bonds. The binding site for the antigen is located at the tip of the Y-shaped structure, formed by the variable regions of the heavy and light chains.

There are five classes of antibodies in humans: IgA, IgD, IgE, IgG, and IgM. Each class has a different function and is distributed differently throughout the body. For example, IgG is the most common type of antibody found in the bloodstream and provides long-term immunity against viruses, while IgA is found primarily in mucous membranes and helps to protect against respiratory and gastrointestinal infections.

In addition to their role in the immune response, viral antibodies can also be used as diagnostic tools to detect the presence of a specific virus in a patient's blood or other bodily fluids.

An epitope is a specific region on an antigen (a substance that triggers an immune response) that is recognized and bound by an antibody or a B-lymphocyte (a type of white blood cell that produces antibodies). Epitopes are also sometimes referred to as antigenic determinants.

B-lymphocytes, or B cells, are a type of immune cell that plays a key role in the humoral immune response. They produce and secrete antibodies, which are proteins that recognize and bind to specific epitopes on antigens. When a B cell encounters an antigen, it binds to the antigen at its surface receptor, which recognizes a specific epitope on the antigen. This binding activates the B cell, causing it to divide and differentiate into plasma cells, which produce and secrete large amounts of antibody that is specific for the epitope on the antigen.

The ability of an antibody or a B cell to recognize and bind to a specific epitope is determined by the structure of the variable region of the antibody or B cell receptor. The variable region is made up of several loops of amino acids, called complementarity-determining regions (CDRs), that form a binding site for the antigen. The CDRs are highly variable in sequence and length, allowing them to recognize and bind to a wide variety of different epitopes.

In summary, an epitope is a specific region on an antigen that is recognized and bound by an antibody or a B-lymphocyte. The ability of an antibody or a B cell to recognize and bind to a specific epitope is determined by the structure of the variable region of the antibody or B cell receptor.

The Diphtheria-Tetanus-Pertussis (DTaP) vaccine is a combination immunization that protects against three bacterial diseases: diphtheria, tetanus (lockjaw), and pertussis (whooping cough).

Diphtheria is an upper respiratory infection that can lead to breathing difficulties, heart failure, paralysis, or even death. Tetanus is a bacterial infection that affects the nervous system and causes muscle stiffness and spasms, leading to "lockjaw." Pertussis is a highly contagious respiratory infection characterized by severe coughing fits, which can make it difficult to breathe and may lead to pneumonia, seizures, or brain damage.

The DTaP vaccine contains inactivated toxins (toxoids) from the bacteria that cause these diseases. It is typically given as a series of five shots, with doses administered at 2 months, 4 months, 6 months, 15-18 months, and 4-6 years of age. The vaccine helps the immune system develop protection against the diseases without causing the actual illness.

It is important to note that there are other combination vaccines available that protect against these same diseases, such as DT (diphtheria and tetanus toxoids) and Tdap (tetanus, diphtheria, and acellular pertussis), which contain higher doses of the diphtheria and pertussis components. These vaccines are recommended for different age groups and may be used as booster shots to maintain immunity throughout adulthood.

The chickenpox vaccine, also known as varicella vaccine, is a preventive measure against the highly contagious viral infection caused by the varicella-zoster virus. The vaccine contains a live but weakened form of the virus, which stimulates the immune system to produce a response without causing the disease itself.

The chickenpox vaccine is typically given in two doses, with the first dose administered between 12 and 15 months of age and the second dose between 4 and 6 years of age. In some cases, the vaccine may be given to older children, adolescents, or adults who have not previously been vaccinated or who have never had chickenpox.

The chickenpox vaccine is highly effective at preventing severe cases of the disease and reducing the risk of complications such as bacterial infections, pneumonia, and encephalitis. It is also effective at preventing transmission of the virus to others.

Like any vaccine, the chickenpox vaccine can cause mild side effects such as soreness at the injection site, fever, or a mild rash. However, these side effects are generally mild and short-lived. Serious side effects are rare but may include allergic reactions or severe immune responses.

Overall, the chickenpox vaccine is a safe and effective way to prevent this common childhood disease and its potential complications.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Interferon-gamma (IFN-γ) is a soluble cytokine that is primarily produced by the activation of natural killer (NK) cells and T lymphocytes, especially CD4+ Th1 cells and CD8+ cytotoxic T cells. It plays a crucial role in the regulation of the immune response against viral and intracellular bacterial infections, as well as tumor cells. IFN-γ has several functions, including activating macrophages to enhance their microbicidal activity, increasing the presentation of major histocompatibility complex (MHC) class I and II molecules on antigen-presenting cells, stimulating the proliferation and differentiation of T cells and NK cells, and inducing the production of other cytokines and chemokines. Additionally, IFN-γ has direct antiproliferative effects on certain types of tumor cells and can enhance the cytotoxic activity of immune cells against infected or malignant cells.

The Mumps Vaccine is a biological preparation intended to induce immunity against mumps, a contagious viral infection that primarily affects the salivary glands. The vaccine contains live attenuated (weakened) mumps virus, which stimulates the immune system to develop a protective response without causing the disease.

There are two types of mumps vaccines available:

1. The Jeryl Lynn strain is used in the United States and is part of the Measles, Mumps, and Rubella (MMR) vaccine and the Measles, Mumps, Rubella, and Varicella (MMRV) vaccine. This strain is derived from a clinical isolate obtained from the throat washings of a child with mumps in 1963.
2. The Urabe AM9 strain was used in some countries but has been discontinued in many places due to an increased risk of meningitis as a rare complication.

The MMR vaccine is typically given to children at 12-15 months of age and again at 4-6 years of age, providing long-lasting immunity against mumps in most individuals. The vaccine has significantly reduced the incidence of mumps and its complications worldwide.

Antibody formation, also known as humoral immune response, is the process by which the immune system produces proteins called antibodies in response to the presence of a foreign substance (antigen) in the body. This process involves several steps:

1. Recognition: The antigen is recognized and bound by a type of white blood cell called a B lymphocyte or B cell, which then becomes activated.
2. Differentiation: The activated B cell undergoes differentiation to become a plasma cell, which is a type of cell that produces and secretes large amounts of antibodies.
3. Antibody production: The plasma cells produce and release antibodies, which are proteins made up of four polypeptide chains (two heavy chains and two light chains) arranged in a Y-shape. Each antibody has two binding sites that can recognize and bind to specific regions on the antigen called epitopes.
4. Neutralization or elimination: The antibodies bind to the antigens, neutralizing them or marking them for destruction by other immune cells. This helps to prevent the spread of infection and protect the body from harmful substances.

Antibody formation is an important part of the adaptive immune response, which allows the body to specifically recognize and respond to a wide variety of pathogens and foreign substances.

Hepatitis A vaccines are inactivated or live attenuated viral vaccines that are administered to prevent infection and illness caused by the hepatitis A virus. The vaccine contains antigens that stimulate an immune response in the body, leading to the production of antibodies that protect against future infection with the virus.

The inactivated hepatitis A vaccine is made from viruses that have been chemically treated to destroy their ability to cause disease while preserving their ability to stimulate an immune response. This type of vaccine is typically given in two doses, six months apart, and provides long-term protection against the virus.

The live attenuated hepatitis A vaccine contains a weakened form of the virus that is unable to cause illness but can still stimulate an immune response. This type of vaccine is given as a single dose and provides protection against the virus for at least 20 years.

Hepatitis A vaccines are recommended for people who are at increased risk of infection, including travelers to areas where hepatitis A is common, men who have sex with men, people who use injection drugs, and people with chronic liver disease or clotting factor disorders. The vaccine is also recommended for children in certain states and communities where hepatitis A is endemic.

'Aotus trivirgatus' is a species of New World monkey, also known as the owl monkey or the white-bellied night monkey. It is native to South America, particularly in countries like Colombia, Ecuador, Peru, and Brazil. This nocturnal primate is notable for being one of the few monogamous species of monkeys, and it has a diet that mainly consists of fruits, flowers, and insects.

The medical community may study 'Aotus trivirgatus' due to its use as a model organism in biomedical research. Its genetic similarity to humans makes it a valuable subject for studies on various diseases and biological processes, including infectious diseases, reproductive biology, and aging. However, the use of this species in research has been controversial due to ethical concerns regarding animal welfare.

"Intramuscular injections" refer to a medical procedure where a medication or vaccine is administered directly into the muscle tissue. This is typically done using a hypodermic needle and syringe, and the injection is usually given into one of the large muscles in the body, such as the deltoid (shoulder), vastus lateralis (thigh), or ventrogluteal (buttock) muscles.

Intramuscular injections are used for a variety of reasons, including to deliver medications that need to be absorbed slowly over time, to bypass stomach acid and improve absorption, or to ensure that the medication reaches the bloodstream quickly and directly. Common examples of medications delivered via intramuscular injection include certain vaccines, antibiotics, and pain relievers.

It is important to follow proper technique when administering intramuscular injections to minimize pain and reduce the risk of complications such as infection or injury to surrounding tissues. Proper site selection, needle length and gauge, and injection technique are all critical factors in ensuring a safe and effective intramuscular injection.

Simian adenoviruses are a group of viruses that primarily infect non-human primates, such as monkeys and apes. They belong to the family Adenoviridae and are closely related to human adenoviruses. Like human adenoviruses, simian adenoviruses can cause a wide range of respiratory, gastrointestinal, and ocular diseases in their hosts.

There are several different species of simian adenoviruses, including species A to G, and each species contains multiple serotypes. Some simian adenoviruses have been associated with severe disease outbreaks in captive primates, while others appear to cause only mild or asymptomatic infections.

Simian adenoviruses are not known to commonly infect humans, but there have been a few reported cases of human infection, usually in individuals who have close contact with non-human primates. In recent years, simian adenoviruses have gained attention as potential vectors for gene therapy and vaccine development. Researchers have engineered simian adenovirus vectors to deliver therapeutic genes or vaccines against various diseases, including HIV, tuberculosis, and COVID-19. However, the use of these vectors in humans is still being studied and requires careful evaluation to ensure safety and efficacy.

I'm sorry for any confusion, but "seasons" is not a term that has a medical definition. Seasons refer to the four divisions of the year (spring, summer, autumn or fall, and winter) based on the position of the earth in its orbit around the sun. If you have any questions related to health or medicine, I'd be happy to try to help answer those!

Chloroquine is an antimalarial and autoimmune disease drug. It works by increasing the pH or making the environment less acidic in the digestive vacuoles of malaria parasites, which inhibits the polymerization of heme and the formation of hemozoin. This results in the accumulation of toxic levels of heme that are harmful to the parasite. Chloroquine is also used as an anti-inflammatory agent in the treatment of rheumatoid arthritis, discoid or systemic lupus erythematosus, and photodermatitis.

The chemical name for chloroquine is 7-chloro-4-(4-diethylamino-1-methylbutylamino)quinoline, and it has a molecular formula of C18H26ClN3. It is available in the form of phosphate or sulfate salts for oral administration as tablets or solution.

Chloroquine was first synthesized in 1934 by Bayer scientists, and it has been widely used since the 1940s as a safe and effective antimalarial drug. However, the emergence of chloroquine-resistant strains of malaria parasites has limited its use in some areas. Chloroquine is also being investigated for its potential therapeutic effects on various viral infections, including COVID-19.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

Humoral immunity is a type of immune response in which the body produces proteins called antibodies that circulate in bodily fluids such as blood and help to protect against infection. This form of immunity involves the interaction between antigens (foreign substances that trigger an immune response) and soluble factors, including antibodies, complement proteins, and cytokines.

When a pathogen enters the body, it is recognized as foreign by the immune system, which triggers the production of specific antibodies to bind to and neutralize or destroy the pathogen. These antibodies are produced by B cells, a type of white blood cell that is part of the adaptive immune system.

Humoral immunity provides protection against extracellular pathogens, such as bacteria and viruses, that exist outside of host cells. It is an important component of the body's defense mechanisms and plays a critical role in preventing and fighting off infections.

The Measles-Mumps-Rubella (MMR) vaccine is a combination immunization that protects against three infectious diseases: measles, mumps, and rubella. It contains live attenuated viruses of each disease, which stimulate an immune response in the body similar to that produced by natural infection but do not cause the diseases themselves.

The MMR vaccine is typically given in two doses, the first at 12-15 months of age and the second at 4-6 years of age. It is highly effective in preventing these diseases, with over 90% effectiveness reported after a single dose and near 100% effectiveness after the second dose.

Measles is a highly contagious viral disease that can cause fever, rash, cough, runny nose, and red, watery eyes. It can also lead to serious complications such as pneumonia, encephalitis (inflammation of the brain), and even death.

Mumps is a viral infection that primarily affects the salivary glands, causing swelling and tenderness in the cheeks and jaw. It can also cause fever, headache, muscle aches, and fatigue. Mumps can lead to serious complications such as deafness, meningitis (inflammation of the membranes surrounding the brain and spinal cord), and inflammation of the testicles or ovaries.

Rubella, also known as German measles, is a viral infection that typically causes a mild fever, rash, and swollen lymph nodes. However, if a pregnant woman becomes infected with rubella, it can cause serious birth defects such as hearing impairment, heart defects, and developmental delays in the fetus.

The MMR vaccine is an important tool in preventing these diseases and protecting public health.

I'm sorry for any confusion, but "travel" is not a term that has a specific medical definition. In general, travel refers to the act of moving or journeying from one place to another, often over long distances. However, in a medical context, it might refer to the recommendation that individuals with certain medical conditions or those who are immunocompromised avoid traveling to areas where they may be at increased risk of exposure to infectious diseases. It's always best to check with a healthcare professional for advice related to specific medical situations and travel.

Capital financing refers to the process of raising funds to provide capital for a business, organization, or project, particularly in the medical field. This can include obtaining loans, issuing stocks and bonds, seeking grants, or attracting private investments. The goal of capital financing is to secure sufficient financial resources to support long-term growth, expansion, or modernization efforts, as well as to ensure ongoing operations and sustainability. In healthcare, capital financing may be used for various purposes such as building new hospitals or clinics, purchasing medical equipment, conducting research and development, or implementing new technology systems.

Fever, also known as pyrexia or febrile response, is a common medical sign characterized by an elevation in core body temperature above the normal range of 36.5-37.5°C (97.7-99.5°F) due to a dysregulation of the body's thermoregulatory system. It is often a response to an infection, inflammation, or other underlying medical conditions, and it serves as a part of the immune system's effort to combat the invading pathogens or to repair damaged tissues.

Fevers can be classified based on their magnitude:

* Low-grade fever: 37.5-38°C (99.5-100.4°F)
* Moderate fever: 38-39°C (100.4-102.2°F)
* High-grade or severe fever: above 39°C (102.2°F)

It is important to note that a single elevated temperature reading does not necessarily indicate the presence of a fever, as body temperature can fluctuate throughout the day and can be influenced by various factors such as physical activity, environmental conditions, and the menstrual cycle in females. The diagnosis of fever typically requires the confirmation of an elevated core body temperature on at least two occasions or a consistently high temperature over a period of time.

While fevers are generally considered beneficial in fighting off infections and promoting recovery, extremely high temperatures or prolonged febrile states may necessitate medical intervention to prevent potential complications such as dehydration, seizures, or damage to vital organs.

Streptococcal vaccines are immunizations designed to protect against infections caused by Streptococcus bacteria. These vaccines contain antigens, which are substances that trigger an immune response and help the body recognize and fight off specific types of Streptococcus bacteria. There are several different types of streptococcal vaccines available or in development, including:

1. Pneumococcal conjugate vaccine (PCV): This vaccine protects against Streptococcus pneumoniae, a type of bacteria that can cause pneumonia, meningitis, and other serious infections. PCV is recommended for all children under 2 years old, as well as older children and adults with certain medical conditions.
2. Pneumococcal polysaccharide vaccine (PPSV): This vaccine also protects against Streptococcus pneumoniae, but it is recommended for adults 65 and older, as well as younger people with certain medical conditions.
3. Streptococcus pyogenes vaccine: This vaccine is being developed to protect against Group A Streptococcus (GAS), which can cause a variety of infections, including strep throat, skin infections, and serious diseases like rheumatic fever and toxic shock syndrome. There are several different GAS vaccine candidates in various stages of development.
4. Streptococcus agalactiae vaccine: This vaccine is being developed to protect against Group B Streptococcus (GBS), which can cause serious infections in newborns, pregnant women, and older adults with certain medical conditions. There are several different GBS vaccine candidates in various stages of development.

Overall, streptococcal vaccines play an important role in preventing bacterial infections and reducing the burden of disease caused by Streptococcus bacteria.

Pyrimethamine is an antiparasitic medication that is primarily used to treat and prevent protozoan infections, such as toxoplasmosis and malaria. It works by inhibiting the dihydrofolate reductase enzyme, which is essential for the parasite's survival. By doing so, it interferes with the synthesis of folate, a vital component for the growth and reproduction of the parasite.

Pyrimethamine is often used in combination with other medications, such as sulfonamides or sulfones, to increase its effectiveness and prevent the development of drug-resistant strains. Common side effects of pyrimethamine include nausea, vomiting, loss of appetite, and headache. It is important to note that pyrimethamine should only be used under the supervision of a healthcare professional due to its potential for serious side effects and interactions with other medications.

Anthrax vaccines are biological preparations designed to protect against anthrax, a potentially fatal infectious disease caused by the bacterium Bacillus anthracis. Anthrax can affect both humans and animals, and it is primarily transmitted through contact with contaminated animal products or, less commonly, through inhalation of spores.

There are two types of anthrax vaccines currently available:

1. Anthrax Vaccine Adsorbed (AVA): This vaccine is licensed for use in the United States and is approved for pre-exposure prophylaxis in high-risk individuals, such as military personnel and laboratory workers who handle the bacterium. AVA contains a cell-free filtrate of cultured B. anthracis cells that have been chemically treated to render them non-infectious. The vaccine works by stimulating the production of antibodies against protective antigens (PA) present in the bacterial culture.
2. Recombinant Anthrax Vaccine (rPA): This vaccine, also known as BioThrax, is a newer generation anthrax vaccine that was approved for use in the United States in 2015. It contains only the recombinant protective antigen (rPA) of B. anthracis, which is produced using genetic engineering techniques. The rPA vaccine has been shown to be as effective as AVA in generating an immune response and offers several advantages, including a more straightforward manufacturing process, fewer side effects, and a longer shelf life.

Both vaccines require multiple doses for initial immunization, followed by periodic booster shots to maintain protection. Anthrax vaccines are generally safe and effective at preventing anthrax infection; however, they may cause mild to moderate side effects, such as soreness at the injection site, fatigue, and muscle aches. Severe allergic reactions are rare but possible.

It is important to note that anthrax vaccines do not provide immediate protection against anthrax infection. They require several weeks to stimulate an immune response, so they should be administered before potential exposure to the bacterium. In cases of known or suspected exposure to anthrax, antibiotics are used as a primary means of preventing and treating the disease.

Virosomes are artificially created structures that consist of viral envelopes, which have been stripped of their genetic material, combined with liposomes. They maintain the ability to fuse with cell membranes and can be used as delivery systems for vaccines or drugs, as they can carry foreign proteins or nucleic acids into cells. This makes them useful in the development of novel vaccine strategies and targeted therapy.

Dengue vaccines are designed to protect against dengue fever, a mosquito-borne viral disease that can cause severe flu-like symptoms and potentially life-threatening complications. Dengue is caused by four distinct serotypes of the virus (DENV-1, DENV-2, DENV-3, and DENV-4), and infection with one serotype does not provide immunity against the others.

The first licensed dengue vaccine, Dengvaxia (CYD-TDV), is a chimeric yellow fever-dengue tetravalent vaccine developed by Sanofi Pasteur. It is approved for use in several countries and has demonstrated efficacy against dengue fever caused by all four serotypes in clinical trials. However, the vaccine has raised concerns about the risk of severe disease in individuals who have not been previously exposed to dengue. As a result, it is recommended primarily for people with a documented past dengue infection or living in areas with high dengue prevalence and where the benefits outweigh the risks.

Another dengue vaccine candidate, Takeda's TAK-003 (also known as TDV), is a live attenuated tetravalent dengue vaccine that has shown efficacy against all four serotypes in clinical trials. It was granted approval by the European Medicines Agency (EMA) and several other countries for use in individuals aged 4-16 years old, living in endemic areas.

Research and development of additional dengue vaccine candidates are ongoing to address concerns about safety, efficacy, and accessibility, particularly for at-risk populations in low- and middle-income countries where dengue is most prevalent.

Oleic acid is a monounsaturated fatty acid that is commonly found in various natural oils such as olive oil, sunflower oil, and grapeseed oil. Its chemical formula is cis-9-octadecenoic acid, and it is a colorless liquid at room temperature. Oleic acid is an important component of human diet and has been shown to have potential health benefits, including reducing the risk of heart disease and improving immune function. It is also used in the manufacture of soaps, cosmetics, and other personal care products.

The double-blind method is a study design commonly used in research, including clinical trials, to minimize bias and ensure the objectivity of results. In this approach, both the participants and the researchers are unaware of which group the participants are assigned to, whether it be the experimental group or the control group. This means that neither the participants nor the researchers know who is receiving a particular treatment or placebo, thus reducing the potential for bias in the evaluation of outcomes. The assignment of participants to groups is typically done by a third party not involved in the study, and the codes are only revealed after all data have been collected and analyzed.

Sulfadoxine is an antimicrobial drug, specifically a sulfonamide. It is defined in medical terms as a long-acting synthetic antibacterial that is used to treat and prevent various bacterial infections. Sulfadoxine works by inhibiting the growth of bacteria through interfering with their ability to synthesize folic acid, an essential component for their survival.

It is often combined with pyrimethamine (a dihydrofolate reductase inhibitor) to treat and prevent malaria caused by Plasmodium falciparum, particularly in areas where there is resistance to other antimalarial drugs. The combination of sulfadoxine and pyrimethamine is known as a "sulfonamide-pyrimidine" or "SP" treatment.

Sulfadoxine should be used with caution, as it can cause serious side effects such as severe skin reactions, blood disorders, and allergic reactions. It is also not recommended for use in people who have an allergy to sulfonamides or who are breastfeeding infants younger than two months of age.

I believe there may be some confusion in your question. "Fluorenes" is not a medical term, but rather a chemical term referring to organic compounds that contain a fluorene moiety, which is a bicyclic compound made up of two benzene rings fused to a five-membered ring containing two carbon atoms and one double bond.

Fluorenes have various applications in the field of materials science, including organic light-emitting diodes (OLEDs), organic photovoltaics (OPVs), and organic field-effect transistors (OFETs). They are not typically used in a medical context, although some fluorene derivatives have been explored for potential therapeutic applications.

Therefore, I cannot provide a medical definition of "Fluorenes." However, if you have any questions about the chemical properties or applications of fluorenes, I would be happy to try and answer them.

Cellular immunity, also known as cell-mediated immunity, is a type of immune response that involves the activation of immune cells, such as T lymphocytes (T cells), to protect the body against infected or damaged cells. This form of immunity is important for fighting off infections caused by viruses and intracellular bacteria, as well as for recognizing and destroying cancer cells.

Cellular immunity involves a complex series of interactions between various immune cells and molecules. When a pathogen infects a cell, the infected cell displays pieces of the pathogen on its surface in a process called antigen presentation. This attracts T cells, which recognize the antigens and become activated. Activated T cells then release cytokines, chemicals that help coordinate the immune response, and can directly attack and kill infected cells or help activate other immune cells to do so.

Cellular immunity is an important component of the adaptive immune system, which is able to learn and remember specific pathogens in order to mount a faster and more effective response upon subsequent exposure. This form of immunity is also critical for the rejection of transplanted organs, as the immune system recognizes the transplanted tissue as foreign and attacks it.

Insecticides are substances or mixtures of substances intended for preventing, destroying, or mitigating any pest, including insects, arachnids, or other related pests. They can be chemical or biological agents that disrupt the growth, development, or behavior of these organisms, leading to their death or incapacitation. Insecticides are widely used in agriculture, public health, and residential settings for pest control. However, they must be used with caution due to potential risks to non-target organisms and the environment.

CD8-positive T-lymphocytes, also known as CD8+ T cells or cytotoxic T cells, are a type of white blood cell that plays a crucial role in the adaptive immune system. They are named after the CD8 molecule found on their surface, which is a protein involved in cell signaling and recognition.

CD8+ T cells are primarily responsible for identifying and destroying virus-infected cells or cancerous cells. When activated, they release cytotoxic granules that contain enzymes capable of inducing apoptosis (programmed cell death) in the target cells. They also produce cytokines such as interferon-gamma, which can help coordinate the immune response and activate other immune cells.

CD8+ T cells are generated in the thymus gland and are a type of T cell, which is a lymphocyte that matures in the thymus and plays a central role in cell-mediated immunity. They recognize and respond to specific antigens presented on the surface of infected or cancerous cells in conjunction with major histocompatibility complex (MHC) class I molecules.

Overall, CD8+ T cells are an essential component of the immune system's defense against viral infections and cancer.

Membrane proteins are a type of protein that are embedded in the lipid bilayer of biological membranes, such as the plasma membrane of cells or the inner membrane of mitochondria. These proteins play crucial roles in various cellular processes, including:

1. Cell-cell recognition and signaling
2. Transport of molecules across the membrane (selective permeability)
3. Enzymatic reactions at the membrane surface
4. Energy transduction and conversion
5. Mechanosensation and signal transduction

Membrane proteins can be classified into two main categories: integral membrane proteins, which are permanently associated with the lipid bilayer, and peripheral membrane proteins, which are temporarily or loosely attached to the membrane surface. Integral membrane proteins can further be divided into three subcategories based on their topology:

1. Transmembrane proteins, which span the entire width of the lipid bilayer with one or more alpha-helices or beta-barrels.
2. Lipid-anchored proteins, which are covalently attached to lipids in the membrane via a glycosylphosphatidylinositol (GPI) anchor or other lipid modifications.
3. Monotopic proteins, which are partially embedded in the membrane and have one or more domains exposed to either side of the bilayer.

Membrane proteins are essential for maintaining cellular homeostasis and are targets for various therapeutic interventions, including drug development and gene therapy. However, their structural complexity and hydrophobicity make them challenging to study using traditional biochemical methods, requiring specialized techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and single-particle cryo-electron microscopy (cryo-EM).

Cross reactions, in the context of medical diagnostics and immunology, refer to a situation where an antibody or a immune response directed against one antigen also reacts with a different antigen due to similarities in their molecular structure. This can occur in allergy testing, where a person who is allergic to a particular substance may have a positive test result for a different but related substance because of cross-reactivity between them. For example, some individuals who are allergic to birch pollen may also have symptoms when eating certain fruits, such as apples, due to cross-reactive proteins present in both.

A newborn infant is a baby who is within the first 28 days of life. This period is also referred to as the neonatal period. Newborns require specialized care and attention due to their immature bodily systems and increased vulnerability to various health issues. They are closely monitored for signs of well-being, growth, and development during this critical time.

Viral hepatitis vaccines are vaccines that prevent infection caused by various hepatitis viruses, including hepatitis A and B. These vaccines contain antigens that stimulate the immune system to produce antibodies that protect against infection with the corresponding virus. The vaccines are typically administered through injection and may require multiple doses for full protection.

The hepatitis A vaccine is made from inactivated hepatitis A virus, while the hepatitis B vaccine is made from recombinant hepatitis B surface antigen. Both vaccines have been shown to be highly effective in preventing infection and reducing the risk of complications associated with viral hepatitis, such as liver disease and liver cancer.

It's important to note that there are no vaccines available for other types of viral hepatitis, such as hepatitis C, D, or E. Prevention strategies for these types of viral hepatitis typically involve measures to reduce exposure to the virus, such as safe injection practices and avoiding high-risk behaviors like sharing needles or having unprotected sex with infected individuals.

Poliovirus Vaccine, Oral (OPV) is a vaccine used to prevent poliomyelitis (polio). It contains live attenuated (weakened) polioviruses, which stimulate an immune response in the body and provide protection against all three types of wild, infectious polioviruses. OPV is given by mouth, usually in drops, and it replicates in the gastrointestinal tract, where it induces a strong immune response. This response not only protects the individual who receives the vaccine but also helps to stop the spread of poliovirus in the community, providing indirect protection (herd immunity) to those who are not vaccinated. OPV is safe, effective, and easy to administer, making it an important tool for global polio eradication efforts. However, due to the risk of vaccine-associated paralytic polio (VAPP), inactivated poliovirus vaccine (IPV) is recommended for routine immunization in some countries.

Cebidae is a family of primates that includes monkeys and capuchins found in the tropical rainforests and woodlands of Central and South America. This family is divided into two subfamilies: Cebinae (capuchin monkeys) and Saimiriinae (squirrel monkeys). These animals are known for their adaptability, complex social structures, and diverse behaviors. They have a varied diet that includes fruits, nuts, seeds, insects, and small vertebrates. Some notable members of this family include the white-faced capuchin, the black-capped squirrel monkey, and the golden lion tamarin.

The Yellow Fever Vaccine is a vaccine that protects against the yellow fever virus, which is transmitted to humans through the bites of infected mosquitoes. The vaccine contains live, weakened yellow fever virus, and it works by stimulating the immune system to produce an immune response that provides protection against the disease.

The yellow fever vaccine is recommended for people who are traveling to areas where yellow fever is common, including parts of Africa and South America. It is also required for entry into some countries in these regions. The vaccine is generally safe and effective, but it can cause mild side effects such as headache, muscle pain, and fever in some people. Serious side effects are rare, but may include allergic reactions or infection with the weakened virus used in the vaccine.

It's important to note that yellow fever vaccine may not be recommended for certain individuals, including infants younger than 6 months, pregnant women, people with weakened immune systems, and those with a history of severe allergic reaction to a previous dose of the vaccine or any component of the vaccine. It is always best to consult with a healthcare provider before receiving any vaccination.

Bacterial antibodies are a type of antibodies produced by the immune system in response to an infection caused by bacteria. These antibodies are proteins that recognize and bind to specific antigens on the surface of the bacterial cells, marking them for destruction by other immune cells. Bacterial antibodies can be classified into several types based on their structure and function, including IgG, IgM, IgA, and IgE. They play a crucial role in the body's defense against bacterial infections and provide immunity to future infections with the same bacteria.

Microscopy is a technical field in medicine that involves the use of microscopes to observe structures and phenomena that are too small to be seen by the naked eye. It allows for the examination of samples such as tissues, cells, and microorganisms at high magnifications, enabling the detection and analysis of various medical conditions, including infections, diseases, and cellular abnormalities.

There are several types of microscopy used in medicine, including:

1. Light Microscopy: This is the most common type of microscopy, which uses visible light to illuminate and magnify samples. It can be used to examine a wide range of biological specimens, such as tissue sections, blood smears, and bacteria.
2. Electron Microscopy: This type of microscopy uses a beam of electrons instead of light to produce highly detailed images of samples. It is often used in research settings to study the ultrastructure of cells and tissues.
3. Fluorescence Microscopy: This technique involves labeling specific molecules within a sample with fluorescent dyes, allowing for their visualization under a microscope. It can be used to study protein interactions, gene expression, and cell signaling pathways.
4. Confocal Microscopy: This type of microscopy uses a laser beam to scan a sample point by point, producing high-resolution images with reduced background noise. It is often used in medical research to study the structure and function of cells and tissues.
5. Scanning Probe Microscopy: This technique involves scanning a sample with a physical probe, allowing for the measurement of topography, mechanical properties, and other characteristics at the nanoscale. It can be used in medical research to study the structure and function of individual molecules and cells.

A plague vaccine is a type of immunization used to protect against the bacterial infection caused by Yersinia pestis, the causative agent of plague. The vaccine contains killed or weakened forms of the bacteria, which stimulate the immune system to produce antibodies and activate immune cells that can recognize and fight off the infection if the person is exposed to the bacteria in the future.

There are several types of plague vaccines available, including whole-cell killed vaccines, live attenuated vaccines, and subunit vaccines. The choice of vaccine depends on various factors, such as the target population, the route of exposure (e.g., respiratory or cutaneous), and the desired duration of immunity.

Plague vaccines have been used for many years to protect military personnel and individuals at high risk of exposure to plague, such as laboratory workers and people living in areas where plague is endemic. However, their use is not widespread, and they are not currently recommended for general use in the United States or other developed countries.

It's important to note that while plague vaccines can provide some protection against the disease, they are not 100% effective, and other measures such as antibiotics and insect control are also important for preventing and treating plague infections.

An epitope is a specific region on an antigen (a substance that triggers an immune response) that is recognized and bound by an antibody or a T-cell receptor. In the case of T-lymphocytes, which are a type of white blood cell that plays a central role in cell-mediated immunity, epitopes are typically presented on the surface of infected cells in association with major histocompatibility complex (MHC) molecules.

T-lymphocytes recognize and respond to epitopes through their T-cell receptors (TCRs), which are membrane-bound proteins that can bind to specific epitopes presented on the surface of infected cells. There are two main types of T-lymphocytes: CD4+ T-cells, also known as helper T-cells, and CD8+ T-cells, also known as cytotoxic T-cells.

CD4+ T-cells recognize epitopes presented in the context of MHC class II molecules, which are typically expressed on the surface of professional antigen-presenting cells such as dendritic cells, macrophages, and B-cells. CD4+ T-cells help to coordinate the immune response by producing cytokines that activate other immune cells.

CD8+ T-cells recognize epitopes presented in the context of MHC class I molecules, which are expressed on the surface of almost all nucleated cells. CD8+ T-cells are able to directly kill infected cells by releasing cytotoxic granules that contain enzymes that can induce apoptosis (programmed cell death) in the target cell.

In summary, epitopes are specific regions on antigens that are recognized and bound by T-lymphocytes through their T-cell receptors. CD4+ T-cells recognize epitopes presented in the context of MHC class II molecules, while CD8+ T-cells recognize epitopes presented in the context of MHC class I molecules.

'Bedding and linens' is a term that refers to the items used to cover, clean, and maintain beds and other furniture in medical and residential settings. These items include:

1. Sheets: These are flat pieces of cloth that are placed on top of the mattress and beneath the blankets or comforters. They come in various sizes (twin, full, queen, king) to fit different mattress sizes.
2. Blankets/Comforters: These are thicker, often quilted or filled, pieces of fabric that provide warmth and comfort to the user.
3. Pillows and pillowcases: Pillows are used to support the head and neck during sleep, while pillowcases are the removable covers that protect the pillows from dirt, sweat, and stains.
4. Mattress pads/protectors: These are additional layers placed between the mattress and the sheets to provide extra protection against spills, stains, or allergens.
5. Bed skirts: These are decorative pieces of fabric that cover the space between the box spring and the floor, hiding any storage area or providing a more finished look to the bed.
6. Towels and washcloths: While not directly related to the bed, these linens are often included in the 'bedding and linens' category as they share similar cleaning and maintenance requirements.

In medical settings, such as hospitals and nursing homes, strict infection control protocols are followed for handling, washing, and storing bedding and linens to prevent the spread of infectious diseases.

Recombinant proteins are artificially created proteins produced through the use of recombinant DNA technology. This process involves combining DNA molecules from different sources to create a new set of genes that encode for a specific protein. The resulting recombinant protein can then be expressed, purified, and used for various applications in research, medicine, and industry.

Recombinant proteins are widely used in biomedical research to study protein function, structure, and interactions. They are also used in the development of diagnostic tests, vaccines, and therapeutic drugs. For example, recombinant insulin is a common treatment for diabetes, while recombinant human growth hormone is used to treat growth disorders.

The production of recombinant proteins typically involves the use of host cells, such as bacteria, yeast, or mammalian cells, which are engineered to express the desired protein. The host cells are transformed with a plasmid vector containing the gene of interest, along with regulatory elements that control its expression. Once the host cells are cultured and the protein is expressed, it can be purified using various chromatography techniques.

Overall, recombinant proteins have revolutionized many areas of biology and medicine, enabling researchers to study and manipulate proteins in ways that were previously impossible.

A fungal vaccine is a biological preparation that provides active acquired immunity against fungal infections. It contains one or more fungal antigens, which are substances that can stimulate an immune response, along with adjuvants to enhance the immune response. The goal of fungal vaccines is to protect against invasive fungal diseases, especially in individuals with weakened immune systems, such as those undergoing chemotherapy, organ transplantation, or HIV/AIDS treatment.

Fungal vaccines can work by inducing both humoral and cell-mediated immunity. Humoral immunity involves the production of antibodies that recognize and neutralize fungal antigens, while cell-mediated immunity involves the activation of T cells to directly attack infected cells.

Currently, there are no licensed fungal vaccines available for human use, although several candidates are in various stages of development and clinical trials. Some examples include vaccines against Candida albicans, Aspergillus fumigatus, Cryptococcus neoformans, and Pneumocystis jirovecii.

'Anopheles gambiae' is a species of mosquito that is a major vector for the transmission of malaria. The female Anopheles gambiae mosquito bites primarily during the nighttime hours and preferentially feeds on human blood, which allows it to transmit the Plasmodium parasite that causes malaria. This species is widely distributed throughout much of Africa and is responsible for transmitting a significant proportion of the world's malaria cases.

The Anopheles gambiae complex actually consists of several closely related species or forms, which can be difficult to distinguish based on morphological characteristics alone. However, advances in molecular techniques have allowed for more accurate identification and differentiation of these species. Understanding the biology and behavior of Anopheles gambiae is crucial for developing effective strategies to control malaria transmission.

Insecticide-Treated Bednets (ITNs) are bed nets that have been specially treated with insecticides to repel, incapacitate, and kill mosquitoes and other disease-carrying insects. The World Health Organization (WHO) recommends the use of ITNs as a crucial strategy in preventing malaria transmission, especially in areas where the disease is endemic.

The insecticide used in ITNs is typically a pyrethroid, which is safe for humans but highly toxic to mosquitoes. When an infected mosquito lands on the net to bite a person, it comes into contact with the insecticide and dies before it can transmit the malaria parasite.

ITNs are often distributed through mass campaigns or targeted interventions in communities most at risk of malaria transmission. They have been shown to be highly effective in reducing the incidence of malaria and saving lives, particularly among young children and pregnant women who are most vulnerable to the disease.

Blood is the fluid that circulates in the body of living organisms, carrying oxygen and nutrients to the cells and removing carbon dioxide and other waste products. It is composed of red and white blood cells suspended in a liquid called plasma. The main function of blood is to transport oxygen from the lungs to the body's tissues and carbon dioxide from the tissues to the lungs. It also transports nutrients, hormones, and other substances to the cells and removes waste products from them. Additionally, blood plays a crucial role in the body's immune system by helping to fight infection and disease.

Human experimentation is a branch of medical research that involves conducting experiments on human subjects. According to the World Medical Association's Declaration of Helsinki, which sets ethical standards for medical research involving human subjects, human experimentation is defined as "systematic study designed to develop or contribute to generalizable knowledge."

Human experimentation can take many forms, including clinical trials of new drugs or medical devices, observational studies, and interventional studies. In all cases, the principles of informed consent, risk minimization, and respect for the autonomy and dignity of the research subjects must be strictly adhered to.

Human experimentation has a controversial history, with many instances of unethical practices and abuse, such as the notorious Tuskegee syphilis study in which African American men were deliberately left untreated for syphilis without their informed consent. As a result, there are strict regulations and guidelines governing human experimentation to ensure that it is conducted ethically and with the utmost respect for the rights and welfare of research subjects.

Polymerase Chain Reaction (PCR) is a laboratory technique used to amplify specific regions of DNA. It enables the production of thousands to millions of copies of a particular DNA sequence in a rapid and efficient manner, making it an essential tool in various fields such as molecular biology, medical diagnostics, forensic science, and research.

The PCR process involves repeated cycles of heating and cooling to separate the DNA strands, allow primers (short sequences of single-stranded DNA) to attach to the target regions, and extend these primers using an enzyme called Taq polymerase, resulting in the exponential amplification of the desired DNA segment.

In a medical context, PCR is often used for detecting and quantifying specific pathogens (viruses, bacteria, fungi, or parasites) in clinical samples, identifying genetic mutations or polymorphisms associated with diseases, monitoring disease progression, and evaluating treatment effectiveness.

Rubella vaccine is a preventive measure used to immunize individuals against rubella, also known as German measles. It contains inactivated or weakened forms of the rubella virus that stimulate an immune response when introduced into the body. The two types of rubella vaccines available are:

1. Live Attenuated Rubella Vaccine (RAV): This vaccine contains a weakened form of the rubella virus, which triggers an immune response without causing the disease. It is the most commonly used rubella vaccine and is often combined with measles and mumps vaccines to create the Measles-Mumps-Rubella (MMR) or Measles-Mumps-Rubella-Varicella (MMRV) vaccines.

2. Inactivated Rubella Vaccine: This vaccine contains a killed rubella virus, which is less commonly used but can still provide immunity against the disease.

The Centers for Disease Control and Prevention (CDC) recommends that children receive one dose of MMR vaccine at 12-15 months of age and another dose at 4-6 years of age. This schedule ensures optimal protection against rubella and other diseases included in the vaccines.

It is important to note that pregnant women should not receive the rubella vaccine, as it can potentially harm the developing fetus. Women who are planning to become pregnant should ensure they have had their rubella immunization before conceiving.

Quinine is defined as a bitter crystalline alkaloid derived from the bark of the Cinchona tree, primarily used in the treatment of malaria and other parasitic diseases. It works by interfering with the reproduction of the malaria parasite within red blood cells. Quinine has also been used historically as a muscle relaxant and analgesic, but its use for these purposes is now limited due to potential serious side effects. In addition, quinine can be found in some beverages like tonic water, where it is present in very small amounts for flavoring purposes.

Drug discovery is the process of identifying new chemical entities or biological agents that have the potential to be used as therapeutic or preventive treatments for diseases. This process involves several stages, including target identification, lead identification, hit-to-lead optimization, lead optimization, preclinical development, and clinical trials.

Target identification is the initial stage of drug discovery, where researchers identify a specific molecular target, such as a protein or gene, that plays a key role in the disease process. Lead identification involves screening large libraries of chemical compounds or natural products to find those that interact with the target molecule and have potential therapeutic activity.

Hit-to-lead optimization is the stage where researchers optimize the chemical structure of the lead compound to improve its potency, selectivity, and safety profile. Lead optimization involves further refinement of the compound's structure to create a preclinical development candidate. Preclinical development includes studies in vitro (in test tubes or petri dishes) and in vivo (in animals) to evaluate the safety, efficacy, and pharmacokinetics of the drug candidate.

Clinical trials are conducted in human volunteers to assess the safety, tolerability, and efficacy of the drug candidate in treating the disease. If the drug is found to be safe and effective in clinical trials, it may be approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) for use in patients.

Overall, drug discovery is a complex and time-consuming process that requires significant resources, expertise, and collaboration between researchers, clinicians, and industry partners.

Acellular vaccines are a type of vaccine that contain one or more antigens but do not contain whole cell parts or components of the pathogen. They are designed to produce an immune response in the body that is specific to the antigen(s) contained within the vaccine, while minimizing the risk of adverse reactions associated with whole cell vaccines.

Acellular vaccines are often produced using recombinant DNA technology, where a specific gene from the pathogen is inserted into a different organism (such as yeast or bacteria) that can produce large quantities of the antigen. The antigen is then purified and used to create the vaccine.

One example of an acellular vaccine is the DTaP vaccine, which is used to protect against diphtheria, tetanus, and pertussis (whooping cough). This vaccine contains only a small portion of the pertussis bacterium, along with purified versions of the toxins produced by the bacteria. By contrast, whole cell pertussis vaccines contain entire killed bacteria, which can cause more frequent and severe side effects.

Overall, acellular vaccines offer a safer and more targeted approach to immunization than whole cell vaccines, while still providing effective protection against infectious diseases.

T-lymphocytes, also known as T-cells, are a type of white blood cell that plays a key role in the adaptive immune system's response to infection. They are produced in the bone marrow and mature in the thymus gland. There are several different types of T-cells, including CD4+ helper T-cells, CD8+ cytotoxic T-cells, and regulatory T-cells (Tregs).

CD4+ helper T-cells assist in activating other immune cells, such as B-lymphocytes and macrophages. They also produce cytokines, which are signaling molecules that help coordinate the immune response. CD8+ cytotoxic T-cells directly kill infected cells by releasing toxic substances. Regulatory T-cells help maintain immune tolerance and prevent autoimmune diseases by suppressing the activity of other immune cells.

T-lymphocytes are important in the immune response to viral infections, cancer, and other diseases. Dysfunction or depletion of T-cells can lead to immunodeficiency and increased susceptibility to infections. On the other hand, an overactive T-cell response can contribute to autoimmune diseases and chronic inflammation.

Primaquine is an antimalarial medication used to prevent and treat malaria caused by Plasmodium falciparum and P. vivax parasites. It is the only antimalarial drug effective against the liver stages (hypnozoites) of P. vivax and P. ovale, which can cause relapses if not treated.

Primaquine works by producing free radicals that damage the malaria parasite's DNA, leading to its death. It is a relatively inexpensive drug and is often used in mass drug administration programs for malaria elimination. However, primaquine can cause hemolysis (destruction of red blood cells) in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency, so it is important to screen for this condition before prescribing the drug.

In addition to its antimalarial properties, primaquine has also been used off-label to treat certain types of cutaneous leishmaniasis, a parasitic disease caused by Leishmania species.

"Plasmodium malariae" is a species of protozoan parasite that causes malaria in humans. It's one of the five Plasmodium species known to cause malaria in humans, with the other four being P. falciparum, P. vivax, P. ovale, and P. knowlesi.

P. malariae is transmitted through the bites of infected Anopheles mosquitoes. Once inside the human body, the parasites travel to the liver where they multiply and then infect red blood cells. The infection caused by P. malariae can persist for several years, even a lifetime, if not treated properly.

The symptoms of P. malariae infection include fever, chills, headache, muscle and joint pain, and anemia. However, the severity of these symptoms is generally less than that caused by P. falciparum, which is the most deadly form of malaria.

It's worth noting that while P. malariae can be effectively treated with antimalarial drugs such as chloroquine and primaquine, drug resistance has been reported in some areas, making accurate diagnosis and treatment even more critical for controlling the spread of this disease.

I believe there may be a slight confusion in your question. AIDS is a condition caused by the human immunodeficiency virus (HIV) infection, and it weakens the immune system, making people more susceptible to other infections and diseases. There is no vaccine for AIDS itself. However, there are vaccines being developed and tested to prevent HIV infection, which would help prevent AIDS from developing.

SAIDS is not a medical term. If you meant to ask about "HIV vaccines," I can provide a definition:

An HIV vaccine aims to stimulate the immune system to produce an effective response against the human immunodeficiency virus (HIV). An effective HIV vaccine would ideally prevent the initial infection or significantly reduce viral replication and disease progression in infected individuals. Currently, no licensed HIV vaccines are available, but research is ongoing to develop a protective vaccine against HIV infection.

Salmonella vaccines are immunizations that are developed to protect against Salmonella infections, which are caused by bacteria of the Salmonella enterica species. These vaccines typically contain antigens or weakened forms of the Salmonella bacteria that stimulate an immune response in the body, enabling it to recognize and fight off future Salmonella infections.

There are two main types of Salmonella vaccines:

1. Live Attenuated Vaccines: These vaccines contain weakened (attenuated) forms of the Salmonella bacteria that can still replicate but at a much slower rate and with reduced virulence compared to the wild-type bacteria. Examples include Ty21a, a live oral typhoid vaccine, and χ 144, an experimental live oral vaccine against nontyphoidal Salmonella serovars.
2. Inactivated (Killed) Vaccines: These vaccines contain killed Salmonella bacteria or their components, such as proteins or polysaccharides. They cannot replicate and are generally considered safer than live attenuated vaccines. However, they may not stimulate as strong an immune response compared to live vaccines. An example is the Vi polysaccharide vaccine against typhoid fever.

Salmonella vaccines are primarily used for preventing Salmonella infections in humans and animals, particularly those that cause typhoid fever and nontyphoidal Salmonella (NTS) infections. Vaccination is an essential component of controlling Salmonella infections, especially in areas with poor sanitation and hygiene, where the risk of exposure to Salmonella bacteria is higher.

"Macaca mulatta" is the scientific name for the Rhesus macaque, a species of monkey that is native to South, Central, and Southeast Asia. They are often used in biomedical research due to their genetic similarity to humans.

C57BL/6 (C57 Black 6) is an inbred strain of laboratory mouse that is widely used in biomedical research. The term "inbred" refers to a strain of animals where matings have been carried out between siblings or other closely related individuals for many generations, resulting in a population that is highly homozygous at most genetic loci.

The C57BL/6 strain was established in 1920 by crossing a female mouse from the dilute brown (DBA) strain with a male mouse from the black strain. The resulting offspring were then interbred for many generations to create the inbred C57BL/6 strain.

C57BL/6 mice are known for their robust health, longevity, and ease of handling, making them a popular choice for researchers. They have been used in a wide range of biomedical research areas, including studies of cancer, immunology, neuroscience, cardiovascular disease, and metabolism.

One of the most notable features of the C57BL/6 strain is its sensitivity to certain genetic modifications, such as the introduction of mutations that lead to obesity or impaired glucose tolerance. This has made it a valuable tool for studying the genetic basis of complex diseases and traits.

Overall, the C57BL/6 inbred mouse strain is an important model organism in biomedical research, providing a valuable resource for understanding the genetic and molecular mechanisms underlying human health and disease.

In epidemiology, the incidence of a disease is defined as the number of new cases of that disease within a specific population over a certain period of time. It is typically expressed as a rate, with the number of new cases in the numerator and the size of the population at risk in the denominator. Incidence provides information about the risk of developing a disease during a given time period and can be used to compare disease rates between different populations or to monitor trends in disease occurrence over time.

Virus-like particles (VLPs) are nanostructures that mimic the organization and conformation of authentic viruses but lack the genetic material required for replication. VLPs can be produced from one or more viral proteins, which can be derived from various expression systems including bacteria, yeast, insect, or mammalian cells.

VLP-based vaccines are a type of vaccine that uses these virus-like particles to induce an immune response in the body. These vaccines can be designed to target specific viruses or other pathogens and have been shown to be safe and effective in inducing both humoral and cellular immunity.

VLPs resemble authentic viruses in their structure, size, and antigenic properties, making them highly immunogenic. They can be designed to present specific epitopes or antigens from a pathogen, which can stimulate the immune system to produce antibodies and activate T-cells that recognize and attack the pathogen.

VLP vaccines have been developed for several viruses, including human papillomavirus (HPV), hepatitis B virus (HBV), and respiratory syncytial virus (RSV). They offer several advantages over traditional vaccines, such as a strong immune response, safety, and stability.

A genetic vector is a vehicle, often a plasmid or a virus, that is used to introduce foreign DNA into a host cell as part of genetic engineering or gene therapy techniques. The vector contains the desired gene or genes, along with regulatory elements such as promoters and enhancers, which are needed for the expression of the gene in the target cells.

The choice of vector depends on several factors, including the size of the DNA to be inserted, the type of cell to be targeted, and the efficiency of uptake and expression required. Commonly used vectors include plasmids, adenoviruses, retroviruses, and lentiviruses.

Plasmids are small circular DNA molecules that can replicate independently in bacteria. They are often used as cloning vectors to amplify and manipulate DNA fragments. Adenoviruses are double-stranded DNA viruses that infect a wide range of host cells, including human cells. They are commonly used as gene therapy vectors because they can efficiently transfer genes into both dividing and non-dividing cells.

Retroviruses and lentiviruses are RNA viruses that integrate their genetic material into the host cell's genome. This allows for stable expression of the transgene over time. Lentiviruses, a subclass of retroviruses, have the advantage of being able to infect non-dividing cells, making them useful for gene therapy applications in post-mitotic tissues such as neurons and muscle cells.

Overall, genetic vectors play a crucial role in modern molecular biology and medicine, enabling researchers to study gene function, develop new therapies, and modify organisms for various purposes.

Ebola vaccines are medical products designed to confer immunity against the Ebola virus, a deadly pathogen that causes hemorrhagic fever. Several Ebola vaccine candidates have been developed and tested in clinical trials, with some showing promising results. The most advanced Ebola vaccine is rVSV-ZEBOV, which has been shown to be highly effective in preventing the disease in clinical trials. It uses a weakened version of the vesicular stomatitis virus (VSV) to deliver a protein from the Ebola virus surface, triggering an immune response that protects against infection. Other Ebola vaccine candidates use different approaches, such as delivering Ebola virus genes using a harmless adenovirus vector or using inactivated whole Ebola viruses. These vaccines are still in development and have not yet been approved for widespread use.

An epitope is a specific region on the surface of an antigen (a molecule that can trigger an immune response) that is recognized by an antibody, B-cell receptor, or T-cell receptor. It is also commonly referred to as an antigenic determinant. Epitopes are typically composed of linear amino acid sequences or conformational structures made up of discontinuous amino acids in the antigen. They play a crucial role in the immune system's ability to differentiate between self and non-self molecules, leading to the targeted destruction of foreign substances like viruses and bacteria. Understanding epitopes is essential for developing vaccines, diagnostic tests, and immunotherapies.

Antibody specificity refers to the ability of an antibody to bind to a specific epitope or antigenic determinant on an antigen. Each antibody has a unique structure that allows it to recognize and bind to a specific region of an antigen, typically a small portion of the antigen's surface made up of amino acids or sugar residues. This highly specific binding is mediated by the variable regions of the antibody's heavy and light chains, which form a pocket that recognizes and binds to the epitope.

The specificity of an antibody is determined by its unique complementarity-determining regions (CDRs), which are loops of amino acids located in the variable domains of both the heavy and light chains. The CDRs form a binding site that recognizes and interacts with the epitope on the antigen. The precise fit between the antibody's binding site and the epitope is critical for specificity, as even small changes in the structure of either can prevent binding.

Antibody specificity is important in immune responses because it allows the immune system to distinguish between self and non-self antigens. This helps to prevent autoimmune reactions where the immune system attacks the body's own cells and tissues. Antibody specificity also plays a crucial role in diagnostic tests, such as ELISA assays, where antibodies are used to detect the presence of specific antigens in biological samples.

Influenza, also known as the flu, is a highly contagious viral infection that attacks the respiratory system of humans. It is caused by influenza viruses A, B, or C and is characterized by the sudden onset of fever, chills, headache, muscle pain, sore throat, cough, runny nose, and fatigue. Influenza can lead to complications such as pneumonia, bronchitis, and ear infections, and can be particularly dangerous for young children, older adults, pregnant women, and people with weakened immune systems or chronic medical conditions. The virus is spread through respiratory droplets produced when an infected person coughs, sneezes, or talks, and can also survive on surfaces for a period of time. Influenza viruses are constantly changing, which makes it necessary to get vaccinated annually to protect against the most recent and prevalent strains.

"Drug approval" is the process by which a regulatory agency, such as the US Food and Drug Administration (FDA), grants formal authorization for a pharmaceutical company to market and sell a drug for a specific medical condition. The approval process is based on rigorous evaluation of clinical trial data to ensure that the drug is safe and effective for its intended use.

The FDA's approval process typically involves several stages, including preclinical testing in the lab and animal studies, followed by three phases of clinical trials in human subjects. The first phase tests the safety of the drug in a small group of healthy volunteers, while the second and third phases test the drug's efficacy and side effects in larger groups of patients with the medical condition for which the drug is intended.

If the results of these studies demonstrate that the drug is safe and effective, the pharmaceutical company can submit a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA for review. The application includes data from the clinical trials, as well as information about the manufacturing process, labeling, and proposed use of the drug.

The FDA reviews the application and may seek input from independent experts before making a decision on whether to approve the drug. If approved, the drug can be marketed and sold to patients with the medical condition for which it was approved. The FDA continues to monitor the safety and efficacy of approved drugs after they reach the market to ensure that they remain safe and effective for their intended use.

A dose-response relationship in immunology refers to the quantitative relationship between the dose or amount of an antigen (a substance that triggers an immune response) and the magnitude or strength of the resulting immune response. Generally, as the dose of an antigen increases, the intensity and/or duration of the immune response also increase, up to a certain point. This relationship helps in determining the optimal dosage for vaccines and immunotherapies, ensuring sufficient immune activation while minimizing potential adverse effects.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Mefloquine is an antimalarial medication that is used to prevent and treat malaria caused by the Plasmodium falciparum parasite. It works by interfering with the growth of the parasite in the red blood cells of the body. Mefloquine is a synthetic quinoline compound, and it is available under the brand name Lariam, among others.

Mefloquine is typically taken once a week, starting one to two weeks before traveling to an area where malaria is common, and continuing for four weeks after leaving the area. It may also be used to treat acute malaria infection in conjunction with other antimalarial medications.

It's important to note that mefloquine has been associated with serious neuropsychiatric side effects, including anxiety, depression, hallucinations, and seizures. Therefore, it is usually reserved for use in situations where other antimalarial drugs cannot be used or have failed. Before taking mefloquine, individuals should discuss their medical history and potential risks with their healthcare provider.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Neutralizing antibodies are a type of antibody that defends against pathogens such as viruses or bacteria by neutralizing their ability to infect cells. They do this by binding to specific regions on the surface proteins of the pathogen, preventing it from attaching to and entering host cells. This renders the pathogen ineffective and helps to prevent or reduce the severity of infection. Neutralizing antibodies can be produced naturally in response to an infection or vaccination, or they can be generated artificially for therapeutic purposes.

Pregnancy is a physiological state or condition where a fertilized egg (zygote) successfully implants and grows in the uterus of a woman, leading to the development of an embryo and finally a fetus. This process typically spans approximately 40 weeks, divided into three trimesters, and culminates in childbirth. Throughout this period, numerous hormonal and physical changes occur to support the growing offspring, including uterine enlargement, breast development, and various maternal adaptations to ensure the fetus's optimal growth and well-being.

CD4-positive T-lymphocytes, also known as CD4+ T cells or helper T cells, are a type of white blood cell that plays a crucial role in the immune response. They express the CD4 receptor on their surface and help coordinate the immune system's response to infectious agents such as viruses and bacteria.

CD4+ T cells recognize and bind to specific antigens presented by antigen-presenting cells, such as dendritic cells or macrophages. Once activated, they can differentiate into various subsets of effector cells, including Th1, Th2, Th17, and Treg cells, each with distinct functions in the immune response.

CD4+ T cells are particularly important in the immune response to HIV (human immunodeficiency virus), which targets and destroys these cells, leading to a weakened immune system and increased susceptibility to opportunistic infections. The number of CD4+ T cells is often used as a marker of disease progression in HIV infection, with lower counts indicating more advanced disease.

Disease eradication is the complete and permanent elimination of a specific disease from all humans or animals worldwide. This is achieved through various methods, including vaccination programs, improved sanitation, and public health measures. The disease is no longer present in any form, and there is no risk of it re-emerging. Smallpox is the only human disease to have been successfully eradicated so far. Efforts are currently underway to eradicate polio, with significant progress made but still ongoing.

Drug resistance, also known as antimicrobial resistance, is the ability of a microorganism (such as bacteria, viruses, fungi, or parasites) to withstand the effects of a drug that was originally designed to inhibit or kill it. This occurs when the microorganism undergoes genetic changes that allow it to survive in the presence of the drug. As a result, the drug becomes less effective or even completely ineffective at treating infections caused by these resistant organisms.

Drug resistance can develop through various mechanisms, including mutations in the genes responsible for producing the target protein of the drug, alteration of the drug's target site, modification or destruction of the drug by enzymes produced by the microorganism, and active efflux of the drug from the cell.

The emergence and spread of drug-resistant microorganisms pose significant challenges in medical treatment, as they can lead to increased morbidity, mortality, and healthcare costs. The overuse and misuse of antimicrobial agents, as well as poor infection control practices, contribute to the development and dissemination of drug-resistant strains. To address this issue, it is crucial to promote prudent use of antimicrobials, enhance surveillance and monitoring of resistance patterns, invest in research and development of new antimicrobial agents, and strengthen infection prevention and control measures.

I'm sorry for any confusion, but "Senegal" is not a medical term. It is the name of a country located in West Africa, known officially as the Republic of Senegal. If you have any questions about medical terms or conditions, I would be happy to help with those.

I'm sorry for any confusion, but "Thailand" is not a medical term. It is a country located in Southeast Asia. If you have any questions about medical terms or concepts, I would be happy to help answer those for you!

Staphylococcal vaccines are immunizations that are developed to protect against infections caused by the Staphylococcus bacteria, particularly Staphylococcus aureus. These vaccines typically contain components of the bacterial cell wall or toxins that stimulate an immune response in the body, leading to the production of antibodies that can recognize and neutralize the bacteria if they invade the body in the future.

There are currently no licensed staphylococcal vaccines available for use in humans, although several candidates are in various stages of development. These vaccines aim to prevent a range of staphylococcal infections, including skin and soft tissue infections, pneumonia, bloodstream infections, and toxic shock syndrome.

It's important to note that while antibiotics can be effective against staphylococcal infections, the bacteria have become increasingly resistant to these drugs over time, making vaccines an important area of research and development for preventing and controlling the spread of these infections.

Immunoglobulins, also known as antibodies, are proteins produced by the immune system to recognize and neutralize foreign substances like pathogens or antigens. The term "immunoglobulin isotypes" refers to the different classes of immunoglobulins that share a similar structure but have distinct functions and properties.

There are five main isotypes of immunoglobulins in humans, namely IgA, IgD, IgE, IgG, and IgM. Each isotype has a unique heavy chain constant region (CH) that determines its effector functions, such as binding to Fc receptors, complement activation, or protection against pathogens.

IgA is primarily found in external secretions like tears, saliva, and breast milk, providing localized immunity at mucosal surfaces. IgD is expressed on the surface of B cells and plays a role in their activation and differentiation. IgE is associated with allergic responses and binds to mast cells and basophils, triggering the release of histamine and other mediators of inflammation.

IgG is the most abundant isotype in serum and has several subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their effector functions. IgG can cross the placenta, providing passive immunity to the fetus. IgM is the first antibody produced during an immune response and is primarily found in the bloodstream, where it forms large pentameric complexes that are effective at agglutination and complement activation.

Overall, immunoglobulin isotypes play a crucial role in the adaptive immune response, providing specific and diverse mechanisms for recognizing and neutralizing foreign substances.

Surface antigens are molecules found on the surface of cells that can be recognized by the immune system as being foreign or different from the host's own cells. Antigens are typically proteins or polysaccharides that are capable of stimulating an immune response, leading to the production of antibodies and activation of immune cells such as T-cells.

Surface antigens are important in the context of infectious diseases because they allow the immune system to identify and target infected cells for destruction. For example, viruses and bacteria often display surface antigens that are distinct from those found on host cells, allowing the immune system to recognize and attack them. In some cases, these surface antigens can also be used as targets for vaccines or other immunotherapies.

In addition to their role in infectious diseases, surface antigens are also important in the context of cancer. Tumor cells often display abnormal surface antigens that differ from those found on normal cells, allowing the immune system to potentially recognize and attack them. However, tumors can also develop mechanisms to evade the immune system, making it difficult to mount an effective response.

Overall, understanding the properties and behavior of surface antigens is crucial for developing effective immunotherapies and vaccines against infectious diseases and cancer.

Diphtheria-Tetanus-acellular Pertussis (DTaP) vaccines are a type of combination vaccine that protect against three serious diseases caused by bacteria: diphtheria, tetanus, and pertussis (also known as whooping cough).

Diphtheria is a highly contagious respiratory infection that can cause breathing difficulties, heart failure, paralysis, and even death. Tetanus, also known as lockjaw, is a bacterial infection that affects the nervous system and causes muscle stiffness and spasms, which can be severe enough to cause broken bones or suffocation. Pertussis is a highly contagious respiratory infection that causes severe coughing fits, making it difficult to breathe, eat, or drink.

The "a" in DTaP stands for "acellular," which means that the pertussis component of the vaccine contains only parts of the bacteria, rather than the whole cells used in older vaccines. This reduces the risk of side effects associated with the whole-cell pertussis vaccine while still providing effective protection against the disease.

DTaP vaccines are typically given as a series of five shots, starting at 2 months of age and ending at 4-6 years of age. Booster doses may be recommended later in life to maintain immunity. DTaP vaccines are an essential part of routine childhood immunization schedules and have significantly reduced the incidence of these diseases worldwide.

Biomedical research is a branch of scientific research that involves the study of biological processes and diseases in order to develop new treatments and therapies. This type of research often involves the use of laboratory techniques, such as cell culture and genetic engineering, as well as clinical trials in humans. The goal of biomedical research is to advance our understanding of how living organisms function and to find ways to prevent and treat various medical conditions. It encompasses a wide range of disciplines, including molecular biology, genetics, immunology, pharmacology, and neuroscience, among others. Ultimately, the aim of biomedical research is to improve human health and well-being.

Cytomegalovirus (CMV) vaccines are medical products being developed to prevent or ameliorate infection and disease caused by the human cytomegalovirus. CMV is a type of herpesvirus that can cause serious health problems in people with weakened immune systems, such as those undergoing organ transplantation, people living with HIV/AIDS, and newborns infected with the virus before birth (congenital CMV infection).

There are currently no approved vaccines for CMV. However, several vaccine candidates are being investigated in clinical trials to evaluate their safety, immunogenicity, and efficacy. These vaccine candidates use various approaches, such as:

1. Live-attenuated viruses: These vaccines contain weakened forms of the virus that can stimulate an immune response without causing disease. An example is the Towne vaccine, which has been studied in clinical trials for several decades.
2. Recombinant proteins: These vaccines use specific viral proteins to induce an immune response. For instance, a glycoprotein B (gB) subunit vaccine has shown promising results in phase II clinical trials.
3. Virus-like particles (VLPs): VLPs mimic the structure of the virus but do not contain any viral genetic material. They can be used to induce an immune response without causing infection.
4. DNA vaccines: These vaccines use plasmids containing CMV genes to stimulate an immune response. A DNA vaccine encoding the CMV phosphoprotein 65 (pp65) has been tested in clinical trials.
5. mRNA vaccines: Similar to DNA vaccines, mRNA vaccines use genetic material to induce an immune response. Moderna Therapeutics is developing an mRNA vaccine candidate for CMV.

The development of a safe and effective CMV vaccine remains a significant public health priority, as CMV infection can lead to severe complications in vulnerable populations.

Immunization programs, also known as vaccination programs, are organized efforts to administer vaccines to populations or communities in order to protect individuals from vaccine-preventable diseases. These programs are typically implemented by public health agencies and involve the planning, coordination, and delivery of immunizations to ensure that a high percentage of people are protected against specific infectious diseases.

Immunization programs may target specific age groups, such as infants and young children, or populations at higher risk of certain diseases, such as travelers, healthcare workers, or individuals with weakened immune systems. The goals of immunization programs include controlling and eliminating vaccine-preventable diseases, reducing the morbidity and mortality associated with these diseases, and protecting vulnerable populations from outbreaks and epidemics.

Immunization programs may be delivered through a variety of settings, including healthcare facilities, schools, community centers, and mobile clinics. They often involve partnerships between government agencies, healthcare providers, non-governmental organizations, and communities to ensure that vaccines are accessible, affordable, and acceptable to the populations they serve. Effective immunization programs require strong leadership, adequate funding, robust data systems, and ongoing monitoring and evaluation to assess their impact and identify areas for improvement.

Parasitology is a branch of biology that deals with the study of parasites, their life cycles, the relationship between parasites and their hosts, the transmission of parasitic diseases, and the development of methods for their control and elimination. It involves understanding various types of parasites including protozoa, helminths, and arthropods that can infect humans, animals, and plants. Parasitologists also study the evolution, genetics, biochemistry, and ecology of parasites to develop effective strategies for their diagnosis, treatment, and prevention.

Genes in protozoa refer to the hereditary units of these single-celled organisms that carry genetic information necessary for their growth, development, and reproduction. These genes are made up of DNA (deoxyribonucleic acid) molecules, which contain sequences of nucleotide bases that code for specific proteins or RNA molecules. Protozoan genes are responsible for various functions, such as metabolism, response to environmental stimuli, and reproduction.

It is important to note that the study of protozoan genes has contributed significantly to our understanding of genetics and evolution, particularly in areas such as molecular biology, cell biology, and genomics. However, there is still much to be learned about the genetic diversity and complexity of these organisms, which continue to be an active area of research.

I'm sorry for any confusion, but "Uganda" is not a medical term or concept. It is the name of a country located in East Africa, known officially as the Republic of Uganda. If you have any questions about medical terms or concepts, I would be happy to help with those!

The World Health Organization (WHO) is not a medical condition or term, but rather a specialized agency of the United Nations responsible for international public health. Here's a brief description:

The World Health Organization (WHO) is a specialized agency of the United Nations that acts as the global authority on public health issues. Established in 1948, WHO's primary role is to coordinate and collaborate with its member states to promote health, prevent diseases, and ensure universal access to healthcare services. WHO is headquartered in Geneva, Switzerland, and has regional offices around the world. It plays a crucial role in setting global health standards, monitoring disease outbreaks, and providing guidance on various public health concerns, including infectious diseases, non-communicable diseases, mental health, environmental health, and maternal, newborn, child, and adolescent health.

A mosquito net is not so much a medical definition but rather a description of a device used to prevent insect bites, particularly from mosquitoes. However, I can provide you with a general description and the role it plays in medical and public health contexts:

Mosquito nets are specially designed nets that are draped over beds or other sleeping areas to create a protective barrier against mosquitoes and other insects. They are often made of lightweight, breathable material such as polyester or cotton. In many cases, they are treated with insecticides to enhance their ability to repel or kill insects that come into contact with the netting.

In medical and public health contexts, mosquito nets are frequently used in areas where mosquito-borne diseases such as malaria, dengue fever, yellow fever, and Zika virus are prevalent. By creating a barrier between people and mosquitoes, mosquito nets can help prevent the transmission of these diseases, particularly during sleeping hours when people are most vulnerable to mosquito bites.

Mosquito nets can be used by themselves or in combination with other mosquito-borne disease prevention strategies such as insect repellents, long-sleeved clothing, and indoor residual spraying of insecticides. They are a simple, cost-effective intervention that has been shown to significantly reduce the risk of mosquito-borne diseases in many settings.

"World Health" is not a term that has a specific medical definition. However, it is often used in the context of global health, which can be defined as:

"The area of study, research and practice that places a priority on improving health and achieving equity in health for all people worldwide. It emphasizes trans-national health issues, determinants, and solutions; involves many disciplines within and beyond the health sciences and engages stakeholders from across sectors and societies." (World Health Organization)

Therefore, "world health" could refer to the overall health status and health challenges faced by populations around the world. It encompasses a broad range of factors that affect the health of individuals and communities, including social, economic, environmental, and political determinants. The World Health Organization (WHO) plays a key role in monitoring and promoting global health, setting international standards and guidelines, and coordinating responses to global health emergencies.

Genetic polymorphism refers to the occurrence of multiple forms (called alleles) of a particular gene within a population. These variations in the DNA sequence do not generally affect the function or survival of the organism, but they can contribute to differences in traits among individuals. Genetic polymorphisms can be caused by single nucleotide changes (SNPs), insertions or deletions of DNA segments, or other types of genetic rearrangements. They are important for understanding genetic diversity and evolution, as well as for identifying genetic factors that may contribute to disease susceptibility in humans.

Saponins are a type of naturally occurring chemical compound found in various plants, including soapwords, ginseng, and many others. They are known for their foaming properties, similar to that of soap, which gives them their name "saponin" derived from the Latin word "sapo" meaning soap.

Medically, saponins have been studied for their potential health benefits, including their ability to lower cholesterol levels, reduce inflammation, and boost the immune system. However, they can also have toxic effects in high concentrations, causing gastrointestinal disturbances and potentially damaging red blood cells.

Saponins are typically found in the cell walls of plants and can be extracted through various methods for use in pharmaceuticals, food additives, and cosmetics.

The Diphtheria-Tetanus vaccine, also known as the DT vaccine or Td vaccine (if diphtheria toxoid is not included), is a combination vaccine that protects against two potentially serious bacterial infections: diphtheria and tetanus.

Diphtheria is a respiratory infection that can cause breathing difficulties, heart problems, and nerve damage. Tetanus, also known as lockjaw, is a bacterial infection that affects the nervous system and causes muscle stiffness and spasms, particularly in the jaw and neck.

The vaccine contains small amounts of inactivated toxins (toxoids) from the bacteria that cause diphtheria and tetanus. When the vaccine is administered, it stimulates the immune system to produce antibodies that provide protection against these diseases.

In addition to protecting against diphtheria and tetanus, some formulations of the vaccine may also include protection against pertussis (whooping cough), polio, or hepatitis B. The DTaP vaccine is a similar combination vaccine that includes protection against diphtheria, tetanus, and pertussis, but uses acellular pertussis components instead of the whole-cell pertussis component used in the DT vaccine.

The Diphtheria-Tetanus vaccine is typically given as a series of shots in childhood, with booster shots recommended every 10 years to maintain immunity. It is an important part of routine childhood vaccination and is also recommended for adults who have not received the full series of shots or whose protection has waned over time.

Intranasal administration refers to the delivery of medication or other substances through the nasal passages and into the nasal cavity. This route of administration can be used for systemic absorption of drugs or for localized effects in the nasal area.

When a medication is administered intranasally, it is typically sprayed or dropped into the nostril, where it is absorbed by the mucous membranes lining the nasal cavity. The medication can then pass into the bloodstream and be distributed throughout the body for systemic effects. Intranasal administration can also result in direct absorption of the medication into the local tissues of the nasal cavity, which can be useful for treating conditions such as allergies, migraines, or pain in the nasal area.

Intranasal administration has several advantages over other routes of administration. It is non-invasive and does not require needles or injections, making it a more comfortable option for many people. Additionally, intranasal administration can result in faster onset of action than oral administration, as the medication bypasses the digestive system and is absorbed directly into the bloodstream. However, there are also some limitations to this route of administration, including potential issues with dosing accuracy and patient tolerance.

Poliovirus vaccines are preparations used for active immunization against poliomyelitis, a highly infectious disease caused by the poliovirus. The two types of poliovirus vaccines available are:

1. Inactivated Poliovirus Vaccine (IPV): This vaccine contains inactivated (killed) poliovirus strains of all three serotypes. IPV is typically administered through an injection, usually in combination with other vaccines. It provides a strong immune response and does not carry the risk of vaccine-associated paralytic polio (VAPP), which is a rare but serious adverse event associated with the oral poliovirus vaccine (OPV).

2. Oral Poliovirus Vaccine (OPV): This vaccine contains live attenuated (weakened) poliovirus strains of all three serotypes. OPV is administered orally and induces both humoral and intestinal immunity, which helps prevent the spread of the virus in a community. However, there is a small risk of VAPP associated with this vaccine, especially after multiple doses. In rare cases, the weakened virus can revert to its virulent form and cause paralytic polio in the vaccinated individual or their close contacts.

Both IPV and OPV have been instrumental in global efforts to eradicate polio. The World Health Organization (WHO) recommends using IPV in routine immunization programs, while using OPV during supplementary immunization activities in areas with a high risk of poliovirus transmission.

I believe there may be some confusion in your question. "Rabbits" is a common name used to refer to the Lagomorpha species, particularly members of the family Leporidae. They are small mammals known for their long ears, strong legs, and quick reproduction.

However, if you're referring to "rabbits" in a medical context, there is a term called "rabbit syndrome," which is a rare movement disorder characterized by repetitive, involuntary movements of the fingers, resembling those of a rabbit chewing. It is also known as "finger-chewing chorea." This condition is usually associated with certain medications, particularly antipsychotics, and typically resolves when the medication is stopped or adjusted.

Escherichia coli (E. coli) vaccines are designed to protect against infections caused by various strains of the E. coli bacterium. These vaccines typically contain inactivated or attenuated (weakened) forms of the bacteria, which stimulate an immune response when introduced into the body. The immune system learns to recognize and fight off the specific strain of E. coli used in the vaccine, providing protection against future infections with that strain.

There are several types of E. coli vaccines available or in development, including:

1. Shiga toxin-producing E. coli (STEC) vaccines: These vaccines protect against STEC strains, such as O157:H7 and non-O157 STECs, which can cause severe illness, including hemorrhagic colitis and hemolytic uremic syndrome (HUS).
2. Enterotoxigenic E. coli (ETEC) vaccines: These vaccines target ETEC strains that are a common cause of traveler's diarrhea in people visiting areas with poor sanitation.
3. Enteropathogenic E. coli (EPEC) vaccines: EPEC strains can cause persistent diarrhea, especially in young children in developing countries. Vaccines against these strains are still in the research and development stage.
4. Extraintestinal pathogenic E. coli (ExPEC) vaccines: These vaccines aim to protect against ExPEC strains that can cause urinary tract infections, sepsis, and meningitis.

It is important to note that different E. coli vaccines are designed for specific purposes and may not provide cross-protection against other strains or types of E. coli infections.

West Nile Virus (WNV) vaccines are immunizations that are designed to protect against the West Nile virus, which is a single-stranded RNA virus that belongs to the family Flaviviridae. The virus is primarily transmitted to humans through the bite of infected mosquitoes, particularly those of the Culex species.

There are currently no licensed WNV vaccines available for human use in the United States or Europe. However, there are several veterinary vaccines that have been developed and approved for use in horses and other animals, such as birds and geese. These vaccines work by stimulating the immune system to produce antibodies against the virus, which can help prevent infection and reduce the severity of symptoms in animals that do become infected.

Human WNV vaccine candidates are in various stages of development and testing. Some of these vaccines use inactivated or weakened forms of the virus, while others use only a portion of the viral protein to stimulate an immune response. While these vaccines have shown promise in clinical trials, further research is needed to determine their safety and effectiveness in larger populations before they can be approved for widespread use.

Neutralization tests are a type of laboratory assay used in microbiology and immunology to measure the ability of a substance, such as an antibody or antitoxin, to neutralize the activity of a toxin or infectious agent. In these tests, the substance to be tested is mixed with a known quantity of the toxin or infectious agent, and the mixture is then incubated under controlled conditions. After incubation, the mixture is tested for residual toxicity or infectivity using a variety of methods, such as cell culture assays, animal models, or biochemical assays.

The neutralization titer is then calculated based on the highest dilution of the test substance that completely neutralizes the toxin or infectious agent. Neutralization tests are commonly used in the diagnosis and evaluation of immune responses to vaccines, as well as in the detection and quantification of toxins and other harmful substances.

Examples of neutralization tests include the serum neutralization test for measles antibodies, the plaque reduction neutralization test (PRNT) for dengue virus antibodies, and the cytotoxicity neutralization assay for botulinum neurotoxins.

Parasite load, in medical terms, refers to the total number or quantity of parasites (such as worms, protozoa, or other infectious agents) present in a host organism's body. It is often used to describe the severity of a parasitic infection and can be an important factor in determining the prognosis and treatment plan for the infected individual.

Parasite load can vary widely depending on the type of parasite, the route of infection, the immune status of the host, and other factors. In some cases, even a small number of parasites may cause significant harm if they are highly virulent or located in critical areas of the body. In other cases, large numbers of parasites may be necessary to produce noticeable symptoms.

Measuring parasite load can be challenging, as it often requires specialized laboratory techniques and equipment. However, accurate assessment of parasite load is important for both research and clinical purposes, as it can help researchers develop more effective treatments and allow healthcare providers to monitor the progression of an infection and evaluate the effectiveness of treatment.

Amodiaquine is an antimalarial medication used to prevent and treat malaria caused by the Plasmodium falciparum parasite. It works by inhibiting the growth of the parasite in red blood cells. Amodiaquine is often used in combination with other antimalarial drugs, such as artesunate or chloroquine.

The chemical name for amodiaquine is 4-[(7-chloro-4-quinolinyl)methyl]-1-(4-amino-1-methylbutyl)piperazine and it has the molecular formula C18H24ClN3O. It is available in the form of tablets for oral administration.

Like all medications, amodiaquine can cause side effects, including nausea, vomiting, loss of appetite, and headache. In rare cases, it can cause more serious side effects such as liver damage, abnormal heart rhythms, and blood disorders. It is important to take amodiaquine exactly as directed by a healthcare provider and to report any unusual symptoms or side effects promptly.

It's important to note that Amodiaquine is not available in all countries and it's use is limited due to the risk of severe side effects, especially when used alone. It should be used only under the supervision of a healthcare provider and with regular monitoring of blood cells, liver function and heart activity.

Hemagglutination inhibition (HI) tests are a type of serological assay used in medical laboratories to detect and measure the amount of antibodies present in a patient's serum. These tests are commonly used to diagnose viral infections, such as influenza or HIV, by identifying the presence of antibodies that bind to specific viral antigens and prevent hemagglutination (the agglutination or clumping together of red blood cells).

In an HI test, a small amount of the patient's serum is mixed with a known quantity of the viral antigen, which has been treated to attach to red blood cells. If the patient's serum contains antibodies that bind to the viral antigen, they will prevent the antigen from attaching to the red blood cells and inhibit hemagglutination. The degree of hemagglutination inhibition can be measured and used to estimate the amount of antibody present in the patient's serum.

HI tests are relatively simple and inexpensive to perform, but they have some limitations. For example, they may not detect early-stage infections before the body has had a chance to produce antibodies, and they may not be able to distinguish between different strains of the same virus. Nonetheless, HI tests remain an important tool for diagnosing viral infections and monitoring immune responses to vaccination or infection.

Shigella vaccines are immunizations that are developed to protect against Shigella infection, which is caused by the bacterium Shigella spp. These vaccines aim to stimulate the immune system to produce an immune response (the production of antibodies and activation of immune cells) that will provide protection against future Shigella infections.

There are currently no licensed Shigella vaccines available for use, although several candidate vaccines are in various stages of development and clinical trials. These vaccines typically contain inactivated or attenuated (weakened) forms of the bacteria, or specific components of the bacteria that can stimulate an immune response.

Shigella infection can cause a range of symptoms, including diarrhea, fever, abdominal cramps, and tenesmus (the strong, frequent urge to have a bowel movement). In severe cases, it can lead to complications such as dehydration, seizures, and hemolytic-uremic syndrome (HUS), which is a serious condition that can cause kidney failure. Shigella infection is most commonly transmitted through contaminated food or water, or direct contact with an infected person's feces.

An allele is a variant form of a gene that is located at a specific position on a specific chromosome. Alleles are alternative forms of the same gene that arise by mutation and are found at the same locus or position on homologous chromosomes.

Each person typically inherits two copies of each gene, one from each parent. If the two alleles are identical, a person is said to be homozygous for that trait. If the alleles are different, the person is heterozygous.

For example, the ABO blood group system has three alleles, A, B, and O, which determine a person's blood type. If a person inherits two A alleles, they will have type A blood; if they inherit one A and one B allele, they will have type AB blood; if they inherit two B alleles, they will have type B blood; and if they inherit two O alleles, they will have type O blood.

Alleles can also influence traits such as eye color, hair color, height, and other physical characteristics. Some alleles are dominant, meaning that only one copy of the allele is needed to express the trait, while others are recessive, meaning that two copies of the allele are needed to express the trait.

Sesquiterpenes are a class of terpenes that consist of three isoprene units, hence the name "sesqui-" meaning "one and a half" in Latin. They are composed of 15 carbon atoms and have a wide range of chemical structures and biological activities. Sesquiterpenes can be found in various plants, fungi, and insects, and they play important roles in the defense mechanisms of these organisms. Some sesquiterpenes are also used in traditional medicine and have been studied for their potential therapeutic benefits.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

'Diagnostic tests, routine' is a medical term that refers to standard or commonly used tests that are performed to help diagnose, monitor, or manage a patient's health condition. These tests are typically simple, non-invasive, and safe, and they may be ordered as part of a regular check-up or when a patient presents with specific symptoms.

Routine diagnostic tests may include:

1. Complete Blood Count (CBC): A test that measures the number of red and white blood cells, platelets, and hemoglobin in the blood. It can help diagnose conditions such as anemia, infection, and inflammation.
2. Urinalysis: A test that examines a urine sample for signs of infection, kidney disease, or other medical conditions.
3. Blood Chemistry Tests: Also known as a chemistry panel or comprehensive metabolic panel, this test measures various chemicals in the blood such as glucose, electrolytes, and enzymes to evaluate organ function and overall health.
4. Electrocardiogram (ECG): A test that records the electrical activity of the heart, which can help diagnose heart conditions such as arrhythmias or heart attacks.
5. Chest X-ray: An imaging test that creates pictures of the structures inside the chest, including the heart, lungs, and bones, to help diagnose conditions such as pneumonia or lung cancer.
6. Fecal Occult Blood Test (FOBT): A test that checks for hidden blood in the stool, which can be a sign of colon cancer or other gastrointestinal conditions.
7. Pap Smear: A test that collects cells from the cervix to check for abnormalities that may indicate cervical cancer or other gynecological conditions.

These are just a few examples of routine diagnostic tests that healthcare providers may order. The specific tests ordered will depend on the patient's age, sex, medical history, and current symptoms.

Anemia is a medical condition characterized by a lower than normal number of red blood cells or lower than normal levels of hemoglobin in the blood. Hemoglobin is an important protein in red blood cells that carries oxygen from the lungs to the rest of the body. Anemia can cause fatigue, weakness, shortness of breath, and a pale complexion because the body's tissues are not getting enough oxygen.

Anemia can be caused by various factors, including nutritional deficiencies (such as iron, vitamin B12, or folate deficiency), blood loss, chronic diseases (such as kidney disease or rheumatoid arthritis), inherited genetic disorders (such as sickle cell anemia or thalassemia), and certain medications.

There are different types of anemia, classified based on the underlying cause, size and shape of red blood cells, and the level of hemoglobin in the blood. Treatment for anemia depends on the underlying cause and may include dietary changes, supplements, medication, or blood transfusions.

The Herpes Zoster vaccine, also known as the shingles vaccine, is a preventive measure against the reactivation of the varicella-zoster virus (VZV) in individuals who have previously had chickenpox. The vaccine contains a live but weakened form of VZV that boosts the immune system's ability to recognize and fight off the virus, thereby reducing the risk of developing shingles and its complications. It is typically administered as a single dose for people aged 50 and older, or as a two-dose series for those aged 19 and older who have weakened immune systems.

Polysorbates are a type of nonionic surfactant (a compound that lowers the surface tension between two substances, such as oil and water) commonly used in pharmaceuticals, foods, and cosmetics. They are derived from sorbitol and reacted with ethylene oxide to create a polyoxyethylene structure. The most common types of polysorbates used in medicine are polysorbate 20, polysorbate 40, and polysorbate 60, which differ in the number of oxyethylene groups in their molecular structure.

Polysorbates are often added to pharmaceutical formulations as emulsifiers, solubilizers, or stabilizers. They help to improve the solubility and stability of drugs that are otherwise insoluble in water, allowing for better absorption and bioavailability. Polysorbates can also prevent the aggregation and precipitation of proteins in injectable formulations.

In addition to their use in pharmaceuticals, polysorbates are also used as emulsifiers in food products such as ice cream, salad dressings, and baked goods. They help to mix oil and water-based ingredients together and prevent them from separating. In cosmetics, polysorbates are used as surfactants, solubilizers, and stabilizers in a variety of personal care products.

It is important to note that some people may have allergic reactions to polysorbates, particularly those with sensitivities to sorbitol or other ingredients used in their production. Therefore, it is essential to carefully consider the potential risks and benefits of using products containing polysorbates in individuals who may be at risk for adverse reactions.

A cross-sectional study is a type of observational research design that examines the relationship between variables at one point in time. It provides a snapshot or a "cross-section" of the population at a particular moment, allowing researchers to estimate the prevalence of a disease or condition and identify potential risk factors or associations.

In a cross-sectional study, data is collected from a sample of participants at a single time point, and the variables of interest are measured simultaneously. This design can be used to investigate the association between exposure and outcome, but it cannot establish causality because it does not follow changes over time.

Cross-sectional studies can be conducted using various data collection methods, such as surveys, interviews, or medical examinations. They are often used in epidemiology to estimate the prevalence of a disease or condition in a population and to identify potential risk factors that may contribute to its development. However, because cross-sectional studies only provide a snapshot of the population at one point in time, they cannot account for changes over time or determine whether exposure preceded the outcome.

Therefore, while cross-sectional studies can be useful for generating hypotheses and identifying potential associations between variables, further research using other study designs, such as cohort or case-control studies, is necessary to establish causality and confirm any findings.

A disease vector is a living organism that transmits infectious pathogens from one host to another. These vectors can include mosquitoes, ticks, fleas, and other arthropods that carry viruses, bacteria, parasites, or other disease-causing agents. The vector becomes infected with the pathogen after biting an infected host, and then transmits the infection to another host through its saliva or feces during a subsequent blood meal.

Disease vectors are of particular concern in public health because they can spread diseases rapidly and efficiently, often over large geographic areas. Controlling vector-borne diseases requires a multifaceted approach that includes reducing vector populations, preventing bites, and developing vaccines or treatments for the associated diseases.

A Brucella vaccine is a type of immunization used to protect against brucellosis, an infectious disease caused by bacteria of the genus Brucella. The most commonly used vaccine is the Brucella melitensis Rev-1 strain, which is administered to sheep and goats to prevent the spread of the disease to humans through contaminated food and animal contact.

The Brucella vaccine works by stimulating the immune system to produce a protective response against the bacteria. When the vaccinated animal encounters the actual bacterial infection, their immune system is better prepared to fight it off and prevent the development of clinical disease.

It's important to note that the Brucella vaccine is not approved for use in humans due to the risk of severe side effects and the possibility of causing a false positive result on brucellosis diagnostic tests. Therefore, it should only be administered to animals under the supervision of a veterinarian.

Ethanolamines are a class of organic compounds that contain an amino group (-NH2) and a hydroxyl group (-OH) attached to a carbon atom. They are derivatives of ammonia (NH3) in which one or two hydrogen atoms have been replaced by a ethanol group (-CH2CH2OH).

The most common ethanolamines are:

* Monethanolamine (MEA), also called 2-aminoethanol, with the formula HOCH2CH2NH2.
* Diethanolamine (DEA), also called 2,2'-iminobisethanol, with the formula HOCH2CH2NHCH2CH2OH.
* Triethanolamine (TEA), also called 2,2',2''-nitrilotrisethanol, with the formula N(CH2CH2OH)3.

Ethanolamines are used in a wide range of industrial and consumer products, including as solvents, emulsifiers, detergents, pharmaceuticals, and personal care products. They also have applications as intermediates in the synthesis of other chemicals. In the body, ethanolamines play important roles in various biological processes, such as neurotransmission and cell signaling.

Communicable disease control is a branch of public health that focuses on preventing and controlling the spread of infectious diseases within a population. The goal is to reduce the incidence and prevalence of communicable diseases through various strategies, such as:

1. Surveillance: Monitoring and tracking the occurrence of communicable diseases in a population to identify trends, outbreaks, and high-risk areas.
2. Prevention: Implementing measures to prevent the transmission of infectious agents, such as vaccination programs, education campaigns, and environmental interventions (e.g., water treatment, food safety).
3. Case management: Identifying, diagnosing, and treating cases of communicable diseases to reduce their duration and severity, as well as to prevent further spread.
4. Contact tracing: Identifying and monitoring individuals who have been in close contact with infected persons to detect and prevent secondary cases.
5. Outbreak response: Coordinating a rapid and effective response to disease outbreaks, including the implementation of control measures, communication with affected communities, and evaluation of interventions.
6. Collaboration: Working closely with healthcare providers, laboratories, policymakers, and other stakeholders to ensure a coordinated and comprehensive approach to communicable disease control.
7. Research: Conducting research to better understand the epidemiology, transmission dynamics, and prevention strategies for communicable diseases.

Effective communicable disease control requires a multidisciplinary approach that combines expertise in medicine, epidemiology, microbiology, public health, social sciences, and healthcare management.

Genetic variation refers to the differences in DNA sequences among individuals and populations. These variations can result from mutations, genetic recombination, or gene flow between populations. Genetic variation is essential for evolution by providing the raw material upon which natural selection acts. It can occur within a single gene, between different genes, or at larger scales, such as differences in the number of chromosomes or entire sets of chromosomes. The study of genetic variation is crucial in understanding the genetic basis of diseases and traits, as well as the evolutionary history and relationships among species.

Tetanus toxoid is a purified and inactivated form of the tetanus toxin, which is derived from the bacterium Clostridium tetani. It is used as a vaccine to induce active immunity against tetanus, a potentially fatal disease caused by this toxin. The toxoid is produced through a series of chemical treatments that modify the toxic properties of the tetanus toxin while preserving its antigenic qualities. This allows the immune system to recognize and develop protective antibodies against the toxin without causing illness. Tetanus toxoid is often combined with diphtheria and/or pertussis toxoids in vaccines such as DTaP, Tdap, and Td.

I'm sorry for any confusion, but "International Cooperation" is not a medical term. It refers to the collaboration and exchange of resources and information between countries or international organizations in various fields, including politics, economics, culture, environment, and security, among others. In the context of healthcare and medicine, international cooperation can involve joint research projects, sharing of data and clinical trial results, collaborative efforts to combat global health issues (such as infectious diseases or chronic conditions), capacity building in low-resource settings, and standardizing medical practices and guidelines across countries.

Immunologic memory, also known as adaptive immunity, refers to the ability of the immune system to recognize and mount a more rapid and effective response upon subsequent exposure to a pathogen or antigen that it has encountered before. This is a key feature of the vertebrate immune system and allows for long-term protection against infectious diseases.

Immunologic memory is mediated by specialized cells called memory T cells and B cells, which are produced during the initial response to an infection or immunization. These cells persist in the body after the pathogen has been cleared and can quickly respond to future encounters with the same or similar antigens. This rapid response leads to a more effective and efficient elimination of the pathogen, resulting in fewer symptoms and reduced severity of disease.

Immunologic memory is the basis for vaccines, which work by exposing the immune system to a harmless form of a pathogen or its components, inducing an initial response and generating memory cells that provide long-term protection against future infections.

I'm sorry for any confusion, but "Malawi" is not a medical term. It is the name of a country located in southeastern Africa. If you have any questions about medical terminology or health-related topics, I would be happy to help with those!

Lipid A is the biologically active component of lipopolysaccharides (LPS), which are found in the outer membrane of Gram-negative bacteria. It is responsible for the endotoxic activity of LPS and plays a crucial role in the pathogenesis of gram-negative bacterial infections. Lipid A is a glycophosphatidylinositol (GPI) anchor, consisting of a glucosamine disaccharide backbone with multiple fatty acid chains and phosphate groups attached to it. It can induce the release of proinflammatory cytokines, fever, and other symptoms associated with sepsis when introduced into the bloodstream.

DNA Sequence Analysis is the systematic determination of the order of nucleotides in a DNA molecule. It is a critical component of modern molecular biology, genetics, and genetic engineering. The process involves determining the exact order of the four nucleotide bases - adenine (A), guanine (G), cytosine (C), and thymine (T) - in a DNA molecule or fragment. This information is used in various applications such as identifying gene mutations, studying evolutionary relationships, developing molecular markers for breeding, and diagnosing genetic diseases.

The process of DNA Sequence Analysis typically involves several steps, including DNA extraction, PCR amplification (if necessary), purification, sequencing reaction, and electrophoresis. The resulting data is then analyzed using specialized software to determine the exact sequence of nucleotides.

In recent years, high-throughput DNA sequencing technologies have revolutionized the field of genomics, enabling the rapid and cost-effective sequencing of entire genomes. This has led to an explosion of genomic data and new insights into the genetic basis of many diseases and traits.

"Plasmodium ovale" is a species of protozoan parasites that are transmitted to humans through the bites of infected female Anopheles mosquitoes. This parasite causes a type of malaria known as "ovale malaria," which is generally milder than other forms of malaria caused by Plasmodium falciparum or Plasmodium vivax.

The life cycle of Plasmodium ovale involves two hosts: the mosquito and humans. When an infected mosquito bites a human, the parasites are injected into the skin along with the mosquito's saliva. The parasites then enter the liver where they multiply and form dormant stages called hypnozoites. After a period of time (usually several weeks to months), the hypnozoites become activated and begin to infect red blood cells, leading to the symptoms of malaria.

The symptoms of ovale malaria are similar to those of other forms of malaria and include fever, chills, headache, muscle and joint pain, and fatigue. However, ovale malaria is less likely to cause severe complications or death than falciparum malaria. Diagnosis of ovale malaria is typically made through microscopic examination of blood smears or by using rapid diagnostic tests (RDTs) that detect parasite antigens in the blood. Treatment usually involves the use of antimalarial drugs such as chloroquine or primaquine.

Health Services Administration (HSA) is not a medical term per se, but rather a field of study and practice within healthcare management. Here's a definition that encompasses its meaning:

Health Services Administration (HSA) refers to the planning, directing, coordinating, and supervising of health services in hospitals, clinics, nursing homes, public health agencies, and other medical facilities. It involves managing financial resources, developing organizational policies, ensuring quality assurance, maintaining regulatory compliance, and promoting efficient delivery of healthcare services to improve patient outcomes and overall population health. HSA professionals may hold titles such as hospital administrator, clinical director, or healthcare executive.

An "injection, intradermal" refers to a type of injection where a small quantity of a substance is introduced into the layer of skin between the epidermis and dermis, using a thin gauge needle. This technique is often used for diagnostic or research purposes, such as conducting allergy tests or administering immunizations in a way that stimulates a strong immune response. The injection site typically produces a small, raised bump (wheal) that disappears within a few hours. It's important to note that intradermal injections should be performed by trained medical professionals to minimize the risk of complications.

Epitope mapping is a technique used in immunology to identify the specific portion or regions (called epitopes) on an antigen that are recognized and bind to antibodies or T-cell receptors. This process helps to understand the molecular basis of immune responses against various pathogens, allergens, or transplanted tissues.

Epitope mapping can be performed using different methods such as:

1. Peptide scanning: In this method, a series of overlapping peptides spanning the entire length of the antigen are synthesized and tested for their ability to bind to antibodies or T-cell receptors. The peptide that shows binding is considered to contain the epitope.
2. Site-directed mutagenesis: In this approach, specific amino acids within the antigen are altered, and the modified antigens are tested for their ability to bind to antibodies or T-cell receptors. This helps in identifying the critical residues within the epitope.
3. X-ray crystallography and NMR spectroscopy: These techniques provide detailed information about the three-dimensional structure of antigen-antibody complexes, allowing for accurate identification of epitopes at an atomic level.

The results from epitope mapping can be useful in various applications, including vaccine design, diagnostic test development, and understanding the basis of autoimmune diseases.

I apologize, but "Brazil" is not a medical term or condition. It is the largest country in both South America and Latin America by land area and population. If you have any questions related to medical terminology or health concerns, please provide more information and I will do my best to help.

Prevalence, in medical terms, refers to the total number of people in a given population who have a particular disease or condition at a specific point in time, or over a specified period. It is typically expressed as a percentage or a ratio of the number of cases to the size of the population. Prevalence differs from incidence, which measures the number of new cases that develop during a certain period.

"Drug design" is the process of creating and developing a new medication or therapeutic agent to treat or prevent a specific disease or condition. It involves identifying potential targets within the body, such as proteins or enzymes that are involved in the disease process, and then designing small molecules or biologics that can interact with these targets to produce a desired effect.

The drug design process typically involves several stages, including:

1. Target identification: Researchers identify a specific molecular target that is involved in the disease process.
2. Lead identification: Using computational methods and high-throughput screening techniques, researchers identify small molecules or biologics that can interact with the target.
3. Lead optimization: Researchers modify the chemical structure of the lead compound to improve its ability to interact with the target, as well as its safety and pharmacokinetic properties.
4. Preclinical testing: The optimized lead compound is tested in vitro (in a test tube or petri dish) and in vivo (in animals) to evaluate its safety and efficacy.
5. Clinical trials: If the preclinical testing is successful, the drug moves on to clinical trials in humans to further evaluate its safety and efficacy.

The ultimate goal of drug design is to create a new medication that is safe, effective, and can be used to improve the lives of patients with a specific disease or condition.

Herpesvirus vaccines are immunizations designed to protect against infections caused by herpesviruses. These viruses include herpes simplex virus type 1 (HSV-1), which primarily causes oral herpes, and herpes simplex virus type 2 (HSV-2), which primarily causes genital herpes. Additionally, other herpesviruses such as varicella-zoster virus (VZV), which causes chickenpox and shingles, and cytomegalovirus (CMV), which can cause serious complications in newborns and immunocompromised individuals, are also targeted by herpesvirus vaccines.

Herpesvirus vaccines work by exposing the immune system to a weakened or inactivated form of the virus, or to specific viral proteins, which triggers an immune response. This response includes the production of antibodies and activation of T-cells that recognize and attack the virus if it enters the body in the future.

Currently, there are vaccines available for HSV-1 and HSV-2, but they are not widely used. The only FDA-approved herpesvirus vaccine is for VZV, which is marketed as Varivax and prevents chickenpox and reduces the risk of shingles. There are also several experimental vaccines in development for other herpesviruses, including HSV-1, HSV-2, and CMV.

Recombinant fusion proteins are artificially created biomolecules that combine the functional domains or properties of two or more different proteins into a single protein entity. They are generated through recombinant DNA technology, where the genes encoding the desired protein domains are linked together and expressed as a single, chimeric gene in a host organism, such as bacteria, yeast, or mammalian cells.

The resulting fusion protein retains the functional properties of its individual constituent proteins, allowing for novel applications in research, diagnostics, and therapeutics. For instance, recombinant fusion proteins can be designed to enhance protein stability, solubility, or immunogenicity, making them valuable tools for studying protein-protein interactions, developing targeted therapies, or generating vaccines against infectious diseases or cancer.

Examples of recombinant fusion proteins include:

1. Etaglunatide (ABT-523): A soluble Fc fusion protein that combines the heavy chain fragment crystallizable region (Fc) of an immunoglobulin with the extracellular domain of the human interleukin-6 receptor (IL-6R). This fusion protein functions as a decoy receptor, neutralizing IL-6 and its downstream signaling pathways in rheumatoid arthritis.
2. Etanercept (Enbrel): A soluble TNF receptor p75 Fc fusion protein that binds to tumor necrosis factor-alpha (TNF-α) and inhibits its proinflammatory activity, making it a valuable therapeutic option for treating autoimmune diseases like rheumatoid arthritis, ankylosing spondylitis, and psoriasis.
3. Abatacept (Orencia): A fusion protein consisting of the extracellular domain of cytotoxic T-lymphocyte antigen 4 (CTLA-4) linked to the Fc region of an immunoglobulin, which downregulates T-cell activation and proliferation in autoimmune diseases like rheumatoid arthritis.
4. Belimumab (Benlysta): A monoclonal antibody that targets B-lymphocyte stimulator (BLyS) protein, preventing its interaction with the B-cell surface receptor and inhibiting B-cell activation in systemic lupus erythematosus (SLE).
5. Romiplostim (Nplate): A fusion protein consisting of a thrombopoietin receptor agonist peptide linked to an immunoglobulin Fc region, which stimulates platelet production in patients with chronic immune thrombocytopenia (ITP).
6. Darbepoetin alfa (Aranesp): A hyperglycosylated erythropoiesis-stimulating protein that functions as a longer-acting form of recombinant human erythropoietin, used to treat anemia in patients with chronic kidney disease or cancer.
7. Palivizumab (Synagis): A monoclonal antibody directed against the F protein of respiratory syncytial virus (RSV), which prevents RSV infection and is administered prophylactically to high-risk infants during the RSV season.
8. Ranibizumab (Lucentis): A recombinant humanized monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), used in the treatment of age-related macular degeneration, diabetic retinopathy, and other ocular disorders.
9. Cetuximab (Erbitux): A chimeric monoclonal antibody that binds to epidermal growth factor receptor (EGFR), used in the treatment of colorectal cancer and head and neck squamous cell carcinoma.
10. Adalimumab (Humira): A fully humanized monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), used in the treatment of various inflammatory diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease.
11. Bevacizumab (Avastin): A recombinant humanized monoclonal antibody that binds to VEGF-A, used in the treatment of various cancers, including colorectal, lung, breast, and kidney cancer.
12. Trastuzumab (Herceptin): A humanized monoclonal antibody that targets HER2/neu receptor, used in the treatment of breast cancer.
13. Rituximab (Rituxan): A chimeric monoclonal antibody that binds to CD20 antigen on B cells, used in the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis.
14. Palivizumab (Synagis): A humanized monoclonal antibody that binds to the F protein of respiratory syncytial virus, used in the prevention of respiratory syncytial virus infection in high-risk infants.
15. Infliximab (Remicade): A chimeric monoclonal antibody that targets TNF-α, used in the treatment of various inflammatory diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis.
16. Natalizumab (Tysabri): A humanized monoclonal antibody that binds to α4β1 integrin, used in the treatment of multiple sclerosis and Crohn's disease.
17. Adalimumab (Humira): A fully human monoclonal antibody that targets TNF-α, used in the treatment of various inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
18. Golimumab (Simponi): A fully human monoclonal antibody that targets TNF-α, used in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
19. Certolizumab pegol (Cimzia): A PEGylated Fab' fragment of a humanized monoclonal antibody that targets TNF-α, used in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
20. Ustekinumab (Stelara): A fully human monoclonal antibody that targets IL-12 and IL-23, used in the treatment of psoriasis, psoriatic arthritis, and Crohn's disease.
21. Secukinumab (Cosentyx): A fully human monoclonal antibody that targets IL-17A, used in the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis.
22. Ixekizumab (Taltz): A fully human monoclonal antibody that targets IL-17A, used in the treatment of psoriasis and psoriatic arthritis.
23. Brodalumab (Siliq): A fully human monoclonal antibody that targets IL-17 receptor A, used in the treatment of psoriasis.
24. Sarilumab (Kevzara): A fully human monoclonal antibody that targets the IL-6 receptor, used in the treatment of rheumatoid arthritis.
25. Tocilizumab (Actemra): A humanized monoclonal antibody that targets the IL-6 receptor, used in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, and chimeric antigen receptor T-cell-induced cytokine release syndrome.
26. Siltuximab (Sylvant): A chimeric monoclonal antibody that targets IL-6, used in the treatment of multicentric Castleman disease.
27. Satralizumab (Enspryng): A humanized monoclonal antibody that targets IL-6 receptor alpha, used in the treatment of neuromyelitis optica spectrum disorder.
28. Sirukumab (Plivensia): A human monoclonal antibody that targets IL-6, used in the treatment

A rural population refers to people who live in areas that are outside of urban areas, typically defined as having fewer than 2,000 residents and lacking certain infrastructure and services such as running water, sewage systems, and paved roads. Rural populations often have less access to healthcare services, education, and economic opportunities compared to their urban counterparts. This population group can face unique health challenges, including higher rates of poverty, limited access to specialized medical care, and a greater exposure to environmental hazards such as agricultural chemicals and industrial pollutants.

I'm not aware of any medical definitions associated with the term "Benin." Benin is a country located in West Africa, and its name is used in medical literature to describe conditions or issues related to that country, such as diseases prevalent there. However, without additional context, it's difficult to provide a specific medical definition for 'Benin.'

Leishmaniasis vaccines do not currently exist for human use, despite extensive research efforts. However, the concept and goal of a leishmaniasis vaccine refer to a potential prophylactic treatment that would prevent or significantly reduce the risk of contracting Leishmania infections, which cause various clinical manifestations of the disease.

Leishmaniasis is a vector-borne neglected tropical disease caused by protozoan parasites of the Leishmania genus, transmitted through the bite of infected female sandflies. The disease has diverse clinical presentations, ranging from self-healing cutaneous lesions (localized cutaneous leishmaniasis) to destructive mucocutaneous forms (mucocutaneous leishmaniasis) and potentially fatal visceral leishmaniasis, also known as kala-azar.

The development of an effective vaccine against Leishmania infections is challenging due to the complexity of the parasite's life cycle, genetic diversity, and the variety of clinical outcomes it can cause. Several vaccine candidates have been investigated, primarily focusing on inducing cell-mediated immunity, particularly a Th1 response. These candidates include:

1. First-generation vaccines: These are whole-parasite or live-attenuated vaccines, such as Leishmania major (Lm) strain Friedlin and Leishmania tarentolae. Although these vaccines have shown promising results in animal models, their use in humans is limited due to safety concerns.
2. Second-generation vaccines: These involve subunit or recombinant protein vaccines, which utilize specific antigens from the parasite to stimulate an immune response. Examples include Leishmania antigens such as Leishmania major stress-inducible protein 1 (LiSP1), Leishmania donovani A2, and Leishmania infantum nucleoside hydrolase (LiNH36).
3. Third-generation vaccines: These are DNA or RNA/mRNA vaccines that encode specific antigens from the parasite to stimulate an immune response. Examples include plasmid DNA vaccines encoding Leishmania major HSP70 and Leishmania donovani A2.
4. Adjuvant systems: To enhance the immunogenicity of these vaccine candidates, various adjuvants are being explored, such as saponins (QS-21), cytokines (GM-CSF), and TLR agonists (CpG oligodeoxynucleotides).

Despite significant progress in developing Leishmania vaccines, no licensed vaccine is currently available for human use. Further research is required to optimize the formulation, delivery, and safety of these vaccine candidates to ensure their effectiveness against various Leishmania species and clinical manifestations.

I'm sorry for any confusion, but "rain" is not a medical term. In general, rain refers to water droplets that fall from the sky as part of the Earth's weather cycle. These drops form when moisture in the air condenses and cools, creating clouds which eventually become heavy enough to release the collected water.

If you have any medical concerns or questions, I'd be happy to try and help answer those for you!

'Influenza A Virus, H1N1 Subtype' is a specific subtype of the influenza A virus that causes flu in humans and animals. It contains certain proteins called hemagglutinin (H) and neuraminidase (N) on its surface, with this subtype specifically having H1 and N1 antigens. The H1N1 strain is well-known for causing the 2009 swine flu pandemic, which was a global outbreak of flu that resulted in significant morbidity and mortality. This subtype can also cause seasonal flu, although the severity and symptoms may vary. It is important to note that influenza viruses are constantly changing, and new strains or subtypes can emerge over time, requiring regular updates to vaccines to protect against them.

Diphtheria toxoid is a modified form of the diphtheria toxin that has been made harmless but still stimulates an immune response. It is used in vaccines to provide immunity against diphtheria, a serious bacterial infection that can cause breathing difficulties, heart failure, and paralysis. The toxoid is typically combined with other components in a vaccine, such as tetanus toxoid and pertussis vaccine, to form a combination vaccine that protects against multiple diseases.

The diphtheria toxoid is made by treating the diphtheria toxin with formaldehyde, which modifies the toxin's structure and makes it nontoxic while still retaining its ability to stimulate an immune response. When the toxoid is introduced into the body through vaccination, the immune system recognizes it as a foreign substance and produces antibodies against it. These antibodies then provide protection against future infections with the diphtheria bacteria.

The diphtheria toxoid vaccine is usually given as part of a routine childhood immunization schedule, starting at 2 months of age. Booster shots are recommended throughout childhood and adolescence, and adults may also need booster shots if they have not received them previously or if their immune status has changed.

I'm not aware of any medical condition or term that is specifically associated with or referred to as "Cameroon." Cameroon is a country located in Central Africa, known for its rich biodiversity and cultural diversity. If you have more context about why you are looking for a medical definition of "Cameroon," I may be able to provide a more helpful response.

Placental diseases, also known as placental pathologies, refer to a group of conditions that affect the development and function of the placenta during pregnancy. The placenta is an organ that develops in the uterus during pregnancy and provides oxygen and nutrients to the developing fetus while removing waste products.

Placental diseases can have serious consequences for both the mother and the fetus, including preterm labor, growth restriction, stillbirth, and long-term health problems for the child. Some common placental diseases include:

1. Placental abruption: This occurs when the placenta separates from the uterine wall before delivery, causing bleeding and potentially harming the fetus.
2. Placental previa: This is a condition where the placenta implants in the lower part of the uterus, covering the cervix. It can cause bleeding and may require cesarean delivery.
3. Preeclampsia: This is a pregnancy-related disorder characterized by high blood pressure and damage to organs such as the liver and kidneys. Placental dysfunction is thought to play a role in its development.
4. Intrauterine growth restriction (IUGR): This occurs when the fetus does not grow properly due to poor placental function, leading to low birth weight and potential health problems.
5. Chorioamnionitis: This is an infection of the membranes surrounding the fetus, which can lead to preterm labor and other complications.
6. Placental infarction: This occurs when a portion of the placenta dies due to a lack of blood flow, which can lead to growth restriction or stillbirth.

Prompt diagnosis and treatment of placental diseases are essential for ensuring the best possible outcomes for both the mother and the fetus.

Lymphocyte activation is the process by which B-cells and T-cells (types of lymphocytes) become activated to perform effector functions in an immune response. This process involves the recognition of specific antigens presented on the surface of antigen-presenting cells, such as dendritic cells or macrophages.

The activation of B-cells leads to their differentiation into plasma cells that produce antibodies, while the activation of T-cells results in the production of cytotoxic T-cells (CD8+ T-cells) that can directly kill infected cells or helper T-cells (CD4+ T-cells) that assist other immune cells.

Lymphocyte activation involves a series of intracellular signaling events, including the binding of co-stimulatory molecules and the release of cytokines, which ultimately result in the expression of genes involved in cell proliferation, differentiation, and effector functions. The activation process is tightly regulated to prevent excessive or inappropriate immune responses that can lead to autoimmunity or chronic inflammation.

"Pichia" is a genus of single-celled yeast organisms that are commonly found in various environments, including on plant and animal surfaces, in soil, and in food. Some species of Pichia are capable of causing human infection, particularly in individuals with weakened immune systems. These infections can include fungemia (bloodstream infections), pneumonia, and urinary tract infections.

Pichia species are important in a variety of industrial processes, including the production of alcoholic beverages, biofuels, and enzymes. They are also used as model organisms for research in genetics and cell biology.

It's worth noting that Pichia was previously classified under the genus "Candida," but it has since been reclassified due to genetic differences between the two groups.

Phase II clinical trials are a type of medical research study that aims to assess the safety and effectiveness of a new drug or intervention in a specific patient population. These studies typically follow successful completion of Phase I clinical trials, which focus primarily on evaluating the safety and dosage of the treatment in a small group of healthy volunteers.

In Phase II clinical trials, the treatment is tested in a larger group of patients (usually several hundred) who have the condition or disease that the treatment is intended to treat. The main goals of these studies are to:

1. Determine the optimal dosage range for the treatment
2. Evaluate the safety and side effects of the treatment at different doses
3. Assess how well the treatment works in treating the target condition or disease

Phase II clinical trials are typically randomized, controlled studies, meaning that participants are randomly assigned to receive either the new treatment or a comparison group, such as a placebo or standard of care. The study is also often blinded, meaning that neither the participants nor the researchers know who is receiving which treatment. This helps to minimize bias and ensure that the results are due to the treatment itself rather than other factors.

Overall, Phase II clinical trials play an important role in determining whether a new drug or intervention is safe and effective enough to move on to larger, more expensive Phase III clinical trials, which involve even larger groups of patients and are designed to confirm and expand upon the results of Phase II studies.

Bacterial antigens are substances found on the surface or produced by bacteria that can stimulate an immune response in a host organism. These antigens can be proteins, polysaccharides, teichoic acids, lipopolysaccharides, or other molecules that are recognized as foreign by the host's immune system.

When a bacterial antigen is encountered by the host's immune system, it triggers a series of responses aimed at eliminating the bacteria and preventing infection. The host's immune system recognizes the antigen as foreign through the use of specialized receptors called pattern recognition receptors (PRRs), which are found on various immune cells such as macrophages, dendritic cells, and neutrophils.

Once a bacterial antigen is recognized by the host's immune system, it can stimulate both the innate and adaptive immune responses. The innate immune response involves the activation of inflammatory pathways, the recruitment of immune cells to the site of infection, and the production of antimicrobial peptides.

The adaptive immune response, on the other hand, involves the activation of T cells and B cells, which are specific to the bacterial antigen. These cells can recognize and remember the antigen, allowing for a more rapid and effective response upon subsequent exposures.

Bacterial antigens are important in the development of vaccines, as they can be used to stimulate an immune response without causing disease. By identifying specific bacterial antigens that are associated with virulence or pathogenicity, researchers can develop vaccines that target these antigens and provide protection against infection.

Attenuated vaccines consist of live microorganisms that have been weakened (attenuated) through various laboratory processes so they do not cause disease in the majority of recipients but still stimulate an immune response. The purpose of attenuation is to reduce the virulence or replication capacity of the pathogen while keeping it alive, allowing it to retain its antigenic properties and induce a strong and protective immune response.

Examples of attenuated vaccines include:

1. Sabin oral poliovirus vaccine (OPV): This vaccine uses live but weakened polioviruses to protect against all three strains of the disease-causing poliovirus. The weakened viruses replicate in the intestine and induce an immune response, which provides both humoral (antibody) and cell-mediated immunity.
2. Measles, mumps, and rubella (MMR) vaccine: This combination vaccine contains live attenuated measles, mumps, and rubella viruses. It is given to protect against these three diseases and prevent their spread in the population.
3. Varicella (chickenpox) vaccine: This vaccine uses a weakened form of the varicella-zoster virus, which causes chickenpox. By introducing this attenuated virus into the body, it stimulates an immune response that protects against future infection with the wild-type virus.
4. Yellow fever vaccine: This live attenuated vaccine is used to prevent yellow fever, a viral disease transmitted by mosquitoes in tropical and subtropical regions of Africa and South America. The vaccine contains a weakened form of the yellow fever virus that cannot cause the disease but still induces an immune response.
5. Bacillus Calmette-Guérin (BCG) vaccine: This live attenuated vaccine is used to protect against tuberculosis (TB). It contains a weakened strain of Mycobacterium bovis, which does not cause TB in humans but stimulates an immune response that provides some protection against the disease.

Attenuated vaccines are generally effective at inducing long-lasting immunity and can provide robust protection against targeted diseases. However, they may pose a risk for individuals with weakened immune systems, as the attenuated viruses or bacteria could potentially cause illness in these individuals. Therefore, it is essential to consider an individual's health status before administering live attenuated vaccines.

Herpes simplex virus vaccines are types of vaccines that are being developed to prevent infections caused by the herpes simplex viruses (HSV), which include HSV-1 and HSV-2. These viruses can cause painful blisters or sores on the skin or mucous membranes, such as those found inside the mouth or genitals.

There are currently no approved vaccines for HSV-1 or HSV-2, although several candidates are in various stages of development. The goal of an HSV vaccine is to stimulate the immune system to produce a strong and durable response that can prevent infection with the virus or reduce the severity and frequency of outbreaks in people who are already infected.

HSV vaccines typically work by introducing a harmless piece of the virus, such as a protein or a weakened or killed virus, to the body. This triggers the immune system to produce antibodies and activate immune cells that can recognize and attack the virus if it enters the body in the future. Some HSV vaccine candidates are designed to stimulate both arms of the immune system (humoral and cell-mediated immunity), while others focus on one or the other.

While there is no cure for herpes simplex virus infections, a successful vaccine could help prevent the spread of the virus and reduce the burden of disease.

Squalene is a organic compound that is a polyunsaturated triterpene. It is a natural component of human skin surface lipids and sebum, where it plays a role in maintaining the integrity and permeability barrier of the stratum corneum. Squalene is also found in various plant and animal tissues, including olive oil, wheat germ oil, and shark liver oil.

In the body, squalene is an intermediate in the biosynthesis of cholesterol and other sterols. It is produced in the liver and transported to other tissues via low-density lipoproteins (LDLs). Squalene has been studied for its potential health benefits due to its antioxidant properties, as well as its ability to modulate immune function and reduce the risk of certain types of cancer. However, more research is needed to confirm these potential benefits.

Respiratory Syncytial Virus (RSV) vaccines are immunizations designed to protect against the RSV infection, which is a major cause of respiratory tract illnesses in infants and young children worldwide. The virus can also cause serious illness in older adults and people with weakened immune systems.

There are currently no approved RSV vaccines available on the market, although several candidates are in various stages of development and clinical trials. Most of the vaccine candidates are aimed at preventing severe lower respiratory tract disease caused by RSV infection in infants and young children.

RSV vaccines typically work by stimulating the immune system to produce antibodies against the virus, which can help prevent infection or reduce the severity of symptoms if infection occurs. Some vaccine candidates use live-attenuated viruses, while others use inactivated viruses or viral proteins to induce an immune response.

While RSV vaccines have shown promise in clinical trials, developing a safe and effective vaccine has proven challenging due to the risk of vaccine-associated enhanced respiratory disease (VAERD), a rare but serious complication that can occur when certain types of RSV vaccines are given to people who have previously been infected with the virus. Therefore, ongoing research is focused on developing vaccines that can safely and effectively protect against RSV infection while minimizing the risk of VAERD.

A disease outbreak is defined as the occurrence of cases of a disease in excess of what would normally be expected in a given time and place. It may affect a small and localized group or a large number of people spread over a wide area, even internationally. An outbreak may be caused by a new agent, a change in the agent's virulence or host susceptibility, or an increase in the size or density of the host population.

Outbreaks can have significant public health and economic impacts, and require prompt investigation and control measures to prevent further spread of the disease. The investigation typically involves identifying the source of the outbreak, determining the mode of transmission, and implementing measures to interrupt the chain of infection. This may include vaccination, isolation or quarantine, and education of the public about the risks and prevention strategies.

Examples of disease outbreaks include foodborne illnesses linked to contaminated food or water, respiratory infections spread through coughing and sneezing, and mosquito-borne diseases such as Zika virus and West Nile virus. Outbreaks can also occur in healthcare settings, such as hospitals and nursing homes, where vulnerable populations may be at increased risk of infection.

DDT (dichlorodiphenyltrichloroethane) is a synthetic insecticide that was widely used in the mid-20th century to control agricultural pests and vector-borne diseases such as malaria. It belongs to a class of chemicals called organochlorines, which are known for their persistence in the environment and potential for bioaccumulation in the food chain.

DDT was first synthesized in 1874, but its insecticidal properties were not discovered until 1939. Its use as an insecticide became widespread during World War II, when it was used to control typhus and malaria-carrying lice and mosquitoes among troops. After the war, DDT was widely adopted for agricultural and public health purposes.

However, concerns about the environmental and human health effects of DDT led to its ban or severe restriction in many countries starting in the 1970s. The United States banned the use of DDT for most purposes in 1972, and the Stockholm Convention on Persistent Organic Pollutants (POPs) prohibited its production and use globally in 2004, except in cases where there is a risk of vector-borne diseases.

DDT has been linked to several health problems, including reproductive effects, developmental toxicity, neurotoxicity, and endocrine disruption. It is also highly persistent in the environment, with a half-life of up to 15 years in soil and up to 30 years in water. This means that DDT can accumulate in the food chain, posing risks to wildlife and humans who consume contaminated food or water.

In summary, DDT is a synthetic insecticide that was widely used in the mid-20th century but has been banned or restricted in many countries due to its environmental and health effects. It belongs to a class of chemicals called organochlorines, which are known for their persistence in the environment and potential for bioaccumulation in the food chain. DDT has been linked to several health problems, including reproductive effects, developmental toxicity, neurotoxicity, and endocrine disruption.

Medical topography refers to the detailed description and mapping of the locations and relative positions of various anatomical structures, abnormalities, or lesions in the body. It is often used in the context of imaging techniques such as X-rays, CT scans, or MRI scans, where it helps to visualize and communicate the spatial relationships between different bodily features. Medical topography may also involve the use of physical examination, surgical exploration, or other diagnostic methods to gather information about the location and extent of medical conditions.

In summary, medical topography is a detailed mapping and description of the location and position of anatomical structures or pathological changes in the body.

I'm sorry for any confusion, but "Nigeria" is not a medical term. It is a country located in West Africa, and it is the most populous country in Africa. If you have any questions about medical conditions or terms, I would be happy to help clarify those for you.

Cytokines are a broad and diverse category of small signaling proteins that are secreted by various cells, including immune cells, in response to different stimuli. They play crucial roles in regulating the immune response, inflammation, hematopoiesis, and cellular communication.

Cytokines mediate their effects by binding to specific receptors on the surface of target cells, which triggers intracellular signaling pathways that ultimately result in changes in gene expression, cell behavior, and function. Some key functions of cytokines include:

1. Regulating the activation, differentiation, and proliferation of immune cells such as T cells, B cells, natural killer (NK) cells, and macrophages.
2. Coordinating the inflammatory response by recruiting immune cells to sites of infection or tissue damage and modulating their effector functions.
3. Regulating hematopoiesis, the process of blood cell formation in the bone marrow, by controlling the proliferation, differentiation, and survival of hematopoietic stem and progenitor cells.
4. Modulating the development and function of the nervous system, including neuroinflammation, neuroprotection, and neuroregeneration.

Cytokines can be classified into several categories based on their structure, function, or cellular origin. Some common types of cytokines include interleukins (ILs), interferons (IFNs), tumor necrosis factors (TNFs), chemokines, colony-stimulating factors (CSFs), and transforming growth factors (TGFs). Dysregulation of cytokine production and signaling has been implicated in various pathological conditions, such as autoimmune diseases, chronic inflammation, cancer, and neurodegenerative disorders.

"Malaria Vaccines". PubChem. U.S. National Library of Medicine. Malaria Vaccine Initiative Malaria vaccines UK Gates Foundation ... S malaria candidate vaccine reduces malaria by approximately one-third in African infants". malariavaccine.org. Malaria Vaccine ... The vaccine reduces hospital admissions from severe malaria by around 30%. RTS,S was developed by PATH Malaria Vaccine ... The vaccine reduces hospital admissions from severe malaria by around 30%. Research continues with other malaria vaccines. The ...
This vaccine is the first to meet the World Health Organization's Malaria Vaccine Technology Roadmap goal of a vaccine with at ... In 2013, WHO and the malaria vaccine funders group set a goal to develop vaccines designed to interrupt malaria transmission ... "Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond". Vaccine. 27 (1): 2-9 ... The first vaccine, called RTS,S, was approved by European regulators in 2015. As of 2019, only one malaria vaccine is licensed ...
... the European Malaria Vaccine Initiative (EMVI) was established in 1998 with the specific aim of accelerating malaria vaccine ... "European Vaccine Initiative: lessons from developing malaria vaccines". Expert Review of Vaccines. 10 (12): 1697-1708. doi: ... Although malaria vaccine development remains an important activity for EVI, today EVI is dedicated to support and accelerate ... "European malaria vaccine initiative". Community Research and Development Information Service (CORDIS). European Commission. ...
"Maxygen Lands Grant to Pursue Malaria vaccine". www.bizjournals.com. Retrieved 20 October 2021. Howard, R J; Uni, S; Aikawa, M ... Howard, R.J.; Pasloske, B.L. (October 1993). "Target antigens for asexual malaria vaccine development". Parasitology Today. 9 ( ... Howard, RJ (1 August 1989). "Malaria: the search for vaccine antigens and new chemotherapeutic strategies". Blood. 74 (2): 533- ... Thirteen years of his group's malaria research on antigenic variation in malaria culminated in the first molecular cloning of ...
SaRNA vaccines being researched include a malaria vaccine. Gritstone bio started in 2021 a phase 1 trial of an saRNA COVID-19 ... mRNA vaccines offer specific advantages over traditional vaccines. Because mRNA vaccines are not constructed from an active ... In addition to sharing the advantages of theoretical DNA vaccines over established traditional vaccines, mRNA vaccines also ... An mRNA vaccine is a type of vaccine that uses a copy of a molecule called messenger RNA (mRNA) to produce an immune response. ...
"Pre-Erythrocytic Vaccines against Malaria". Vaccines. 8 (3): E400. doi:10.3390/vaccines8030400. ISSN 2076-393X. PMC 7565498. ... S and other malaria vaccines. The amino-acid sequence of CSP consists of an immunodominant central repeat region flanked by ... The structure and function of CSP is highly conserved across the various strains of malaria that infect humans, non-human ... Circumsporozoite protein (CSP) is a secreted protein of the sporozoite stage of the malaria parasite (Plasmodium sp.) and is ...
Gaur D, Chauhan VS (June 2013). "Current status of malaria vaccines". Indian J Pediatr. 80 (6): 441-3. doi:10.1007/s12098-013- ... "Indian Discovery Gives Boost to Hopes for Malaria Vaccine". ND TV. 24 January 2015. Retrieved 6 November 2017. "India awaits ... and was a member of the Malaria Vaccine Development Program (MVDP) of the organization. He has been a member of the program ... as a full professor at the School of Biotechnology of the university since 2014 and heads the Laboratory of Malaria and Vaccine ...
"Malaria advice 'risks lives'". BBC News. 13 July 2006. Retrieved 29 October 2019. "Cases dropped against malaria homeopaths". ... as vaccine alternatives, telling parents that the treatment is as effective as vaccines against diseases such as measles, polio ... "absolutely no reason to think that homeopathy works to prevent malaria" and that "people may even die of malaria if they follow ... Posing as a traveller to countries known to be affected by malaria a researcher visited pharmacies in London and recorded her ...
India portal Recombinant vaccine Malaria International Centre for Genetic Engineering and Biotechnology National Academy of ... He is known for his contributions to the development of a recombinant vaccine for malaria. and for synthetic structural ... Gaur D, Chauhan VS (June 2013). "Current status of malaria vaccines". Indian J Pediatr. 80 (6): 441-3. doi:10.1007/s12098-013- ... His team is known to have developed a recombinant vaccine, the first time such vaccine developed entirely in India, which is ...
... vaccine Tularemia vaccine Yersinia pestis vaccine Chagas disease vaccine Hookworm vaccine Leishmaniasis vaccine Malaria vaccine ... vaccine Caries vaccine Gonorrhea vaccine Ehrlichiosis vaccine Helicobacter pylori vaccine Leprosy vaccine Lyme disease vaccine ... encephalitis virus vaccine for humans Enterovirus 71 vaccine Epstein-Barr vaccine H5N1 vaccine Hepatitis C vaccine HIV vaccine ... MERS vaccine Nipah virus vaccine Norovirus vaccine Respiratory syncytial virus vaccine SARS vaccine West Nile virus vaccine for ...
He is the head of the Malaria Parasite Biology and Vaccines Unit at the Institut Pasteur in Paris and an elected fellow of the ... "Malaria Parasite Biology and Vaccines Unit". Institut Pasteur. Retrieved 31 March 2017. "Indian Academy of Sciences - ... At ICGEB, Chitnis has also established a protein production facility for the production of malaria vaccines based on novel ... Chitnis has published over 100 international papers and has three patents pertaining to malaria vaccines. Chitnis's work is ...
"Malaria Vaccine Study". Archived from the original on 2013-10-11. Retrieved 2013-10-12. "Agenus Expands QS-21 Adjuvant License ... RTS,S is the most advanced vaccine for malaria in development. Agenus is the sole US-manufacturer of a patented and FDA- ... In October 2013, GlaxoSmithKline and Agenus announced positive data from an 18-month follow-up of GSK's RTS,S malaria vaccine ... Wang, Pengfei (2021-03-05). "Natural and Synthetic Saponins as Vaccine Adjuvants". Vaccines. 9 (3): 222. doi:10.3390/ ...
In 2008, among the studies performed were the effectiveness of different types of Malaria vaccines in high and low malaria ... "What Should Vaccine Developers Ask? Simulation of the Effectiveness of Malaria Vaccines". PLOS ONE. 3 (9): e3193. Bibcode: ... In 2012, malariacontrol.net has studied the effectiveness of using RTS,S malaria vaccine in World Health Organization's ... "Open Malaria" which can be used to simulate outcomes in various types of malaria transmission settings. On 21 June 2016, ...
"Designing malaria vaccines to circumvent antigen variability". Vaccine. 33 (52): 7506-12. doi:10.1016/j.vaccine.2015.09.110. ... Naturally acquired immune responses to malaria vaccine candidate antigens MSP3 and GLURP in Guahibo and Piaroa indigenous ... Anti-malarial vaccines have been developed to target the merozoite at different stages in its life cycle. Vaccines that target ... immunity and vaccines against malaria". FEMS Microbiology Reviews. 40 (3): 343-72. doi:10.1093/femsre/fuw001. PMC 4852283. PMID ...
"Janssen (formerly Crucell)". PATH Malaria Vaccine Initiative. 2020. "GEN - News Highlights:Kura Oncology Licenses Janssen's ... One of the projects in the contract is the development of a universal flu vaccine. The intent of the vaccine would be to ... "Janssen Vaccines AG". Bloomberg L.P. 2020. Lopez-Munoz, Francisco; Alamo, Cecilio (2009). "The Consolidation of Neuroleptic ... "Johnson & Johnson, BARDA join forces to prep for pandemic flu, inking deal for vaccine and drug R&D - FiercePharma". ...
"Groundbreaking malaria vaccine discovery". April 22, 2020. "Punjab NRI's company to try its new malaria vaccine on Covid-19 ... "Immune children aid malaria vaccine hunt". BBC News. May 22, 2014. Raj, Dipak K.; Nixon, Christian P.; Nixon, Christina E.; ... "New Malaria Vaccine Shows Promise in Mice". www.science.org. "partnerships". ocean biomedical. "Brown Alpert Medical School ... Ocean Biomedical has worked on developing vaccines for tropical diseases such as malaria, as well as for emerging diseases like ...
"First malaria vaccine receives positive scientific opinion from EMA". 17 September 2018. "Q&A on the malaria vaccine ... Marcel Tanner, he worked in the evaluation of the malaria vaccine SPf66. In collaboration with Dr. Clara Menéndez, Pedro L. ... S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised ... list of most cited authors in the malaria field and also is on list of the 50 most influential people in the vaccines field. ...
"Adrian Hill: Malaria Vaccines - Nuffield Department of Medicine". ndm.ox.ac.uk. Archived from the original on 11 January 2016. ... Hill is a leader in the field of malaria vaccine development and was a co-leader of the research team which produced the Oxford ... His group has developed numerous candidate vaccines against malaria which have been tested in clinical trials in the UK and ... From 1997 he has developed candidate vaccines for malaria which produce cellular (T-cell) immunity and partial efficacy using ...
Malaria is an endemic illness in sub-Saharan Africa, where the majority of malaria cases and deaths worldwide occur. Routine ... Vaccine. 30 (9): 1594-600. doi:10.1016/j.vaccine.2011.12.123. PMID 22230581. "WHO , Onchocerciasis". Who.int. Archived from the ... "WHO , Malaria". Who.int. Archived from the original on 3 September 2014. Retrieved 29 September 2015. Verguet S, Jassat W, ...
"Malaria and Malaria Vaccine Candidates". The College of Physicians of Philadelphia. 19 April 2017. Retrieved 11 February 2018. ... Walsh, Fergus (24 July 2015). "Malaria vaccine gets 'green light'". BBC. Retrieved 25 July 2015. Hoddle, M. S.; Van Driesche, R ... and the development of a malaria vaccine. All of these have proven problematic, with drug resistance, insecticide resistance ... Various methods of malaria prophylaxis have been tried including the use of antimalarial drugs to kill off the parasites in the ...
"Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle". Vaccine. 31 (28): ... Glycosylation of proteins that are not naturally modified like the malaria vaccine candidate pfs25 can occur in common ... The vaccine was grown in C. reinhardtii algae and provided oral vaccination in mice, but was hindered by low vaccine antigen ... doi:10.1016/j.vaccine.2013.04.034. PMC 3683851. PMID 23623858. Gregory, James A.; Li, Fengwu; Tomosada, Lauren M.; Cox, Chesa J ...
Areas of research included malaria, vaccines and travelers' diarrhea. He conducted a study on the oral antibiotic formulation ... Travel vaccine preventable diseases-updated logarithmic scale with monthly incidence rates. Influenza in travelers: ... "Im Kampf gegen Sars, Malaria und Diarrhö , NZZ". Neue Zürcher Zeitung (in German). Retrieved 2020-02-13. "Ebola outbreak in the ... Steffen, Robert (2018). "Travel vaccine preventable diseases-updated logarithmic scale with monthly incidence rates". Journal ...
Tuberculosis and Malaria; UNICEF; Gavi, the Vaccine Alliance; the U.S. Centers for Disease Control and Prevention; the Bill & ... In addition, some countries use DHIS2 for vaccine cold chain or other electronic Logistics Management Information System (eLMIS ... and Malaria, among others, as well as for general public health programs such as disease surveillance, routine immunization, ... this involves regular reporting of aggregate data on stocks and usage of common medical supply items such as vaccines, ...
"Malaria vaccine hailed as potential breakthrough". BBC News. 23 April 2021. Retrieved 23 April 2021. Datoo, Mehreen S.; Natama ... 23 April A malaria vaccine with 77% efficacy after 1 year - and first to meet the WHO's goal of 75% efficacy - is reported by ... "Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina ... "Why COVID-19 vaccines can provide stronger immunity than natural infection". New Atlas. 28 June 2021. Retrieved 11 July 2021. ...
"Malaria Vaccine to be Reality soon". Only My Health. Retrieved 2012-08-08. Neafsey DE, Galinsky K, Jiang RH, Young L, Sykes SM ... and a closely related monkey malaria parasite (Plasmodium cynomolgi), producing a more detailed picture of malaria evolution ... As Program Director of a seven-year NIH International Center of Excellence in Malaria Research based jointly in New Delhi and ... The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum. Nat Genetics. 2012 Sep;44( ...
8 August In its latest trial, a new malaria vaccine has been shown to be 100 percent effective. A breakthrough in tissue ... "Zapped Malaria Parasite Raises Vaccine Hopes". Scientific American. 8 August 2013. Retrieved 10 August 2013. "Scientists 'grow ... "HIV vaccine produces no adverse effects in trials". Western University. 3 September 2013. Retrieved 8 September 2013. " ... Phase 1 clinical trials of an implantable vaccine to treat melanoma have been initiated. The National Institutes of Health has ...
Johnstone, Michael (17 September 1987). "Malaria: prospects for an effective vaccine". New Scientist: 69-73. "Obituary. David ... known for his research on malaria vaccines and chemotherapy. Born in Meerut, India, as the son of a father who was a physician ... as the head of malaria studies at the University of Maryland School of Medicine's Center for Vaccine Development and Global ... In 1966 Clyde left Tanzania to do research at the University of Maryland School of Medicine on malaria prevention and therapies ...
"Vaccine candidate discovery for the next generation of malaria vaccines". Immunology. 152 (2): 195-206. doi:10.1111/imm.12780. ... The vaccine sponsor may have required proof of safety and efficacy of adjuvants for delivering the vaccine, demonstrated what ... A challenge study to test promising vaccines for prevention of COVID-19 was under consideration during 2020 by several vaccine ... Other than expediting clinical evaluation of vaccine properties, advantages of using challenge studies for vaccine candidates ...
Recent research on many vaccines, including the malaria vaccine, has focused on how to anticipate this diversity and create ... This parasitic antigen diversity is particularly troublesome for the development of the malaria vaccines. In order to fix this ... While vaccines are created to strengthen the immune response to pathogens, in many cases these vaccines are not able to cover ... Barry, Alyssa; Arnott, Alicia (2014). "Strategies for Designing and Monitoring Malaria Vaccines Targeting Diverse Antigens". ...
In addition, BioNTech is working on an mRNA vaccine to prevent malaria and investigating the production of vaccines in Africa. ... "BioNTech's Ozlem Tureci on malaria vaccine development". CNBC. Retrieved 19 August 2021. "SPEAKERS", Science Asia Conference, ... COVID-19 vaccine from Pfizer BioNtech - Type of vaccine for humansPages displaying short descriptions of redirect targets Turks ... the couple decided to apply the mRNA vaccine technology they had been researching for two decades to developing a vaccine ...
Information on the quest for a malaria vaccine. ... Malaria Vaccines: The Way Forward The RTS,S/AS01 vaccine and ... Barriers to Developing a Malaria Vaccine. The development of a malaria vaccine has faced several obstacles: the lack of a ... Nurse Dinah Mauti Maragwa gives malaria candidate vaccine to an infant at the Siaya KEMRI/CDC Malaria Vaccine Trial Site in ... The roadmap includes the following strategic goals for malaria vaccines by 2030:. *Develop and license malaria vaccines with ...
Yellow Fever Vaccine & Malaria Prevention Information, by Country. CDC Yellow Book 2024. Preparing International Travelers ... Malaria Prevention. 2Refers to Plasmodium falciparum malaria, unless otherwise noted.. 3Tafenoquine can cause potentially life- ... Malaria Prevention. The following recommendations to protect travelers from malaria were developed using the best available ... If the information is available, trends in malaria incidence and other data are considered in the context of malaria control ...
"Malaria Vaccines". PubChem. U.S. National Library of Medicine. Malaria Vaccine Initiative Malaria vaccines UK Gates Foundation ... S malaria candidate vaccine reduces malaria by approximately one-third in African infants". malariavaccine.org. Malaria Vaccine ... The vaccine reduces hospital admissions from severe malaria by around 30%. RTS,S was developed by PATH Malaria Vaccine ... The vaccine reduces hospital admissions from severe malaria by around 30%. Research continues with other malaria vaccines. The ...
A vaccine against the parasitic disease malaria cut illnesses by more than half in field trials and could be safely given with ... MALARIA VACCINE….My morning paper reports some spectacularly good news for Africa: ... A vaccine against the parasitic disease malaria cut illnesses by more than half in field trials and could be safely given with ... MALARIA VACCINE….My morning paper reports some spectacularly good news for Africa: ...
1 A new malaria vaccine could protect millions of vulnerable people Its the most effective known jab to date. (The Guardian). ... The Download: inhaled covid vaccines, and fighting malaria. Plus: the Twitter whistleblowers claims can be used in court ... regulatory bodies in both India and China have approved inhaled vaccines for covid-19. The companies behind these vaccines say ... And while injected vaccines provide good protection from severe disease, they dont stop us from catching the virus or ...
... Science. 1994 Sep 2;265(5177):1381-3. doi: 10.1126/science.8073276. ...
said it intends to submit an experimental malaria vaccine for regulatory approval next year, after new data from a long-running ... Glaxo to Seek Approval for Malaria Vaccine. .css-jiugt2-Dek-Dek{margin:0px;color:var(--secondary-text-color);direction:var(-- ... study continued to show that the vaccine provides partial protection against the disease. ...
... that might constitute the path to a highly protective malaria vaccine has been developed by scientists. Malaria is caused by ... there remains no effective vaccine capable of eradicating malaria. ... mRNA Vaccine Yields Full Protection Against Malaria in Mice. June 18, 2021 Scientists developed an mRNA vaccine that protects ... that might constitute the path to a highly protective malaria vaccine has been developed by scientists. Malaria is caused by ...
Vaccination with RTS,S induces antibodies against circumsporozoite protein (CSP), which is expressed by sporozoites, the infective form of Plasmodium that mosquitos transmit. During infection in unvaccinated individuals, sporozoites travel to the liver, where they move through hepatocytes and differentiate to hepatic merozoites. CSP is expressed in the early liver stages, but not by liver stage merozoites. Antibodies to CSP following RTS,S vaccination immobilize the sporozoites, thereby preventing infection of hepatocytes. RTS,S-induced protection from infection and severe disease wanes over time and correlates with the level of anti-CSP antibodies. RTS,S-induced immune responses do not interfere with the infectivity of Plasmodium gametocytes to mosquitoes. Even following vaccination, most children will carry parasites that will infect mosquitoes; thus, transmission in the population will remain unchanged. Image adapted from Raphemot et al ...
A vaccine targeting a protein complex that allows malaria-causing parasite to enter red blood cells has been produced. Malaria ... The groups vaccine conferred more effective protection in monkeys than prior candidates that targeted only one component of ... 1 has been a target of vaccine development but vaccination with apical membrane antigen 1 alone in controlled human malaria ... A team of researchers at the National Institutes of Health led by Prakash Srinivasan, currently at the Johns Hopkins Malaria ...
Our vaccine and RTSS target exactly the same protein on the surface of the malaria parasite so they are really similar, the ... And this vaccine unfortunately doesnt target that type of malaria.. Chris - Could it be adjusted, updated? Will the same ... 00:59 - Malaria vaccine to save millions of lives. The new jab is cheaper and easier to make.... ... And so what happens is that this malaria specific protein on the surface of this vaccine is identified as a foreign object and ...
Whole-organism malaria vaccine?. Genetically modified parasite induces immunity in rodents, but some doubt use in humans. Cathy ... A novel approach to attenuating the malaria parasite could herald a whole-organism vaccine for humans, according to research ... are "very exciting." But safety and production issues could prevent the development of the vaccine for humans, say other ... A research collaboration between Stefan H.I. Kappe, assistant member of the Seattle Biomedical Research Institutes Malaria ...
The worlds first malaria shots may not reach millions of children who need it. ... Mary Hamel, WHOs agencys malaria vaccine implementation head, said Covid-19 vaccines had shown how quickly things could move ... The vaccines effectiveness at preventing severe cases of malaria in children is relatively low, at around 30% in a large-scale ... Adding malaria vaccines could cost between USD$325mil (RM1.44bil)and more than USD$600mil (RM2.67bil) annually, depending on ...
EU funding has supported University of Oxford led programmes to create and validate vaccines for some of the most prevalent and ... and continued to meet the WHOs Malaria Vaccine Technology Roadmap goal. The vaccine is now undergoing further large scale ... Development of a Malaria vaccine - R21/Matrix-M. EU funding has supported University of Oxford led programmes to create and ... If approved, the vaccine has the potential to save millions of lives and significantly reduce the burden of malaria in sub- ...
And until now, there have been no vaccines available for it. ... there were 229 million cases of malaria worldwide in 2019, 94% ... Director of WHOs Global Malaria Programme Pedro Alonso has told Sky News that malaria vaccine breakthrough is a historical ... Malaria vaccine breakthrough is a turning point - WHO. According to the WHOs latest report, there were 229 million cases of ... malaria worldwide in 2019, 94% of which were in Africa. And until now, there have been no vaccines available for it. ...
Vaccines , Malaria Consortium Blog , The Malaria Consortium Blog ... Will a vaccine end the fight against malaria?. Posted on 6 May ... Vaccine hesitancy: a key consideration for successful uptake of malaria vaccine. Posted on 5 August 2022. Approx reading time: ... There were 386,000 malaria deaths in sub-Saharan Africa in 2018, and projections suggest that the COVID-19 pandemic could cause ... Whilst the COVID-19 vaccine was developed in an unprecedented timeframe, it has taken combined efforts, spanning 30 years, for ...
A malaria vaccine with world-changing potential has been developed by scientists at the University of Oxford. ... This malaria vaccine is the 14th that Prof Katie Ewer has worked on at Oxford as this is not like Covid where we have seven ... The vaccines are built using a combination of proteins from the malaria parasite and the hepatitis B virus, but Oxfords ... We think these data are the best data yet in the field with any malaria vaccine, said Prof Adrian Hill, director of the Jenner ...
A promising vaccine target for the most deadly type of malaria has had its molecular structure solved by Institute researchers ... It is widely accepted that malaria vaccines will play a crucial role in eliminating malaria infections, and the eventual ... A promising vaccine target for the most deadly type of malaria has had its molecular structure solved by Institute researchers ... This work was supported by the Howard Hughes Medical Institute (US), PATH/Malaria Vaccine Initiative, US Agency for ...
Kenya among 12 countries set to receive malaria vaccine. Christine Muchira - July 8, 2023. 0 ... among the twelve countries across different regions in Africa set to receive 18 million doses of the first-ever malaria vaccine ... Home Tags Malaria Vaccine Implementation Programme (MVIP). Tag: Malaria Vaccine Implementation Programme (MVIP) ...
Read stories, features and news related to malaria vaccine. ... Worlds first malaria vaccine launched in a pilot program by ... Malaria still kills thousands of children in Africa each year -- but a vaccine might change all that. ... The first malaria vaccine is finally here: WHO endorsement received byTibi Puiu ... Three African countries chosen for the 1st large-scale malaria vaccine pilot program byTibi Puiu ...
More on the RTS,S and R21 vaccines here. ... Malaria kills half a million people a year in Africa. We can ... We finally have malaria vaccines. The next hurdle: Distributing them.. Malaria kills half a million people a year in Africa. We ... But new hope in the fight against malaria arrived two years ago via the worlds first-ever malaria vaccine. In October 2021, ... The logistical challenges of delivering malaria vaccines In 2015, GSK began producing its vaccine but stopped due to WHO ...
Dividing her days between treating malaria in Kenyas coastal regions and administering the latest malaria vaccine prototype, ... director of communications at the PATH Malaria Vaccine Initiative.. "I think its fair to say that if malaria had been killing ... a group of 250 of the worlds top malariologists drafted the Malaria Vaccine Technology Roadmap. The goal: To have a malaria ... technical officer for the Malaria Vaccine section at the WHO in Geneva. "Additionally, with malaria, even after being infected ...
The RTS,S Malaria Vaccine: First Malaria Vaccine Recommended by the WHO for Children at Risk. ... Preparing for malaria vaccine decisions*Global policy and regulatory pathways. *Decision-making framework*The decision-making ... Frequently Asked Questions (FAQs): Product Transfer for the RTS,S/AS01 Malaria Vaccine. ... PATHs Malaria Vaccine Initiative Accelerating Malaria Vaccine Development. *Malaria vaccines & biologics*Need for vaccines* ...
GAVI alliance offers matched funds for GSK malaria vaccine pilot ... 27.5M In Matching Funds To Support Malaria Vaccine Research. ... Reuters: GAVI alliance offers matched funds for GSK malaria vaccine pilot. "The GAVI global vaccine alliance has offered ... Sanofi, GSK To Provide Potential COVID-19 Vaccine To COVAX; Vaccine Nationalism Poses Challenges; Russia Applies For WHO ... 27.5 million for pilot tests of GlaxoSmithKlines first-generation malaria vaccine, but only if other organizations promise to ...
"RTS,S is the first malaria vaccine to reach this stage and is likely the best new widely implementable tool to combat malaria ... "WHO recommends that in the context of comprehensive malaria control the RTS,S/AS01 malaria vaccine be used for the prevention ... RTS,S/AS01 malaria vaccine should be provided in a schedule of 4 doses in children from 5 months of age for the reduction of ... In Kenya, where malaria is still one of the leading killers of young children, the new vaccine has the potential to save ...
Preparing for malaria vaccine decisions*Global policy and regulatory pathways. *Decision-making framework*The decision-making ... PATHs Malaria Vaccine Initiative Accelerating Malaria Vaccine Development. *Malaria vaccines & biologics*Need for vaccines* ... Malaria vaccines & biologics*Need for vaccines*Malaria vaccine roadmap. *Preferred product characteristics ... Next-generation vaccines*Pre-erythrocytic vaccine candidates. *Blood-stage vaccine candidates. *Transmission-blocking vaccine ...
Malaria vaccine: WHO and vaccine alliance Gavi invite developing countries to apply for funding 21/07/2022 ... Malaria vaccine: WHO and vaccine alliance Gavi invite developing countries to apply for funding 21/07/2022 ... Malaria More than one million children in Ghana, Kenya and Malawi have now received at least one dose of the first malaria ... Cameroon set to administer malaria vaccine to population in 2024 29/11 - 22:16 ...
Melbourne researchers have shown for the first time that carbohydrates on the surface of malaria parasites play a critical role ... in malarias ability to infect mosquito and human hosts. ... particularly an effective malaria vaccine.. The first malaria ... "The protein used in the RTS,S vaccine mimics one of the proteins weve been studying on the surface of the malaria parasite ... The discovery also suggests steps that may improve the only malaria vaccine approved to protect people against Plasmodium ...
Scientists Discover a Promising Target for a Malaria Vaccine ... Scientists Discover a Promising Target for a Malaria Vaccine. ... or use a vaccine based on PfRh5 along with another vaccine---perhaps the GlaxoSmithKline vaccine announced earlier this year ... While PfRh5 is one of the most promising leads found yet, it takes more than a common molecule to make a vaccine. The molecule ... and outreach, malaria has largely evaded our best efforts at eradication. . The various strains of the protozoan that causes it ...
  • October 6, 2021, marks an historic day in the development of malaria vaccines, with release of the World Health Organization (WHO) recommendation for widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children living in sub-Saharan Africa and other regions with moderate to high P. falciparum malaria transmission. (cdc.gov)
  • Most of the deaths are among children younger than 5 in sub-Saharan Africa, the population that the vaccine targets. (motherjones.com)
  • 28, 2021 A major tool against malaria in Africa has been the use of rapid diagnostic tests, which have been part of the 'test-treat-track' strategy in Ethiopia, the second most-populated country in Africa. (sciencedaily.com)
  • Yet the world's inability to fund more Mosquirix shots dismays many in Africa as children on the continent account for the vast majority of the roughly 600,000 global malaria deaths every year. (thestar.com.my)
  • This is a disease of the poor, so it's not been that appealing in terms of the market," said Corine Karema, chief executive of the nonprofit RBM Partnership to End Malaria, which is working with governments in Africa to eliminate the disease. (thestar.com.my)
  • The vaccine is now undergoing further large scale clinical trials in other countries in sub-Saharan Africa, and it is hoped that it will be approved for use by regulatory authorities in the near future. (ox.ac.uk)
  • If approved, the vaccine has the potential to save millions of lives and significantly reduce the burden of malaria in sub-Saharan Africa, where the disease is most prevalent. (ox.ac.uk)
  • According to the WHO's latest report, there were 229 million cases of malaria worldwide in 2019, 94% of which were in Africa. (sky.com)
  • There were 386,000 malaria deaths in sub-Saharan Africa in 2018, and projections suggest that the COVID-19 pandemic could cause th. (malariaconsortium.org)
  • Last year, the World Health Organization gave the historic go-ahead for the first vaccine - developed by pharmaceutical giant GSK - to be used in Africa. (bbc.com)
  • The success of the GSK vaccine has partly paved the way for Oxford to be optimistic of having their vaccine out next year - such as by assessing how feasible a vaccination programme in Africa would be. (bbc.com)
  • Plasmodium falciparum is the most deadly strain of malaria parasite, and is predominantly found in Africa, where it causes up to half a million deaths each year. (edu.au)
  • Kenya is among the twelve countries across different regions in Africa set to receive 18 million doses of the first-ever malaria vaccine over the. (co.ke)
  • Malaria kills half a million people a year in Africa. (vox.com)
  • In 2000, nearly 900,000 people died of malaria, the vast majority of whom lived in poorer regions of the world, such as sub-Saharan Africa. (vox.com)
  • And for a time, these interventions helped lower the transmission of the disease in Africa , preventing an estimated 663 million malaria cases in the region between 2000 and 2015. (vox.com)
  • Still today, half a million people die in Africa from malaria every year, and since the Covid-19 pandemic began, that number has been on the rise. (vox.com)
  • In October 2021, the World Health Organization (WHO) recommended the RTS,S vaccine (developed by the pharmaceutical company GSK) for use in Africa. (vox.com)
  • According to the World Health Organisation's (WHO) World Malaria Report 2011 released in December, 650,000 malaria deaths occurred in 2010, almost all in children under age five, the majority in sub-Saharan Africa. (aljazeera.com)
  • Malaria still kills thousands of children in Africa each year -- but a vaccine might change all that. (zmescience.com)
  • On October 6th, the World Health Organization (WHO) formally recommended the RTS,S malaria vaccine for broader use external icon among children in sub-Saharan Africa and in other regions with moderate to high malaria transmission. (cdc.gov)
  • Nearly half the world's population still lives in areas at risk of malaria transmission, and in 2019, malaria was responsible for the deaths of an estimated 409,000 people-mostly children under the age of five in sub-Saharan Africa. (cdc.gov)
  • The "RTS,S" vaccine could save the lives of 40,000 to 80,000 children per year in sub-Saharan Africa and high-risk areas. (africanews.com)
  • The new vaccine works against the mosquito-borne parasite, Plasmodium Falciparum , the most deadly parasite worldwide and the most prevalent in Africa. (africanews.com)
  • About 90% of the world's malaria cases are in Africa, where 260,000 children die each year. (africanews.com)
  • In 2021, WHO endorsed the first malaria vaccine in what it described as a "historic" effort to end the devastating toll the mosquito-transmitted disease has on Africa, home to most of the world's estimated 200 million cases and 400,000 deaths. (com.pk)
  • Guardian: A vaccine against malaria has been shown to be highly effective in trials in Africa , holding out the real possibility of slashing the death toll of a disease that kills 400,000 mostly small children every year. (veteranstoday.com)
  • One, the Mosquirix vaccine developed by GlaxoSmithKline, has been through lengthy clinical trials but is only partially effective, preventing 39% of malaria cases and 29% of severe malaria cases among small children in Africa over four years. (veteranstoday.com)
  • The burden of malaria on the lives of the very young and their mothers, as well as HIV co-infected individuals - especially in sub-Saharan Africa - is heart breaking. (edctp.org)
  • Important progress has been made in recent years, especially in sub-Saharan Africa, with the introduction of strategies to prevent malaria in pregnancy consisting primarily of administration of intermittent preventive treatment during pregnancy with an antimalarial drug and the use of long-lasting insecticide-treated nets. (glowm.com)
  • And thus the implication of this is that today, we face about the same number of malaria cases in sub-Saharan Africa as we did 20 years ago. (kmuw.org)
  • The WHO has given a green light to widespread use of GlaxoSmithKline's malaria vaccine in Africa, in what could be a major turning point in the fight against the disease. (pharmaphorum.com)
  • The RTS,S/AS01 vaccine - also known as Mosquirix - will be administered to children living in sub-Saharan Africa and other regions with moderate to high malaria transmission in what WHO Director-General Dr Tedros Adhanom Ghebreyesus described as "a historic moment. (pharmaphorum.com)
  • If the new vaccine is rolled out widely across Africa, it could dramatically reduce the amount of severe illness and deaths caused by malaria in a few years, Craig said. (wtnh.com)
  • Matshidiso Moeti, the WHO regional director for Africa, said the vaccine "offers a glimmer of hope for the continent. (gabio.org)
  • The long lifespan and strong human-biting habit of the Anopheles species that carry malaria are the main reasons for the high incidence of malaria in Africa. (who.int)
  • Malaria vaccine-related adverse events among children under 5 in sub-Saharan Africa: systematic review and meta-analysis protocol. (bvsalud.org)
  • vaccine among children in sub-Saharan Africa and in other regions with moderate to high Plasmodium falciparum malaria transmission. (msdmanuals.com)
  • This was an important new intervention to prevent malaria, which causes hundreds of thousands of deaths each year, mostly in children in Africa. (msdmanuals.com)
  • It acts against P. falciparum , the most deadly malaria parasite globally and the most prevalent in Africa. (bvsalud.org)
  • Malaria remains one of the world's leading killer diseases with most of these deaths being in Africa. (who.int)
  • The development of a malaria vaccine has faced several obstacles: the lack of a traditional market, few developers, and the technical complexity of developing any vaccine against a parasite. (cdc.gov)
  • RTS,S was engineered using genes from the outer protein of P. falciparum malaria parasite and a portion of a hepatitis B virus plus a chemical adjuvant to boost the immune response. (wikipedia.org)
  • A next generation genetically attenuated parasite (GAP) that might constitute the path to a highly protective malaria vaccine has been developed by scientists. (sciencedaily.com)
  • Seattle BioMed researchers today announced they have developed a next generation genetically attenuated parasite (GAP) that might constitute the path to a highly protective malaria vaccine. (sciencedaily.com)
  • The manuscript describes the development of genetically engineered malaria parasites that are weakened by the precise removal of genes and designed to effectively prevent the parasite from inducing an infection in humans. (sciencedaily.com)
  • While vaccination with live-attenuated parasites is capable of providing complete protection from malaria infection, it is imperative that we permanently cripple the very complex malaria parasite so that it cannot cause disease, and instead, effectively primes the immune system," said Stefan Kappe, Ph.D., corresponding author and professor, Seattle BioMed. (sciencedaily.com)
  • The first generation GAP strain had two genes removed from the malaria parasite, but this new 'triple punch', developed in collaboration with scientists at the Walter and Eliza Hall Institute in Australia, removes three separate genes associated with the pathogenicity of the parasite, effectively abrogating its ability to establish an infection in humans. (sciencedaily.com)
  • In terms of how it works, this vaccine shows the human body a part of the parasite, much like the Covid vaccine using spike to introduce the body to what the spike protein looks like, so that they're ready when they get infected. (thenakedscientists.com)
  • A novel approach to attenuating the malaria parasite could herald a whole-organism vaccine for humans, according to research published this week in Nature . (the-scientist.com)
  • It has taken more than a century to develop effective vaccines as the malaria parasite, which is spread by mosquitoes, is spectacularly complex and elusive. (bbc.com)
  • The vaccines are built using a combination of proteins from the malaria parasite and the hepatitis B virus, but Oxford's version has a higher proportion of malaria proteins. (bbc.com)
  • Professor Cowman and his team have spent more than 30 years unravelling the complicated processes used by the malaria parasite to invade the human host. (edu.au)
  • This binding is absolutely essential for parasite survival, marking CyRPA as a potential malaria vaccine candidate. (edu.au)
  • In an article published July 20 in Nature Immunotherapy, researchers from New Zealand's Ferrier Research Institute, the Malaghan Institute of Medical Research and Australia's Peter Doherty Institute for Infection and Immunity showed their novel malaria vaccine generates an immune response in mouse models, and was able to prevent infection with Plasmodium berghei, a form of the parasite. (fiercebiotech.com)
  • It generates antibodies to specific proteins found on the surface of malaria sporozoites, an immature form of the parasite. (fiercebiotech.com)
  • The same month, a research group out of George Washington University and the University of Pennsylvania-co-led by Drew Weissman, M.D., Ph.D., one of the pioneers of mRNA technology- showed that its mRNA malaria vaccine series could prevent both infection and transmission of the parasite by targeting different stages of the parasite's life cycle. (fiercebiotech.com)
  • Because malaria comes from a parasite, not a virus, creating a highly efficacious vaccine against the infection is extremely difficult. (vox.com)
  • The severity and symptoms of malaria can differ based on the exact species of parasite the individual was infected with. (vox.com)
  • The mosquito becomes infected by feeding on someone with a malaria-causing parasite, and then subsequently bites other people, infecting them. (vox.com)
  • There are at least four species of Plasmodium that cause malaria in humans, and the malaria parasite is notoriously adaptable. (aljazeera.com)
  • There has never before been a vaccine that targets any parasite. (aljazeera.com)
  • Unlike bacteria and viruses for which we've developed vaccines, the life cycle of a parasite is more complex," explains Dr Vasee Moorthy, technical officer for the Malaria Vaccine section at the WHO in Geneva. (aljazeera.com)
  • Goddard-Borger have shown that malaria parasites have carbohydrate 'tags' that are crucial for parasite survival. (edu.au)
  • Associate Professor Boddey said the team had shown that the malaria parasite 'tags' its proteins with carbohydrates in order to stabilise and transport them, and that this process was crucial to completing the parasite's lifecycle. (edu.au)
  • The protein used in the RTS,S vaccine mimics one of the proteins we've been studying on the surface of the malaria parasite that is readily recognised by the immune system. (edu.au)
  • It was hoped that the vaccine would generate a good antibody response that protected against the parasite, however it has unfortunately not been as effective at evoking protective immunity as hoped. (edu.au)
  • With this study, we've shown that the parasite protein is tagged with carbohydrates, making it slightly different to the vaccine, so the antibodies produced may not be optimal for recognising target parasites," Dr Goddard-Borger said. (edu.au)
  • Now that we know how important these carbohydrates are to the parasite, we can be confident that the malaria parasite cannot 'escape' vaccination pressure by doing away with its carbohydrates. (edu.au)
  • This is exciting because to ultimately eradicate malaria we need combined approaches that attack different stages of the parasite at once," Associate Professor Boddey said. (edu.au)
  • One of the greatest global public health risks facing the world today is malaria, an infectious disease transmitted by a parasite transmitted by mosquitoes, that the Centers for Disease Control and Prevention (CDC) estimates as responsible for over 1 million deaths each year. (infectioncontroltoday.com)
  • Finally, Fleury stated "We also believe that the vaccine effectiveness will be improved by targeting the different maturation forms of the parasite during the infectious cycle, instead of the classical strategy to target only one of them. (infectioncontroltoday.com)
  • Anti-sporozoite vaccines such as RTS,S need to be 100% effective in stopping the parasite from invading the liver to prevent disease," says senior author Angela Minassian, a clinician scientist at the University of Oxford. (sciencedaily.com)
  • Having a blood-stage vaccine like RH5 on board gives you a second line of defense once the parasite has entered the bloodstream, allowing a second chance to stop malaria before it causes illness. (sciencedaily.com)
  • RTS,S and many other vaccine candidates teach the immune system how to target the parasite at this sporozoite stage, before it invades the liver. (sciencedaily.com)
  • In the laboratory, these antibodies were able to inhibit the growth of the malaria parasite at high levels that are associated with disease protection. (sciencedaily.com)
  • These data justify onward progression to phase IIb field efficacy trials to determine whether parasite growth-inhibition levels of this magnitude can ultimately protect against clinical malaria. (sciencedaily.com)
  • Given that both anti-sporozoite and blood-stage malaria vaccine strategies necessitate very high levels of antibody to protect against parasite infection, current efforts remain focused on infants and young children. (sciencedaily.com)
  • Unlike comparatively simple viruses and bacteria, malaria is a parasite with many stages to its life cycle and thousands of genes. (smithsonianmag.com)
  • Both Mosquirix and R21 vaccines carry a single protein that the malaria parasite secretes during the first stage of its life cycle. (smithsonianmag.com)
  • The R21 vaccine also targets the most dangerous form of the malaria parasite, but there are many varieties. (smithsonianmag.com)
  • With encouraging progress in malaria vaccine development, MMVC (Multi-Stage Malaria Vaccine Consortium (MMVC) will test a novel vaccine combination targeting four stages of the malaria parasite life cycle, aiming to develop a candidate four-stage vaccine with 75% efficacy. (edctp.org)
  • The WHO is recommending fours doses of RTS,S in children from 5 months of age for the reduction of malaria disease and burden caused by Plasmodium falciparum , the form of the parasite associated with the most severe illness. (pharmaphorum.com)
  • Preclinical data from earlier studies indicated significantly enhanced immune responses against the malaria parasite (circumsporozoite stage of the Plasmodium falciparum ) when Crucell's Adenovirus (AdVac) technology and GSK's RTS,S/AS technology are used in combination, versus either component alone. (biopharminternational.com)
  • It is made by inserting the gene for the CSP from the P. falciparum malaria parasite into adenoviral vectors, which act as a vehicle for vaccination delivery. (biopharminternational.com)
  • He said he believed the vaccine - the first for a human parasite - would save tens of thousands of lives. (gabio.org)
  • First, using a strain of the malaria parasite with PMIF genetically deleted, they observed that mice infected with that strain developed memory T cells and showed stronger anti-parasite immunity. (yale.edu)
  • The research shows, first, that PMIF is critical to the completion of the parasite life cycle because it ensures transmission to new hosts, said the scientists, noting it also demonstrates the effectiveness of the anti-PMIF vaccine. (yale.edu)
  • If you vaccinate with this specific protein used by the malaria parasite to evade an immune response, you can elicit protection against re-infection," said Bucala. (yale.edu)
  • The vaccine would be used in children so that they would already have an immune response to this particular malaria product, and when they became infected with malaria, they would have a normal T cell response, clear the parasite, and be protected from future infection," he stated. (yale.edu)
  • The researchers also noted that because the PMIF protein has been conserved by evolution in different malaria strains and targets a host pathway, it would be virtually impossible for the parasite to develop resistance to this vaccine. (yale.edu)
  • WHO recommends that all suspected cases of malaria be confirmed using parasite-based diagnostic testing. (who.int)
  • It is the first vaccine to protect against a parasite and could save tens of thousands of young lives every year. (who.int)
  • It is a recombinant vaccine, consisting of the Plasmodium falciparum circumsporozoite protein (CSP) from the pre-erythrocytic stage. (wikipedia.org)
  • Malaria is caused by Plasmodium parasites that are transmitted to humans by a mosquito bite, leading to 219 million documented cases and 627,000 deaths worldwide in 2012. (sciencedaily.com)
  • Malaria caused by Plasmodium falciparum ( Pf ) remains one of the most deadly infectious diseases in the world. (nature.com)
  • So this vaccine that we've just had WHO recommendation for specifically targets plasmodium falciparum. (thenakedscientists.com)
  • Plasmodium is the malaria pathogen and then falciparum is the specific subtype. (thenakedscientists.com)
  • A research collaboration between Stefan H.I. Kappe , assistant member of the Seattle Biomedical Research Institute's Malaria Antigen Discovery Program, and Kai Matuschewski's group at Heidelberg University School of Medicine induced complete protection against malaria by infecting mice with living Plasmodium berghei lacking a single gene, known as UIS3 for "upregulated in infectious sporozoites gene 3. (the-scientist.com)
  • After confirming that the vaccine generated an immune response in mice, the researchers tested it in challenge experiments against Plasmodium berghei sporozoites in mice that hadn't previously been exposed to malaria. (fiercebiotech.com)
  • The discovery also suggests steps that may improve the only malaria vaccine approved to protect people against Plasmodium falciparum malaria - the most deadly form of the disease. (edu.au)
  • The various strains of the protozoan that causes it, Plasmodium falciparum , use a number of different molecular methods to gain access to the red blood cells they infect, with no single molecule in common, and a common molecule, of course, is a requirement for developing an effective vaccine. (discovermagazine.com)
  • However, in the results of the early-stage phase Ib trial, researchers find that targeting RH5 -- a protein that the malaria pathogen Plasmodium falciparum uses to invade red blood cells -- can generate a promising immune response that is most pronounced in an infant cohort. (sciencedaily.com)
  • However, in the results of the early-stage phase Ib trial conducted in Tanzania and published on August 11th in the journal Med , researchers find that targeting RH5 -- a protein that the malaria pathogen Plasmodium falciparum uses to invade red blood cells -- can generate a promising immune response that is most pronounced in an infant cohort. (sciencedaily.com)
  • A person is infected with malaria when bitten by an infected mosquito, which releases Plasmodium falciparum into the body. (sciencedaily.com)
  • For prevention, we invest in chemo-prevention for high-risk populations and development of second-generation vaccines against both Plasmodium falciparum and P. vivax malaria. (edctp.org)
  • Malaria is caused by four human plasmodium parasites. (kmuw.org)
  • In a prior study, senior author Richard Bucala, M.D. described a unique protein produced by malaria parasites, Plasmodium macrophage migration inhibitory factor (PMIF), which suppresses memory T cells, the infection-fighting cells that respond to threats and protect the body against reinfection. (yale.edu)
  • Malaria is a mosquito-borne infectious disease caused by protozoan parasites belonging to the genus Plasmodium. (who.int)
  • Eight cases of locally acquired, mosquito-transmitted (i.e., autochthonous) Plasmodium vivax malaria, which has not been reported in the United States since 2003, were reported to CDC from state health departments in Florida and Texas during May 18-July 17, 2023. (medscape.com)
  • Malaria Malaria is infection of red blood cells with one of five species of the protozoa Plasmodium . (msdmanuals.com)
  • More than a dozen vaccine candidates are now in clinical development, and one, GlaxoSmithKline Biologicals' RTS,S/AS01, completed Phase III clinical testing, and on October 6, 2021, following a large scale pilot implementation, became the first malaria vaccine to receive a WHO recommendation for widespread use among children living in areas of moderate to high malaria transmission. (cdc.gov)
  • In October 2021, the vaccine was endorsed by the World Health Organization for "broad use" in children, making it the first malaria vaccine to receive this recommendation. (wikipedia.org)
  • From April 2019 to August 2021, over 800,000 children received at least one dose of vaccine. (cdc.gov)
  • Since 2000, expanded access to WHO-recommended malaria prevention tools and strategies has led to a significant reduction in the global burden of this disease: in 2021, there were 84 malaria-endemic countries, down from 108 in 2000. (who.int)
  • In 2021, WHO recommended a groundbreaking malaria vaccine for children living in high-transmission areas. (who.int)
  • Will a vaccine end the fight against malaria? (malariaconsortium.org)
  • But new hope in the fight against malaria arrived two years ago via the world's first-ever malaria vaccine. (vox.com)
  • To make further progress in the fight against malaria, we need better tools. (cdc.gov)
  • In addition to the existing control and elimination efforts, scaling up of malaria research and innovation is necessary, including developing new and improved drugs and regimens to address emerging drug resistance, as well as vaccines, diagnostics and vector control research & development (R&D). The fight against malaria requires combined and integrated approaches which necessitates a concerted effort of many partners. (edctp.org)
  • GSK welcomed the news, saying that the approval will " reinvigorate the fight against malaria in the region at a time when progress on malaria control has stalled. (pharmaphorum.com)
  • The decision, which was announced by WHO Director-General Tedros Adhanom Ghebreyesus, marks a landmark moment in the fight against malaria, for which no other vaccines exist. (gabio.org)
  • Groundbreaking British-led science has today taken us a step further in the fight against malaria. (malarianomore.org.uk)
  • The RTS,S vaccine reduced clinical and severe cases of malaria by about one-third in 5-17-month-old children over four years who received the three-dose vaccine series plus a booster dose. (cdc.gov)
  • The vaccine's effectiveness at preventing severe cases of malaria in children is relatively low, at around 30% in a large-scale clinical trial. (thestar.com.my)
  • Since 2000, 1.5 billion cases of malaria and 7.6 million deaths have been averted. (cdc.gov)
  • The pivotal Phase III trial (completed in 2014) showed that the vaccine prevented approximately 4 in 10 (39%) cases of malaria over 4 years and about 3 in 10 (29%) cases of severe malaria among children who received 4 doses of RTS,S. 3 external icon There were also significant reductions in hospital admissions due to malaria. (cdc.gov)
  • There are fears that, as climate change causes more irregular and intense weather patterns, cases of malaria could rise , particularly among the poorest and most vulnerable groups, and spread to new locations. (oxfordstudent.com)
  • In 2019, there were 229 million cases of malaria worldwide. (kmuw.org)
  • While the pilots are still on-going until 2023, sufficient data on safety and efficacy have been collected to allow for a broader recommendation for the use of the vaccine to take place. (cdc.gov)
  • As of April 2023[update], the vaccine has been given to 1.5 million children living in areas with moderate-to-high malaria transmission. (wikipedia.org)
  • In April 2023, Ghana's Food and Drugs Authority approved the use of the R21 vaccine for use in children aged between five months and three years old. (wikipedia.org)
  • As of April 2023[update], 1.5 million children in Ghana, Kenya and Malawi had received at least one injection of the vaccine, with more than 4.5 million doses of the vaccine administered through the countries' routine immunization programs. (wikipedia.org)
  • On April 17, 2023 , Nigeria approved a promising new malaria vaccine. (wskg.org)
  • It is the first vaccine that meets the World Health Organization's (WHO) goal of a malaria vaccine with at least 75% efficacy, and only the second malaria vaccine to be recommended by the WHO. (wikipedia.org)
  • Chris - Yours is the second malaria vaccine that the WHO have recommended. (thenakedscientists.com)
  • The World Health Organization authorized a second malaria vaccine on Monday, a decision that could offer countries a cheaper and a more readily available option than the world's first shot against the parasitic disease. (com.pk)
  • News of a second malaria vaccine is another example of the tremendous power of UK backed research and development. (malarianomore.org.uk)
  • By adding a second malaria vaccine to our arsenal we will be able to extend the reach of this vital preventative tool to thousands more children and avert further unacceptable and preventable deaths. (malarianomore.org.uk)
  • The vaccine has been in development since the mid-1980s and has advanced thanks to a unique public-private partnership of GSKBio, the PATH Malaria Vaccine Initiative, and African and other research organizations, with funding support from the Bill and Melinda Gates Foundation. (cdc.gov)
  • RTS,S was developed by PATH Malaria Vaccine Initiative (MVI) and GlaxoSmithKline (GSK) with support from the Bill and Melinda Gates Foundation. (wikipedia.org)
  • This work was supported by the Howard Hughes Medical Institute (US), PATH/Malaria Vaccine Initiative , US Agency for International Development , Australian National Health and Medical Research Council and the Victorian Government Operational Infrastructure Support Program . (edu.au)
  • It has been developed over the last 25 years as a joint public-private collaboration by GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative (an international non-profit organisation) with grants from the Bill and Melinda Gates Foundation. (aljazeera.com)
  • How Can Malaria Cases and Deaths Be Reduced? (cdc.gov)
  • Malaria vaccines are vaccines that prevent malaria, a mosquito-borne infectious disease which annually affects an estimated 247 million people worldwide and causes 619,000 deaths. (wikipedia.org)
  • The World Health Organisation (WHO) estimates that malaria causes over 600,000 deaths each year globally, and says that progress in reducing malaria mortality has stalled in recent years. (ox.ac.uk)
  • Gareth Jenkins, from the charity Malaria No More UK said: 'Today's R21 vaccine results from Oxford's renowned Jenner Institute are another encouraging signal that, with the right support, the world could end child deaths from malaria in our lifetimes. (bbc.com)
  • Over the last 20 years, insecticide-treated bed nets , antimalarial medications , and the spraying of homes with insecticides significantly reduced global malaria cases and deaths. (vox.com)
  • Relatively new interventions like bed nets and improved availability of antimalarial drugs have helped drive down malaria cases and deaths in recent years. (cdc.gov)
  • While 39% efficacy seems low for a vaccine, when we consider the sheer burden of malaria, this means potentially a huge reduction in cases and deaths among children," says Samuels. (cdc.gov)
  • According to Samuels, if RTS,S is implemented at scale, "over 100,000 cases of clinical malaria and 417 deaths will be averted per 100,000 children receiving at least three doses. (cdc.gov)
  • America saw 1,337 cases, including eight deaths, as recently as 2002 - the importance of developing a vaccine for the disease is becoming more and more urgent. (infectioncontroltoday.com)
  • Those studies raised questions about whether increased rates of meningitis, cerebral malaria, and an overall increase in deaths among girls were seen in children who had received the vaccines. (gabio.org)
  • Its death toll from the disease makes up nearly a third of the world's 619,000 malaria deaths a year. (wskg.org)
  • The reality is that malaria financing globally is far from where it needs to be and annual deaths from malaria rose during the pandemic and are still above pre-pandemic levels, so we cannot afford to be complacent as new tools are developed. (malarianomore.org.uk)
  • Malaria deaths were reduced by more than 99% in the same period of time. (bvsalud.org)
  • Malaria parasites have a complex life cycle , and there is poor understanding of the complex immune response to malaria infection. (cdc.gov)
  • Malaria parasites are also genetically complex, producing thousands of potential antigens. (cdc.gov)
  • Unlike the diseases for which we currently have effective vaccines, exposure to malaria parasites does not confer lifelong protection. (cdc.gov)
  • While this vaccine strategy has proven very successful in providing protection against viruses and bacteria, it remains a novel approach in combating parasites. (sciencedaily.com)
  • Importantly, we show that antibodies from animals vaccinated with the complex have significantly higher neutralization activity against non-vaccine type parasites. (nature.com)
  • Therefore, a vaccine that blocks the parasites from entering the RBC could prevent disease. (nature.com)
  • People living in malaria endemic countries develop resistance to clinical disease after years of repeated exposure to the parasites. (nature.com)
  • The vaccine could also inform the creation of future vaccines against other parasites. (ox.ac.uk)
  • It is widely accepted that malaria vaccines will play a crucial role in eliminating malaria infections, and the eventual eradication of the parasites. (edu.au)
  • There's a handful of parasites that lead to malaria infections, and they vary in their characteristics. (vox.com)
  • Melbourne researchers have shown for the first time that carbohydrates on the surface of malaria parasites play a critical role in malaria's ability to infect mosquito and human hosts. (edu.au)
  • Malaria parasites have a complex lifecycle that involves constant shapeshifting to evade detection and infect humans and subsequently mosquitoes," he said. (edu.au)
  • Carbohydrates have long been considered unimportant to malaria parasites. (edu.au)
  • The complex lifecycle of the malaria parasites - of which there are 5 known to cause malaria in humans - mean that efforts to develop widely-distributable vaccines have so far failed. (oxfordstudent.com)
  • Both pregnancy-specific immunological responses and malaria-specific interactions, such as sequestration of parasites in the placenta, might contribute to this susceptibility. (glowm.com)
  • Malaria is caused by parasites and transmitted to humans through infected female Anopheles mosquitoes. (un.dk)
  • A Yale-led team of researchers have created a vaccine that protects against malaria infection in mouse models, paving the way for the development of a human vaccine that works by targeting the specific protein that parasites use to evade the immune system. (yale.edu)
  • There are 4 types of malaria parasites. (medlineplus.gov)
  • Malaria kills nearly 1 million people each year and sickens about 2 million others, according to estimates from the World Health Organization. (motherjones.com)
  • After decades of work, the World Health Organization (WHO) endorsed the first-ever malaria vaccine last year - a historic milestone that promised to drive back a disease that kills a child every minute. (thestar.com.my)
  • The World Health Organization has approved a new malaria vaccine that can be produced on a massive scale. (thenakedscientists.com)
  • There is currently only one malaria vaccine, 'RTS,S' that is approved by the World Health Organization and offers partial disease protection. (sciencedaily.com)
  • The World Health Organization called on the scientific community in 2013 to develop and license a vaccine that is at least 75 percent effective by 2030. (smithsonianmag.com)
  • He is the director of the Global Malaria Program at the World Health Organization, and he's joining us from Geneva, Switzerland. (kmuw.org)
  • More than 30 countries have areas with moderate to high malaria transmission, according to data from the World Health Organization ( WHO ), and the vaccine could provide added protection to more than 25 million children each year once supply ramps up. (un.dk)
  • The World Health Organization, acting on the advice of its scientific advisers, announced Wednesday that it would recommend a broad rollout of a much-needed malaria vaccine, saying pilot testing had shown that it was safe and could be effectively deployed in remote and rural settings. (gabio.org)
  • When tested in trials as an emulsion of oil in water and with the added adjuvants of monophosphoryl A and QS21 (SBAS2), the vaccine gave protective immunity to 7 out of 8 volunteers when challenged with P. falciparum. (wikipedia.org)
  • It said it had set up a funding deal with international vaccine alliance Gavi to help stockpile a key ingredient of the shot to ensure there was no gap in supply during that process. (thestar.com.my)
  • In a major step forward, Gavi, WHO, and UNICEF announced July that they will be committing 18 million doses of the RTS,S vaccine to 12 African countries. (vox.com)
  • The GAVI global vaccine alliance has offered funding of up to $27.5 million for pilot tests of GlaxoSmithKline's first-generation malaria vaccine, but only if other organizations promise to match that commitment…" (Kelland, 6/23). (kff.org)
  • More than $155 million has been mobilised by the Vaccine Alliance (Gavi) to enable the delivery of these vaccines. (africanews.com)
  • The foundation said it has continued helping with the vaccine rollout by supporting Gavi, a global vaccines alliance that is buying the GSK shots for distribution in poorer countries. (wgntv.com)
  • Actually getting the vaccine to the people who need it is the next challenge of course, and WHO said that financing has already been mobilised through non-governmental organisations Gavi, the Vaccine Alliance, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and Unitaid. (pharmaphorum.com)
  • That December, Gavi, the Vaccine Alliance, took the decision to provide funding for malaria vaccine programmes in eligible countries, thus opening the pathway for broader roll-out of the vaccine. (un.dk)
  • We urge the government to continue its long-standing commitment to global institutions including Gavi, The Vaccine Alliance, and The Global Fund to Fight AIDS, Tuberculosis and Malaria, which ensure vaccines and lifesaving tools are rolled out at scale. (malarianomore.org.uk)
  • While control measures, such as bed nets, are increasingly implemented, there remains no effective vaccine capable of eradicating malaria. (sciencedaily.com)
  • The recent development of resistance to front-line antimalarial drugs underscores the urgent need to develop an effective vaccine. (nature.com)
  • As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. (com.pk)
  • As some of you may know, I started my career as a malaria researcher, and I longed for the day that we would have an effective vaccine against this ancient and terrible disease," Tedros said during a news conference from Geneva. (gabio.org)
  • To date, no completely effective vaccine exists, and infected individuals only develop partial immunity against disease symptoms. (yale.edu)
  • With malaria still claiming more than half a million lives every year, mostly threatening young children and pregnant women, a second safe and effective vaccine is a major milestone in an urgent fight to save lives, protect livelihoods and strengthen health systems around the world. (malarianomore.org.uk)
  • The most effective malaria vaccine is the R21/Matrix-M, with a 77% efficacy rate shown in initial trials and significantly higher antibody levels than with the RTS,S vaccine. (wikipedia.org)
  • Missing the booster dose reduced the efficacy against severe malaria to a negligible effect. (wikipedia.org)
  • Consequently, apical membrane antigen 1 has been a target of vaccine development but vaccination with apical membrane antigen 1 alone in controlled human malaria infections failed to protect and showed limited efficacy in field trials. (nature.com)
  • In late 2022 they found that a vaccine booster dose at one year following a primary three-dose regime maintained high efficacy against malaria, and continued to meet the WHO's Malaria Vaccine Technology Roadmap goal. (ox.ac.uk)
  • Though it's unquestionably a feat, Mosquirix's efficacy rate leaves something to be desired: On average, it prevents malaria infection 35% of the time, though it staves off severe disease 50% of the time during the first year after administration. (fiercebiotech.com)
  • Unfortunately, we don't have anything which has 100 or 90 percent efficacy," said Thomas Breuer , the chief global health officer of the pharmaceutical company GSK, which created the RTS,S vaccine. (vox.com)
  • The first malaria vaccine approved for human use - RTS,S/AS01 - was approved by European regulators in July 2015 but has not been as successful as hoped, with marginal efficacy that wanes over time. (edu.au)
  • Dr Goddard-Borger said there were many documented cases where attaching carbohydrates to a protein improved its efficacy as a vaccine. (edu.au)
  • The vaccine, developed by scientists at the Jenner Institute of Oxford University, showed up to 77% efficacy in a trial of 450 children in Burkina Faso over 12 months. (veteranstoday.com)
  • A small clinical trial testing a vaccine against malaria has shown promising results, and for the first time, appears to have met the World Health Organization's target efficacy benchmark, Heidi Ledford reports for Nature News . (smithsonianmag.com)
  • The results of the latest trial show that a high dose of the experimental malaria vaccine has a 77 percent efficacy rate at preventing malaria infections over the course of one year. (smithsonianmag.com)
  • The efficacy we have got has never been obtained by any [malaria] vaccine candidate. (smithsonianmag.com)
  • The trial involved 450 children between five and 17 months old, split into three groups: a high dose of vaccine, a lower dose of vaccine, which resulted in a 71 percent efficacy rate, and a group that received a licensed rabies vaccine instead of the trial malaria vaccine. (smithsonianmag.com)
  • If the efficacy rate holds up to further trials, the Oxford University vaccine, called R21, will be far more effective than any previously tested vaccine. (smithsonianmag.com)
  • The Phase III trial will include regions that face malaria year-round, and continued study of the Phase II participants will illuminate whether the R21 vaccine holds its efficacy over time. (smithsonianmag.com)
  • After a single booster dose, given a year after the first inoculation, efficacy levels for the drug remain at 77% , exceeding the WHO's targets for vaccines. (oxfordstudent.com)
  • Though artemisinin-based combination therapies (ACT) are currently recommended for the treatment of malaria in the 2nd and 3rd trimesters of pregnancy, their tolerability, safety and efficacy vary considerably, limiting treatment options. (edctp.org)
  • Initial clinical trials of the vaccine only revealed a protective efficacy of around 39%, lower than would usually be considered suitable for immunisations at scale, but the WHO says RTS,S has since shown its value in real-world settings. (pharmaphorum.com)
  • The new vaccine has completed its phase III trials for safety and efficacy and will join the growing list of new tools bolstering the global effort to end malaria. (malarianomore.org.uk)
  • Director of WHO's Global Malaria Programme Pedro Alonso has told Sky News that malaria vaccine breakthrough is a 'historical event' and a 'turning point', which proves that we 'should not leave anyone behind' in a post-COVID era. (sky.com)
  • Over the past two decades, the collective efforts of the global malaria community have dramatically reduced the global burden of malaria, but progress has stalled in recent years," wrote Philip Welkhoff, the director for malaria at the Bill & Melinda Gates Foundation, in an email. (vox.com)
  • The World Malaria Report 2018 states that after an unprecedented period of success in global malaria control, progress has stalled. (edctp.org)
  • Data from 2015-2017 show no significant progress in reducing global malaria cases. (edctp.org)
  • And funding will need to be raised to help them do so, said Pedro Alonso, head of WHO's global malaria program. (gabio.org)
  • The pilot program confirmed that effectiveness in the field, said Pedro Alonso, director of WHO's Global Malaria Program. (gabio.org)
  • Large-scale pilots of the vaccine began in Ghana, Kenya, and Malawi in 2019, including several hundreds of thousands of infants. (cdc.gov)
  • FILE - A baby from the Malawi village of Tomali is injected with the world's first vaccine against malaria in a pilot program, on Dec. 11, 2019. (wgntv.com)
  • an estimated 279,000 children under the age of 5 died from malaria in 2019. (gabio.org)
  • In early trials conducted in 2019 and 2020, children aged 5 to 17 months were given three doses before malaria season and a booster 12 months later. (wskg.org)
  • This situation has driven the need to explore other preventive strategies that could overcome these problems, such as vaccines to prevent malaria in pregnancy. (glowm.com)
  • Using this vaccine on top of existing tools to prevent malaria could save tens of thousands of young lives each year," said Ghebreyesus. (pharmaphorum.com)
  • In July 2015, the European Medicines Agency (EMA) gave a positive regulatory assessment of the RTS,S/AS01 vaccine for 5-17-month-olds, but WHO recommended in October 2015 that the vaccine be further evaluated in large-scale pilot studies before recommending it. (cdc.gov)
  • RTS,S/AS01 (brand name Mosquirix) is the first malaria vaccine approved for public use. (wikipedia.org)
  • WHO recommends that in the context of comprehensive malaria control the RTS,S/AS01 malaria vaccine be used for the prevention of P. falciparum malaria in children living in regions with moderate to high transmission as defined by WHO. (cdc.gov)
  • RTS,S/AS01 malaria vaccine should be provided in a schedule of 4 doses in children from 5 months of age for the reduction of malaria disease and burden. (cdc.gov)
  • RTS,S/AS01 (RTS,S) is the first and, to date, the only vaccine to show that it can significantly reduce malaria, and life-threatening severe malaria, in young African children. (bvsalud.org)
  • said it intends to submit an experimental malaria vaccine for regulatory approval next year, after new data from a long-running study continued to show that the vaccine provides partial protection against the disease. (wsj.com)
  • An experimental malaria vaccine appears safe and promotes an immune response in African infants, one of the groups most vulnerable to severe malaria disease. (sciencedaily.com)
  • 63 participants aged 6 months to 35 years were enrolled and randomized to receive either the experimental malaria vaccine, called "ChAd63-MVA RH5," or a control rabies vaccine. (sciencedaily.com)
  • Mosquirix has the potential to save a lot of precious lives before another new vaccine arrives," said Kwame Amponsa-Achiano, a public health specialist leading a pilot vaccination programme in Ghana. (thestar.com.my)
  • Rebecca Adhiambo Kwanya in the Kenyan city of Kisumu needs no convincing: her four-year-old child Betrun has suffered numerous malaria bouts since birth, yet her 18-month-old Bradley - vaccinated in the pilot programme - hasn't caught it. (thestar.com.my)
  • This trial was funded by the Multi-stage Malaria vaccine Consortium grant, coordinated by Oxford, part of the EDCTP2 programme supported under Horizon 2020, as well as by the Wellcome Trust and NIHR Oxford Biomedical Research Centre. (ox.ac.uk)
  • EDCTP has supported the campaign for a world free of malaria since the programme was established in 2003. (edctp.org)
  • Pesticide spraying in Yemen, as part of a National Malaria Control Programme campaign. (who.int)
  • malaria infection can persist for months without symptoms of disease. (cdc.gov)
  • Ultimately, when deciding whether to vaccinate travelers, clinicians should take into account destination-specific risks for YF virus infection, and individual risk factors (e.g., age, immune status) for serious YF vaccine-associated adverse events, in the context of the entry requirements. (cdc.gov)
  • Impact of RTS,S vaccine on malaria infection and transmission. (jci.org)
  • Lisa - This is a vaccine against malaria, a parasitic infection that kills hundreds of thousands of people a year. (thenakedscientists.com)
  • Specifically, a type of T-cell called a tissue-resident memory T-cell, that halts malaria infection in the liver to completely stop the spread of infection. (fiercebiotech.com)
  • In this case, the vaccine with the adjuvant protected seven of the 10 uninfected mice, and all nine of the mice that had had an infection. (fiercebiotech.com)
  • 1 Pregnant women are more susceptible to the effects of malaria infection. (glowm.com)
  • 9 Malaria is the most important parasitic infection of humans and a scourge for millennia, but the burden of malaria infection in pregnancy and the detrimental effects on the health of mothers and their infants were not described in detail until early in the 20th century. (glowm.com)
  • Researchers have created a vaccine that protects against malaria infection in mouse models, paving the way for the development of a human vaccine. (yale.edu)
  • Unlike malarial infection in nongravid individuals, pregnant individuals with P vivax are at high risk for severe malaria, and those with P falciparum have a greatly increased predisposition for severe malaria as well. (medscape.com)
  • Malaria infection during pregnancy can also cause premature delivery, stillbirth, or delivery of a baby with low birth weight. (who.int)
  • Malaria is a serious infection and requires treatment with multiple medicines. (who.int)
  • We have been testing it in African countries that have malaria endemic in the population and the latest data that we have is that when it's administered to people living in areas where malaria is seasonal, this is 75% effective. (thenakedscientists.com)
  • A lot of malaria vaccines undergoing trials have worked really well in animal models or when they're given to people who haven't had malaria before, but they don't work well when given to people living in malaria-endemic regions. (fiercebiotech.com)
  • The data in the phase 1b trial reported here confirm, for the first time, that substantial anti-RH5 immune responses can be achieved safely by vaccination in infants from a malaria-endemic area," say the authors. (sciencedaily.com)
  • The primary purpose of this study was to evaluate the safety of this vaccine in a population where malaria is endemic. (sciencedaily.com)
  • 4 , 5 , 6 Owing to these harmful effects, malaria in pregnancy is a significant driver of maternal and neonatal health in endemic areas. (glowm.com)
  • Before traveling internationally to areas with endemic malaria, travelers should consult with a health care provider regarding recommended malaria prevention measures, including potentially taking malaria prophylaxis. (medscape.com)
  • Areas where vaccine preventable diseases such as yellow fever, are endemic. (cdc.gov)
  • On the island of Zanzibar, off the coast of Mozambique, high-tech drones are being used to spray a silicone-based liquid gel (Aquatain) in endemic areas where malaria-carrying mosquitoes lay eggs, and where there are large concentrations of stagnant water. (who.int)
  • The first approved vaccine for malaria is RTS,S, known by the brand name Mosquirix. (wikipedia.org)
  • In July 2015, Mosquirix received a positive scientific opinion from the European Medicines Agency (EMA) on the proposal for the vaccine to be used to vaccinate children aged 6 weeks to 17 months outside the European Union. (wikipedia.org)
  • A GSK spokesperson told Reuters that it could not make enough of its vaccine Mosquirix to meet the vast demand without more funds from international donors, without giving details on the numbers of doses it expected to produce annually in the first years of the roll-out. (thestar.com.my)
  • The limited international appetite to produce and distribute more Mosquirix stands in stark contrast to the record speed and funds with which wealthy countries secured vaccines for Covid-19, a disease that poses relatively little risk to children. (thestar.com.my)
  • There's only one malaria vaccine widely available right now-Mosquirix, developed by GlaxoSmithKline, which was officially rolled out to the world in 2022. (fiercebiotech.com)
  • Like other mRNA vaccines for malaria, the Ferrier, Malaghan and Peter Doherty institutes' vaccine encodes the entire malaria protein rather than select antigens, the way protein-based vaccines such as Mosquirix do. (fiercebiotech.com)
  • But that vaccine, known as Mosquirix and made by GSK, is only about 30% effective, requires four doses and protection fades within months. (com.pk)
  • The second-most effective malaria vaccine, called Mosquirix, is about 56 percent effective over one year, and that falls to 36 percent effective over four years, per Nature News . (smithsonianmag.com)
  • The Oxford vaccine is not the first of its kind, with pharmaceutical giant GSK receiving WHO endorsement for Mosquirix last year. (oxfordstudent.com)
  • Notably, the vaccine provided this protection in settings with ongoing use of other effective malaria prevention and treatment interventions: bed nets, antimalarial drugs for disease treatment, indoor residual insecticide spraying to prevent mosquito-borne transmission, and drugs to protect pregnant women and their newborns from malaria's adverse effects. (cdc.gov)
  • The following pages present country-specific information on yellow fever (YF) vaccine requirements and recommendations, and malaria transmission information and prevention recommendations. (cdc.gov)
  • Now, vaccine manufacturers, charitable organizations, government agencies, and local public health officials have to concentrate on getting shots in arms as equitably and quickly as possible, without forgoing other older methods of malaria prevention. (vox.com)
  • I became involved because I strongly believe in prevention and have always been impressed by [the] impact of vaccines on disease burden," Njuguna told Al Jazeera. (aljazeera.com)
  • Another fear was that parents might assume the vaccine, which only offers partial protection, was more potent than it actually is and as a result, might let down their guard on other malaria prevention measures such as having children sleep under a treated bed net. (gabio.org)
  • Prevention using the live-attenuated 17D vaccine is highly efficacious. (medscape.com)
  • In July 2016, WHO officially amended the IHR to stipulate that a completed International Certificate of Vaccination or Prophylaxis is valid for the lifetime of the vaccinee, and YF vaccine booster doses are not necessary. (cdc.gov)
  • Three doses of vaccine plus a booster reduced the risk of clinical episodes by 26 percent over three years but offered no significant protection against severe malaria. (wikipedia.org)
  • In August 2022, UNICEF awarded a contract to GSK to supply 18 million doses of the RTS,S vaccine over three years. (wikipedia.org)
  • Long-term, WHO officials say roughly 100 million doses a year of the four-dose vaccine will be needed, which would cover around 25 million children. (thestar.com.my)
  • Lisa - The way that the vaccine has been tested so far is that there are three doses given one month apart and then a booster dose given 12 months after the third dose. (thenakedscientists.com)
  • Crucially, say the scientists, their vaccine is cheap and they already have a deal to manufacture more than 100 million doses a year. (bbc.com)
  • The world's largest vaccine manufacturer - the Serum Institute of India - is already lined up to make more than 100 million doses a year. (bbc.com)
  • The evaluation helped determine the feasibility of delivering four doses of RTS,S, assessed the impact of the vaccine, and continued monitoring for safety. (cdc.gov)
  • The Serum Institute has said it could make up to 200 million doses of the Oxford vaccine a year. (com.pk)
  • The Serum Institute of India has already partnered with Oxford University to produce 200 million doses of the R21 vaccine if it is licensed. (smithsonianmag.com)
  • By contrast, the Oxford vaccine makers have partnered with the Serum Institute of India to produce up to 200 million doses annually. (oxfordstudent.com)
  • Around 2.3 million doses of RTS,S have been administered to date, with a good safety profile, said the WHO, and there is no evidence that widespread use affects other measures used to manage malaria or other childhood diseases. (pharmaphorum.com)
  • The landmark award, valued at up to $170 million, will lead to 18 million doses of the RTS,S vaccine being available over the next three years, potentially saving thousands of young lives annually. (un.dk)
  • The vaccine, known as RTS,S and developed by GSK, is given in four doses. (gabio.org)
  • While the initial doses are given at the time other vaccines are administered, the last is not. (gabio.org)
  • Serum Institute of India, the license holder of the R21 vaccine, has expressed commitment to manufacture more than 200 million doses annually. (wskg.org)
  • This is important because GSK, the manufacturers of the RTS,S vaccine only committed to producing 15 million doses annually through 2028, due to limited manufacturing capacity and low funding, falling far behind the current need of the vaccine which WHO estimates to range from about 80-100 million doses annually. (wskg.org)
  • The CDC recommends the use of artemether/lumefantrine as an additional treatment option for uncomplicated malaria in pregnant patients in the United States during the second and third trimester of pregnancy at the same doses recommended for nonpregnant patients. (medscape.com)
  • The vaccine was generally found to be safe, but there were a few safety signals that warranted further study, including febrile convulsions, meningitis, and cerebral malaria. (cdc.gov)
  • The goal of these pilot evaluations is to assess the feasibility of delivering the three-dose vaccine series plus booster through routine health systems, carefully examine the relationship of the vaccine to specific adverse events (febrile seizures, meningitis, cerebral malaria), and also evaluate its impact on all-cause mortality. (cdc.gov)
  • In this picture, a Kenyan woman carries her son, whose cerebral malaria left him blind and unable to sit up. (thestar.com.my)
  • We will conduct random-effects meta-analysis when heterogeneity is appreciable, and express dichotomous outcomes (serious adverse events, cerebral malaria and febrile convulsion ) as risk ratio (RR) with their 95% CI. (bvsalud.org)
  • The vaccine was prequalified by WHO in July 2022. (wikipedia.org)
  • That includes COVID-19 vaccinemaker BioNTech, which announced in December 2022 that it had launched a clinical trial of its malaria vaccine, BNT165. (fiercebiotech.com)
  • Oxford University developed the new three-dose vaccine with help from the Serum Institute of India. (com.pk)
  • GSK treated the project as a non-profit initiative, with most funding coming from the Gates Foundation, a major contributor to malaria eradication. (wikipedia.org)
  • and the expanding scope of malaria-carrying mosquitos all pose a threat to eradication efforts. (vox.com)
  • This database showcases such innovations that have a difference towards malaria eradication globally for adaptation and scalling in the African region. (who.int)
  • GSK's has gone through large real world trials whereas Oxford's data may appear more effective due to being given just ahead of the peak malaria season in Burkina Faso. (bbc.com)
  • Earlier this year, regulatory authorities in Ghana and Burkina Faso approved the vaccine. (com.pk)
  • The companies behind these vaccines say that they'll boost the immune responses of people who have already been vaccinated. (technologyreview.com)
  • The team think this helps the immune system to focus on malaria rather than the hepatitis. (bbc.com)
  • In contrast, our vaccine is still capable of generating protective liver-specific immune cells and providing protection even when the animal models have been pre-exposed to the disease. (fiercebiotech.com)
  • But unlike other mRNA vaccines, like the ones used for COVID-19, their shot is designed to upregulate memory T-cells in the liver, an approach made possible through the use of an adjuvant the Ferrier and Malagahn institutes had developed to boost the immune system's response to cancer. (fiercebiotech.com)
  • Because Europe, North America, and North Asia are now significantly colder than regions of high malaria incidence, developed nations have felt immune from the malaria threat, but that sense may soon be upended. (infectioncontroltoday.com)
  • A secondary outcome of the study was whether the vaccine would promote an immune response. (sciencedaily.com)
  • That teaches the immune system to respond in full force if the person gets infected with malaria later. (smithsonianmag.com)
  • Many other malaria vaccines are also in development, including some that try to introduce the immune system to more than a single protein at a time. (smithsonianmag.com)
  • A substance or combination of substances used in conjunction with a vaccine antigen to enhance (for example, increase, accelerate, prolong and/or possibly target) or modulate a specific immune response to the vaccine antigen in order to enhance the clinical effectiveness of the vaccine. (who.int)
  • If an anti-sporozoite and an anti-RH5 vaccine were used in combination in the future, individuals could potentially experience more effective protection against malaria for a longer period of time. (sciencedaily.com)
  • While the vaccine does not offer full protection against malaria - and indeed is not as effective as vaccines against many childhood diseases such as measles or rubella - even partial protection can have a big impact on the burden of malaria. (gabio.org)
  • These observations indicate the possibility of developing a vaccine that would accelerate the acquisition of protective immunity to disease in children. (nature.com)
  • Unlike the COVID-19 vaccine that works by neutralizing antibodies, our unique approach relies on T-cells which play a critical role in immunity," co-author Mitch Ganley, Ph.D. said in the release. (fiercebiotech.com)
  • the idea of a vaccine to create immunity was a scientific dream, far from viable. (aljazeera.com)
  • Vaccines typically employ an "antigen," or agent that induces disease-fighting immunity. (infectioncontroltoday.com)
  • A vaccine against the parasitic disease malaria cut illnesses by more than half in field trials and could be safely given with other childhood inoculations, two studies have reported. (motherjones.com)
  • And while injected vaccines provide good protection from severe disease, they don't stop us from catching the virus or spreading it to others. (technologyreview.com)
  • Such a vaccine will have an enormous impact on reducing mortality and disease severity in children and pregnant women. (nature.com)
  • With drug resistance towards malarial treatments growing, the medical community is increasingly looking towards vaccines to halt the spread of this mosquito-borne disease. (thestar.com.my)
  • Prof Azra Ghani, chair in infectious disease epidemiology at Imperial College London, said the trial results were 'very welcome', but warned it would take money to get vaccines in arms. (bbc.com)
  • Malaria is actually a very complex disease," said William Moss, a professor of epidemiology, international health, and molecular microbiology and immunology at the Johns Hopkins Bloomberg School of Public Health. (vox.com)
  • Dividing her days between treating malaria in Kenya's coastal regions and administering the latest malaria vaccine prototype, doctor Patricia Njuguna has high hopes for preventing a disease that annually claims more lives than cancer. (aljazeera.com)
  • Until recently, efforts to control malaria have been aimed largely at preventing mosquito bites and treating clinical disease. (aljazeera.com)
  • The goal: To have a malaria vaccine that provides protection against the disease in 50 per cent of infants by the year 2015 and in 80 per cent of infants by 2025. (aljazeera.com)
  • In late trials, the new RTS,S vaccine which Njuguna is testing has prevented transmission of the disease in 55.8 per cent of subjects, which is on target for the Roadmap. (aljazeera.com)
  • This is the first time ever that a vaccine has been recommended to combat malaria, a disease that has killed billions of people globally over many centuries. (cdc.gov)
  • Malaria is a very old disease and it can be fatal if not treated in time. (africanews.com)
  • If we can begin to curb the spread of malaria in high-threat areas, the eventual reach of the disease will be seriously limited. (infectioncontroltoday.com)
  • Where regimen 1 is indicated there is Chloroquine resistance in that region and it is very likely to be the Falciparum malaria which is the most serious form of the disease. (traveldoctor.co.uk)
  • WHO Director-General Tedros Adhanom Ghebreyesus said the U.N. health agency was approving the new malaria vaccine based on the advice of two expert groups, recommending its use in children at risk of the disease. (com.pk)
  • So the current vaccine, which is by and large what many other vaccines for other infectious disease builds on, is on recombinant proteins - so the production of proteins that represent parts of the organism, of the bot that you're trying to attack. (kmuw.org)
  • The pharmaceutical company GSK has been awarded a contract to produce the world's first malaria vaccine so that millions more children will be protected against the killer disease, the UN Children's Fund (UNICEF) announced on Tuesday. (un.dk)
  • The RTS,S malaria vaccine - the result of 35 years of research and development - is the first-ever vaccine against a parasitic disease. (un.dk)
  • Malaria is the second leading cause of infectious disease worldwide, and took more than a half million lives in 2013. (yale.edu)
  • We need a complete suite - vaccines, next-generation mosquito nets, rapid diagnostic tests and life-saving preventative medicines - to fight this disease on all fronts and end malaria in our lifetimes. (malarianomore.org.uk)
  • An AMC is a legally-binding agreement for an amount of funds to subsidize the purchase, at a given price, of an as yet unavailable vaccine against a specific disease causing high morbidity and mortality in low-income countries. (who.int)
  • Prompt diagnosis and treatment of malaria can prevent severe disease or death and limit ongoing transmission to local Anopheles mosquitoes and other persons. (medscape.com)
  • Malaria is a life-threatening disease, but it is both preventable and curable. (who.int)
  • Malaria is a serious disease that spreads by the bite of certain mosquitoes, typically biting between dusk and dawn. (medlineplus.gov)
  • If you are traveling to an area where malaria is common, you may need to take medicines that prevent the disease. (medlineplus.gov)
  • However, because no vaccine is 100% effective, some people who have been vaccinated still may get the disease. (msdmanuals.com)
  • Vaccines have been very effective in preventing serious disease and in improving health worldwide. (msdmanuals.com)
  • More than 30 countries have areas with moderate to high malaria transmission where the vaccine is expected to be useful. (wikipedia.org)
  • Last October, the UN health agency recommended its widespread use in countries with moderate to high malaria transmission. (un.dk)
  • The RTS,S vaccine has been approved for use in children under 5 living in moderate to high malaria transmission areas. (bvsalud.org)
  • Chris - There are multiple different types of malaria, aren't there? (thenakedscientists.com)
  • Getting tested early is important as some types of malaria can cause severe illness and death. (who.int)
  • The treatment of malaria is predicated on the severity of the patient's illness, the infecting species, geographic knowledge of anti-malarial drug resistance, and knowledge of prior antimalarials given to the patient (it is not recommended to use the same prophylactic medication for treatment). (medscape.com)
  • Although the limited availability of quinine and increasing resistance to mefloquine limit these options, strong evidence demonstrates that artemether-lumefantrine (Coartem ) is effective and safe in the treatment of malaria in pregnancy. (medscape.com)
  • EU funding has supported University of Oxford led programmes to create and validate vaccines for some of the most prevalent and deadly diseases affecting low- and middle-income countries. (ox.ac.uk)
  • Malaria is the oldest documented diseases known to man, dating back several million years. (aljazeera.com)
  • Malaria researchers from CDC's Division of Parasitic Diseases and Malaria (DPDM) have been instrumental in this major milestone. (cdc.gov)
  • And understanding what you just explained to us about how these diseases are completely different, but could you explain in lay terms what an RNA vaccine is and how it's different from the other malaria vaccine that is currently in use? (kmuw.org)
  • And definitely this will need to be explored for other infectious diseases, and certainly for malaria. (kmuw.org)
  • This vaccine candidate is currently being tested in a Phase 1 study in partnership with the National Institute of Allergy and Infectious Diseases (NIAID). (biopharminternational.com)
  • Numerous other parasitic pathogens also produce MIF-like proteins, said the scientists, suggesting that this approach may be generalizable to other parasitic diseases - such as Leishmaniasis, Hookworm, and Filariais - for which no vaccines exist. (yale.edu)
  • Preventing mosquito bites and controlling mosquitoes at home can prevent mosquitoborne diseases, including malaria. (medscape.com)
  • We also make recommendations about prophylactic medications travelers need to take to prevent diseases such as malaria. (cdc.gov)
  • You also may need vaccines for diseases that are not commonly found in North America. (medlineplus.gov)
  • Check CDC Destinations pages to see what vaccines or medicines you may need and what diseases or health risks are a concern at your destination. (cdc.gov)
  • Innovative advances in fighting malaria are also helping to improve the way health systems fight other diseases. (who.int)
  • It is currently unlikely to make more than a few million annually before 2026, according to a source close to the vaccine rollout. (thestar.com.my)
  • Next steps include funding decisions from the international community for broader rollout and country decision-making on whether to adopt the vaccine. (cdc.gov)
  • Etleva Kadilli, Director of UNICEF 's Supply Division, said the rollout sends a clear message to malaria vaccine developers to continue their work. (un.dk)
  • Vaccine introduction is feasible, improves health and saves lives, with good and equitable coverage of RTS,S seen through routine immunization systems. (cdc.gov)
  • In 2015, the US Advisory Committee on Immunization Practices published a recommendation that 1 dose of YF vaccine provides long-lasting protection and is adequate for most travelers. (cdc.gov)
  • Together, these results indicate that the suppressive effects of blood-stage preexposure seen for attenuated sporozoite vaccines do not extend to immunization by adjuvanted mRNA vaccines, potentially a major advantage for translation into the field," the researchers concluded in their paper. (fiercebiotech.com)
  • "Lives are at stake, every day, " said Dr. Kate O'Brien, Director of WHO's Department of Immunization, Vaccines and Biologicals. (un.dk)
  • The pilot programs also laid to rest some safety concerns about the vaccine that had arisen during the clinical trials for RTS,S, said Kate O'Brien, director of WHO's department of immunization, vaccines, and biologicals. (gabio.org)
  • Mymetics delivers malaria antigens through a particle called a "virosome," which is essentially an empty, non-infectious virus particle. (infectioncontroltoday.com)
  • Up to 80% of children vaccinated did not develop clinical malaria during the 2-year period of the trial. (wskg.org)
  • The vaccine was found to prevent approximately 4 in 10 malaria cases, including 3 in 10 cases of life-threatening severe malaria. (who.int)
  • Scientists at the Walter Reed Army Institute of Research and GlaxoSmithKline began development of the RTS,S vaccine in 1984. (cdc.gov)
  • Dutch biopharmaceutical company Crucell N.V. (Leiden, the Netherlands) and GlaxoSmithKline Biologicals (GSK, London, UK) will collaborate on developing a second-generation malaria vaccine candidate. (biopharminternational.com)
  • And thus the development of malaria vaccine is probably one of the holy grails of biomedical research. (kmuw.org)
  • We think these data are the best data yet in the field with any malaria vaccine,' said Prof Adrian Hill, director of the Jenner Institute at the university. (bbc.com)
  • That's a real technical challenge," says co-author Adrian Hill, vaccine expert and director of the Jenner Institute, to BBC News ' Philippa Roxby. (smithsonianmag.com)
  • Professor Adrian Hill, founder and director of the Jenner Institute and tutor in medicine and biomedical science at Magdalen College, told Reuters that this marks the first time a major vaccine has been approved first in an African country (rather than rich, or highly developed, nations). (oxfordstudent.com)
  • Malaria No More UK welcomes news today that the WHO have published a policy recommendation on the new R21 malaria vaccine, developed by the Jenner Institute at Oxford University. (malarianomore.org.uk)
  • In 2006, a group of 250 of the world's top malariologists drafted the Malaria Vaccine Technology Roadmap. (aljazeera.com)
  • Countries requiring malaria prophylaxis should be regarded as being at risk all year round and you should also assume that the whole country is at risk unless otherwise indicated. (traveldoctor.co.uk)
  • Vaccines that you inhale through the nose or mouth, on the other hand, potentially could.In the last week, regulatory bodies in both India and China have approved inhaled vaccines for covid-19. (technologyreview.com)
  • Crucell's vaccine candidate was tested as a stand-alone and in combination with GSK's malaria vaccine candidate RTS,S/AS. (biopharminternational.com)
  • We found that the parasite's ability to 'tag' key proteins with carbohydrates is important for two stages of the malaria lifecycle. (edu.au)
  • Of 146 children who received the vaccine, 38 developed malaria, but the study did not include genetic analysis from those malaria cases. (smithsonianmag.com)
  • Seattle BioMed's Malaria Clinical Trials Center is one of only four centers in the world approved to safely and effectively test new malaria treatments and vaccines in humans by the malaria human challenge model. (sciencedaily.com)
  • But safety and production issues could prevent the development of the vaccine for humans, say other scientists. (the-scientist.com)
  • ALONSO: So malaria has been around with humans probably for the last 10,000 years. (kmuw.org)
  • Studies have shown that even such modest temperature increases could extend the proliferation of malaria-bearing mosquitoes. (infectioncontroltoday.com)
  • But in my view, there's a big stumbling block: Many of the people who need the vaccine the most live in poor and rural areas where malaria is troublesome because of living conditions that favor mosquito breeding - for example, low quality housing with broken window nets that mosquitoes can easily infiltrate, standing pools of water in gutters, and the proximity to swamps. (wskg.org)
  • More than one million children in Ghana, Kenya and Malawi have now received at least one dose of the first malaria vaccine. (africanews.com)
  • The Oxford-developed R21/Matrix-M vaccine to combat malaria has been cleared for use in Ghana amongst children aged 5 months to 3 years old. (oxfordstudent.com)
  • Insecticide resistance and parasitic resistance to drugs have perpetuated malaria cases in Ghana and many other sub-Saharan African countries. (oxfordstudent.com)
  • Malaria vaccine pilot programmes running since 2016 in Ghana, Kenya and Malawi and involving more than 800,000 children have shown that the shot can achieve a 30% reduction in severe, life-threatening malaria. (pharmaphorum.com)
  • So even though the R21 vaccine is still undergoing larger-scale human trials, Nigeria has joined Ghana in authorizing it because of its promise to be the most effective in preventing malaria and its potential to be manufactured at large scale due to its low cost of just $3 a dose . (wskg.org)
  • Malaria can be prevented by avoiding mosquito bites and with medicines. (who.int)
  • Malaria symptoms usually start within 10-15 days of getting bitten by an infected mosquito. (who.int)
  • This malaria vaccine is the 14th that Prof Katie Ewer has worked on at Oxford as 'this is not like Covid where we have seven vaccines straight away that will work. (bbc.com)
  • But - and here's the positive part - the scientific community's intense focus this year on a COVID vaccine, specifically, ones that use RNA like those developed by Pfizer and Moderna, could offer some lessons for malaria vaccine development. (kmuw.org)
  • MARTIN: To the issue of the resources devoted to this, it's my understanding that a team from Yale Medical School has developed a new model for a malaria vaccine that is based off of the RNA blueprint that the COVID vaccine uses. (kmuw.org)
  • I think it's been an amazing achievement to use RNA platforms to produce COVID-19 vaccines. (kmuw.org)
  • As the manager of the CHAMPS program in Mwandi, he shared with us about how COVID-19 is affecting programming, the reason behind a recent spike in malaria cases, and more. (cmmb.org)
  • The high antibody titers against AMA1 in malaria-exposed individuals, its surface expression and ability of anti-AMA1 antibodies to block invasion in vitro led to AMA1 being a leading vaccine candidate. (nature.com)
  • Our approach to improving the quality of antibodies elicited by AMA1 vaccination is to develop a vaccine that more closely mimics the AMA1 structure on the invading merozoite. (nature.com)
  • So if you make those antibodies and they're there waiting, when you encounter malaria for real it clogs it up. (thenakedscientists.com)
  • And so when we inject somebody with this vaccine, we push the human body to make antibodies that are specific to that protein. (thenakedscientists.com)
  • Researchers found that participants who received the malaria vaccine developed antibodies against RH5 in their blood upon follow-up. (sciencedaily.com)
  • But we - it is still unclear how with RNA technology one can induce the type of very high levels of antibodies that we know are going to be required if we want to protect against malaria. (kmuw.org)
  • But the R21 vaccine, which works by inducing high levels of malaria-specific antibodies that help to protect against malaria, has shown to be safe and more effective than the RTS,S vaccine in preliminary results from a 2-year long trial. (wskg.org)